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Chapter 1: 
General introduction 
 
1.1. Definition and epidemiology of head and neck cancer 
Head and neck cancer is an anatomically based term defined to describe malignant tumours 
that originate from the upper aerodigestive tract and are located between the thoracic outlet 
and the skull base. These regions include the sinonasal region, oral cavity, the naso-, oro-, and 
hypopharynx and larynx. The majority of head and neck tumours consist of squamous cell 
carcinomas (SCC) which usually occur in the oral cavity, the pharynx,  the larynx and 
sinonasal cavity. Other, but less frequent, types of malignant tumours are adenocarcinomas 
originating from the sinonasal cavities, nasopharyngeal carcinoma, salivary gland carcinoma, 
several subtypes of thyroid carcinoma and skin tumours. Finally, other malignant tumours that 
can occur in this region include sarcomas and lymphomas. 
Although relatively uncommon, the incidence of head and neck SCC (HNSCC) is increasing. 
In 2002, HNSCC was, according to the World Cancer Report of 2002, the 8
th
 most common 
cancer worldwide accounting for 390000 cases annually (1). In a recent report by Jemal et al, 
this number has increased to 500000 (2). 
In Belgium, HNSCC took the 4
th
 place in 2005 of most frequent tumours in men with 6% or 
1806 cases. In women, the incidence HNSCC was roughly 3 times lower than in men with 2% 
or 553 cases. In men, HNSCC is the fifth most frequent cause of cancer related death. 
Notably, the incidence of HNSCC in Belgium is amongst the highest in Europe and for 
women the incidence is even the highest among selected European data (3). The tumours start 
to occur at the age of 35-40 years with a peak incidence at the age of 55-60 years. The 
anatomical subsite most frequently involved in head and neck cancer may vary per country, 
region and sex and relate in part to the underlying carcinogenic factors. For instance, oral 
cancer is most frequent in India, while nasopharyngeal carcinoma most frequently occurs 
along the south-eastern coast of China. In our country, men mostly suffer from laryngeal 
cancer while in women, the majority of tumours occur in the oral cavity. Overall, the most 
frequently affected subsites are oral cavity cancer (30%), pharyngeal cancer (29%) and 
laryngeal cancer (27%) (3). 
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Alcohol and tobacco are the most important risk factors for HNSCC and act synergistic in 
their carcinogenic effect. Other, be it less frequent, etiological factors include dietary 
imbalances and micronutrient deficiencies, occupational exposure to wood dust, nickel and 
asbestos for which the correlation with sinonasal cancer is well known. Wood dust and 
asbestos exposure also increase the risk for developing laryngeal cancer (4). Additionally, an 
association has been found between viral infections and the occurrence of head and neck 
cancer. Epstein-Barr virus has been associated with nasopharyngeal cancer while human 
papillomavirus has been associated with oral cavity and oropharyngeal cancer. However, the 
exact causal contribution of viral infections remain to be determined (5). 
As smoking and alcohol abuse irritate the mucosa of the entire respiratory system and the 
upper digestive system, there is risk for the induction of a metachronous second primary 
tumour at the time of diagnosis of a primary head and neck cancer or in the post-treatment 
phase (6). Second primary tumours may impact patient prognosis more significantly than the 
primary head and neck cancer. A recent study showed that patients with a lung cancer as a 
second primary, had  very poor chances for 5-years survival, while a second primary tumour 
in the head and neck offered better prognosis (7). The difference in prognosis is probably 
related to the better treatment options for obtaining local control and the lower propensity for 
developing distant metastases. 
 
1.2 Histopathology of head and neck squamous cell 
carcinoma 
 
1.2.1. Primary tumour 
The normal mucosa of the upper aerodigestive tract consists of a thick stratified squamous 
epithelium with the lamina propria extending deep into the epithelium by numerous papillae. 
Next to striated fibres, the submucosal lamina propria contains blood and lymph vessels. 
Primary HNSCC usually arises from the superficial mucosal lining and its development can 
coincide with molecular alterations in tumour suppressor genes in the squamous epithelium 
(8). The development from hyperplasia over mild, moderate and severe dysplasia to 
carcinoma in situ is characterized by progressive microstructural alterations, compared to the 
normal epithelium. These microstructural changes include - like for many malignant tumours 
- an increase of cellular volume and cell density, cellular and nuclear polymorphism and a 
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chaotic instead of organized stratified microstructure. Further tumoral progression results in 
invasive carcinoma when the basal membrane of the epithelium is disrupted (Figure 1) . 
 
 
Figure 1: Histological appearance of primary location of head and neck squamous cell carcinoma (arrows). 
The tumour is composed of densely packed, large-sized pleomorphic cells and organized in a girdle-like 
microstructure (arrows) 
 
At earlier stages only the submucosal fibrous tissue is invaded, although frequently, the 
underlying muscular tissue is also affected. Bone or cartilage invasion usually occurs at late 
stage. Perineural and/or intravascular spread is possible at all head and neck locations. 
Next to progressive cellular changes, HNSCC is - similar as all malignant tumours - 
dependent of an angiogeneic network for locoregional growth and metastatic spread. 
The tumoral vasculature shows a substantially different structure and altered function 
compared to normal blood vessels. The tumoral vasculature appears disorganized, with 
tortuous and variably sized vessels, excessive branching and shunting. The vessel wall is 
fragile and shows large gaps in the endothelial surface (9). These structural changes lead to a 
highly altered vascular functionality resulting in a heterogeneous and sometimes insufficient 
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transtumoral blood flow, increased capillary permeability and increased interstitial pressure 
(10,11). 
 
 
1.2.2. Lymph node metastases 
Normal lymph nodes are histologically divided in three regions, the cortex, the intermediate 
area or paracortex and the medulla. The cortex is composed of densely packed lymphocytes, 
organized in spheroid lymphoid follicles and the paracortex of migrating lymphocytes. The 
medulla is composed of three major areas: the medullary trabeculae, medullary cords and 
medullary sinuses (Figure 2). 
 
 
Figure 2: (a) Histological subdivision of normal lymph node in (white double arrow) cortex, (yellow double 
arrow) paracortex, (red margin) medullar sinus, (green arrows) medullar trabeculae and (black arrows) medullar 
cords. (b) Detailed histological image of cortex shows densely packed lymphocytes, partially organized in 
(arrows) lymphoid follicles. 
 
The medullary trabeculae are composed of dense connective tissue and provide a way for the 
blood vessels. The medullary cords are ordered in a parallel pattern and contain mainly small 
lymphocytes and plasma cells (Figure 2). The medullary sinuses are filled with lymph. Lymph 
nodes show a rich vascularity which shows a central or hilar distribution prior to branching in 
the more peripheral areas of the lymph node. 
The likelihood for developing locoregional nodal metastases is dependent of tumour location 
(12). For instance, nasopharyngeal and oropharyngeal carcinoma are associated with a high 
incidence of nodal metastases while glottic carcinoma rarely shows nodal metastatic spread. 
The development of nodal metastases disrupts the normal nodal lymphoid microstructure. 
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Metastatic HNSCC will disrupt the normal follicular structure, increase cell size and lead to 
an increased number of cellular boundaries compared to the normal lymphocytes (Figure 3). 
 
 
 
Figure 3: (a) Histological slide of metastatic lymph node showing metastatic deposit (*) and reactive 
lymphoid tissue (#). (b) Magnified histological image shows clear microstructural contrast between the 
metastatic squamous cell carcinoma consisting of larger cells (*) compared to the lymphoid tissue (#). 
 
Additionally, neovascularisation secondary to tumoral activity is characterized by a shift of 
the vascularisation from the centre to the periphery of the lymph node (13) (Figure 4). 
 
 
 
 
 
 
 
 
 
 
Figure 4: (a) Vascular assessment of normal lymph node (white contour) with color-doppler ultrasound, 
showing a centralized vascularisation (arrow) and fatty hilus (arrowhead). (b) vascular assessment in metastatic 
adenopathy (white contour) shows peripheral distribution of vascularity (arrows). 
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HNSCC shows tendency to develop micrometastatic deposits, especially in oral and 
pharyngeal carcinoma. These are usually defined as intranodal metastatic deposits smaller 
than 3 mm (14). Such small deposits can only be expected to create minimal cellular, 
morphologic, vascular or metabolic alterations to the lymph node environment which makes 
them very difficult to detect prior to treatment. The presence of micrometastases may 
correlate to an increased risk for recurrence and indicate poorer prognosis.  
Extranodular spread is another histological feature that adversely affects prognosis, where the 
tumoral tissue extends through the capsule of the lymph node into the soft tissue of the neck. 
This feature is associated with a high risk for developing distant metastases (15). 
 
1.3 Tumour classification 
HNSCC is staged according to the Tumour-Nodes-Metastasis (TNM) classification of the 
Union Against Cancer and the American Joint Committee on Cancer (seventh edition, 2010). 
The TNM-classification is an anatomical classification system that describes the anatomic 
extent of the primary tumour (T-stage), spread of nodal metastases (N-stage) and presence of 
distant metastases (M-stage). 
The criteria used for T-stage are site-specific. For oral and oropharyngeal tumours, tumour 
diameter is important to determine the T-stage while in the larynx, invasion of laryngeal 
subsites and vocal cord impairment and invasion of the paraglottic space are important 
criteria. Furthermore, the extent of nodal metastases is an important prognostic factor. For 
HNSCC, N-staging of the neck is based on uniform criteria including the size and anatomical 
spread of metastatic lymph nodes. However, in the current classification morphological 
criteria that also hold prognostic value, like extranodal spread, are not included. 
Neck nodal metastases are topographically classified according to the American Academy of 
Otolaryngology Head and Neck Surgery classification (AAO-HNS) (16), where the neck is 
divided in different anatomical levels for localization of nodal metastases. This classification 
bears the advantage that it allows for an accurate and reproducible topographical description 
of nodal disease. A number of specific nodal locations are referred to by their pathological 
name, e.g., supraclavicular, retropharyngeal, parotid, facial, occipital and postauricular. 
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1.4 Treatment 
The most important treatment modalities for HNSCC consist of surgery, radiotherapy (RT) 
and systemic therapy. Recent developments in both treatment modalities aim at an improved 
locoregional control (LRC) with a maximal reduction of therapy-induced damage to the 
surrounding tissue, and maximal preservation of organ functionality (17,18,19). 
For most early stage HNSCC, high cure rates can be achieved with definitive RT or surgery. 
In such patients, treatment choice will be largely influenced by the patient‟s condition, disease 
site, anticipated functional and aesthetic outcome  and long-term quality of life. 
For locally advanced HNSCC, further improvement of LRC has been established with the 
development of concurrent chemoradiotherapy (CRT), cetuximab-radiotherapy and altered 
fractionated radiation schemes (20,21,22). A recent advance, intensity modulated radiotherapy 
(IMRT), allows to shape the three-dimensional dose distribution by varying the beam 
intensity which results in steep dose gradients outside the target and thus a substantial dose 
reduction to the surrounding normal tissues (23). In order to do so, an accurate depiction of 
tumoral tissue at the primary site and lymph nodes is mandatory. 
Recent progress in surgical treatment has also focussed on improved organ preservation. More 
conservative surgical approaches such as laser surgery may raise the question for improved 
nodal staging and risk assessment in order to obviate neck dissection. 
Furthermore, surgery has an important role as a salvage procedure in case of persistent or 
recurrent cancer after CRT. However, a number of issues remain to be dealt with in the 
management of the post-RT head and neck. Depending on the stage and localization of the 
persistent or recurrent tumour, the optimal time window for successful salvage surgery may 
be limited. In hypo- or oropharyngeal cancer, only a limited number of patients with recurrent 
disease may be eligible for salvage surgery (24). This implies that tumour recurrence should 
preferably be detected at an early stage. Also, as modern CRT allows to eradicate nodal 
metastases, the need for a planned neck dissection is questioned. Although adding a planned 
neck dissection improves disease free survival after CRT in patients with extensive nodal 
dissemination at diagnosis, the post-CRT neck dissection often results in negative 
histopathology and may result in significant patient morbidity and mortality (25,26). 
As such, diagnostic modalities should help in the assessment for potential presence of 
persistent nodal metastases to outweigh surgical benefit against its associated risk for the 
patient. 
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1.5 Imaging 
 
1.5.1 Pre-treatment phase 
As HNSCC usually develops as a superficial mucosal lesion, in most cases the primary lesion 
can easily be assessed by clinical examination and histopathology after lesion biopsy. As 
such, except for the detection of tumours of unknown origin or submucosal tumour 
localizations, imaging is rarely used for lesion detection or characterization. However, 
imaging is necessary to determine locoregional tumour or distant metastatic extent.  Imaging 
allows to evaluate local tumoral extension into the deep tissue spaces of the head and neck, 
perineural or intravascular spread which are difficult to assess by clinical examination. This 
information is critical towards treatment management and may be predictive for increased risk 
of later tumour recurrence. Additionally, imaging clearly improves regional staging as it 
allows the identification of clinically non-palpable or non-accessible lymph nodes. 
Computed tomography (CT), and to a lesser extent, magnetic resonance imaging (MRI)  are 
predominantly used in the initial assessment of patients with HNSCC as they simultaneously 
provide detailed information on the anatomical extent of the primary tumour and extent of 
locoregional nodal metastases (27). In laryngeal carcinoma, studies have shown that both CT 
and MRI improved local staging compared to clinical/endoscopic examination alone, more 
specifically in the assessment of invasion of the paraglottic space, the pre-epiglottic space and 
invasion of the laryngeal cartilage and extralaryngeal soft tissues (28,29). The combination of 
clinical/endoscopic examination with CT, respectively MRI reached an accuracy for local 
staging of 80% and 87% compared to 57% for clinical/endoscopic examination alone (29). 
Furthermore, although MRI shows higher sensitivity in detecting neoplastic cartilage 
invasion, it is less specific than CT and tends to overestimate tumoral cartilage invasion (30).  
However, recent reassessment of MRI criteria have significantly improved the specificity of 
the technique for identification of tumoral cartilage invasion (31). 
For detection of nodal metastases, CT and MRI rely on size-related and morphologic criteria 
with overall sensitivities ranging from 54 to 88% and specificities ranging from 39 to 100% 
(32). The main advantage of CT and MRI is that they are routinely available and that 
morphological criteria are highly reproducible. Several size criteria for detecting neck nodal 
metastases have been reported with each cut-off value constituting a compromise between 
sensitivity and specificity. The criterion of 10 mm for short axis diameter, as proposed by van 
den Brekel et al, has now gained widespread acceptance (33). Morphological malignant 
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criteria like necrosis and indistinct margins can improve the detection of nodal metastases. 
However, as these features are rather infrequent in subcentimetric nodal metastases, they 
often fail to provide additional clinically relevant information (34). Therefore, the most 
important shortcoming of anatomical imaging modalities lies in the differentiation of 
subcentimetric lymph nodes. 
Ultrasound (US) may be of additional value for nodal staging in HNSCC. Studies have 
described variable results for US compared to CT and MRI showing respectively higher and 
similar accuracy (32). The main advantages of US are the low cost and widespread 
availability, but as the technique does not allow for evaluation of the primary tumour and 
retropharyngeal lymph nodes, it should be considered as an additional diagnostic imaging 
modality. The potential advantage of US over CT and MRI lays in the higher spatial and 
contrast resolution which allows for a better evaluation of internal lymph node structural, 
abnormalities related to metastatic involvement and the ability to depict tumoral vascular 
alterations (35). However, as these features may be relatively infrequent in subcentimetric 
adenopathies, their added value for discrimination of subcentimetric lymph nodes may be 
variable in HNSCC. 
The accuracy of ultrasonographic nodal evaluation can be increased by adding US-guided fine 
needle aspiration biopsy (US-FNAB). In experienced hands, specificities of 100% can be 
obtained while reported sensitivities range from 42% to 73% in the clinically negative neck 
(32,36). However, it is not clear to what extent US-FNAB may significantly improve nodal 
staging when the head and neck is already evaluated with CT (37). Moreover, as the technique 
is invasive, and the results are observer-dependent, US-FNAB has not gained widespread use 
in the routine evaluation of the patient with HNSCC. 
Fluoro-deoxy-glucose positron emission tomography (FDG-PET) has gained broad attention 
in the pre-treatment evaluation of patients with HNSCC both for the evaluation of primary 
tumour, nodal staging and detection of distant metastases. For evaluation of primary tumours, 
FDG-PET is mainly employed for the detection of unknown primary tumours as prior studies 
have shown that FDG-PET has the ability to supplement clinical examination and anatomical 
imaging in patients with metastatic neck adenopathies of unknown origin (38). For nodal 
staging, FDG-PET has shown superior accuracy compared to CT and MRI (39,40). Despite 
the higher accuracy, the added clinical value for regional staging has not been unambiguously 
shown (41,42). An increased accuracy for detection of nodal metastases will not necessarily to 
higher accuracy on a per patient basis, while the inability to detect micrometastases does not 
allow to omit elective neck dissection. Also, the difficult anatomy of the head and neck, 
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where tumours may arise in areas with high physiological glucose uptake, the rather frequent 
presence of inflammatory lesions or nodal reactivity and the limited spatial resolution of 
FDG-PET may decrease overall accuracy of the technique for locoregional staging. The 
detection of small volume disease remains difficult and is not likely to be obviated by an 
improved anatomical correlation with PET-CT . Nevertheless, PET-CT has been shown to 
improve detection of distant metastases compared to whole-body CT alone and should be 
considered in patients with increased risk for distant metastatic spread (15). 
A relatively new approach for nodal staging consists of ultra small particle iron-oxide 
(USPIO), a novel contrast agent for MRI. USPIO is phagocytised by lymphocytes in normal 
lymph nodes and lack uptake in metastatic intranodal tumoral tissue and therefore allows 
differentiation of benign and metastatic lymph nodes. USPIO-MRI has shown variable 
accuracy for nodal staging in the head and neck (43,44,45). Nevertheless, the increased 
sensitivity compared to anatomical imaging and repeatedly demonstrated high negative 
predictive value (NPV), may improve the diagnostic value for nodal staging and may have an 
impact on therapeutic management.  However, currently, USPIO  is unavailable for clinical 
routine practice. Also, as the contrast agent needs to be injected 24 hours prior to imaging,  
and thus faces potential logistical problems regarding outpatient management. 
 
1.5.2 Post-treatment phase 
The clinical evaluation of  the post-CRT head and neck is difficult due to the presence of 
varying degrees of inflammation, oedema, necrosis and soft tissue swelling or distortion. 
Moreover, post-CRT tumour recurrence and complication like necrosis may show clinically a 
similar presentation. Definite diagnosis based on histopathological examination of biopsies 
may be difficult as a result of sampling error due to the general soft tissue swelling which may 
make the choice of biopsy sites non-straightforward but also because of the difficult 
interpretation of the biopsy specimen as the histological background of post-CRT normal 
tissue may show multiple cellular abnormalities. Moreover, as taking a biopsy may aggravate 
post-CRT necrosis and inflammation; patients should be carefully selected for such 
procedure. Therefore, contrary to the pre-treatment phase, imaging plays a more prominent 
role for lesion characterization next to locoregional staging. 
Similarly as in the pre-treatment setting, anatomical imaging modalities like CT and MRI use 
size-related and morphological criteria for the differentiation of tumour recurrence and a post-
CRT complication in lymph nodes are characterized and primary tumour site. CT has been 
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shown to detect tumour recurrence earlier than clinical examination alone (46). For follow-up 
CT, four months after the end of radiotherapy, an estimated tumour reduction of less than 
50%, recurrent or persistent focal mass with a diameter of more than 1 cm after definitive 
radiotherapy for laryngeal or hypopharyngeal carcinoma indicates a high probability of local 
failure (46). 
Similarly, in the follow-up of treated metastatic lymph nodes, a decrease ratio of more than 
50% measured on CT-imaging at 4 weeks after the end of CRT tends to result in a negative 
hemineck, while a recent report has shown high negative predictive value (NPV) up to 95% if 
a nodal diameter of 1.5 cm and absence of focal lucency were taken into account (47,48). 
However, anatomical imaging criteria are potentially hampered by the CRT-induced swelling 
and distortion of the normal tissue (46,49). For instance, post-CRT necrosis of the normal 
tissue may also present as an ulceration, difficult to differentiate from tumoral recurrence. 
Also, due to the dependence of size-related criteria for nodal staging, anatomical imaging 
modalities are limited in the detection of residual subcentimetric nodal disease or for the 
exclusion of residual disease in persistently enlarged lymph nodes. 
FDG-PET has been shown to provide additional value for detection of post-CRT tumour 
recurrence and higher accuracy for detection of tumour recurrence than anatomical imaging 
modalities, both for the evaluation of the primary tumour site and neck nodes. Sensitivities 
ranging from 50 to 100% and specificities from 67 to 100%  have been reported (50). In the 
post-CRT setting, FDG-PET is hampered by the susceptibility to inflammatory changes and 
low spatial resolution. This may respectively cause false positive and false negative results, 
and diminish the accuracy of the technique, especially in the early post-CRT phase (51). 
Therefore, in the follow-up of head and neck cancer in the post-CRT phase, FDG-PET 
imaging appears less reliable during the first 4 months post-CRT, potentially decreasing its 
value as an early response marker after completion of CRT (50). 
The advent of IMRT, which allows for adaptive irradiation during the treatment, has increased 
the need for predictive imaging during CRT, as this may potentially help to tailor treatment 
regimens to the individual requirements of the patient. In this early response model, 
anatomical imaging modalities are likely to fall short as changes in dimension are usually a 
late treatment effect or do not necessarily show a straightforward relationship with tumour 
response to treatment. Until now, only a limited number of studies have addressed the use of 
FDG-PET imaging during (C)RT and the possibility to use FDG-PET during radiotherapy is 
not entirely clear. Brun et al found that the metabolic response on FDG-PET early during 
CRT for HNSCC correlated with treatment outcome (52). However, the possible induction of 
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tumour hypoxia and inflammation during CRT may interfere with the FDG-uptake in tumoral 
and non-tumoral tissue and decrease the accuracy of FDG-PET during fractionated RT 
(53,54) and potentially inhibits reliable use of the technique. Further research is required, 
possibly by use of dynamic FDG-PET studies, using differences in time activity curves 
between the normal and tumoral tissue. Other traces like (18)F-fluoromisonidazole (18)F-
MISO have currently not clearly shown clinical value for prediction of treatment outcome 
when employed during CRT (55). As a result, until now, no adequate imaging technique is 
available for early response assessment during CRT. 
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1.7 Aims of the study 
The aim of this thesis project is to evaluate whether diffusion-weighted imaging (DWI) and 
dynamic contrast-enhanced (DCE)-MRI, respectively by measuring differences in tissue 
microstructure and tissue perfusion, can be used for tissue characterization, early response 
assessment and post-treatment follow-up in HNSCC. 
In solid malignant lesions, the high microstructural density, leads to a restriction of the 
Brownian or random water molecule movement. Contrary, in benign tissue and necrosis, the 
low or absent microstructural density leads to a facilitation of the random water movement 
due to the lesser interaction with cellular membranes. 
Additionally, the angiogenesis related to tumoral development leads to an altered vascular 
structure and functionality, different from normal tissue or treatment-induced necrosis, in the 
aspect of transtumoral blood flow, capillary permeability and interstitial pressure. 
 
The project will be divided in 4 major projects: 
 
Project 1: In HNSCC, accurate nodal staging is of utmost importance as it has major impact 
on treatment planning and determines patient prognosis. DWI has already been researched in 
a limited number for differentiation of benign and metastatic lymph nodes, be it only in 
enlarged lymph nodes. Until now, results of DWI have not been compared with other imaging 
modalities used for nodal staging of HNSCC. 
The aim of this study is to evaluate DWI for the differentiation of metastatic and benign 
lymph nodes in patients with HNSCC and to determine the added value of DWI in the 
characterization of subcentimetric lymph nodes in comparison to conventional MRI and FDG-
PET. 
 
Project 2: CT is often applied as surveillance imaging modality after CRT for HNSCC. 
Although CT improves the detection of a tumoral recurrence in comparison to clinical 
examination alone, CRT-induced tissue distortions are the cause of false positive en false 
negative findings. This cannot be resolved by conventional MRI as T2- or T1-signal intensity 
(SI) do not show additional value in the differentiation of tumoral tissue. Although FDG-PET, 
has additional value in the differentiation of tumoral recurrence from post-CR inflammation, 
post-CRT inflammation and the low spatial resolution of the technique limit its diagnostic 
accuracy in the post-CRT setting.  The aim of this study is to evaluate DWI and DCE-MRI for 
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the differentiation of post-radiotherapeutic tumour recurrence from inflammation and necrosis 
at the time of clinical presentation. To determine the potential added value, DW- and DCE-
MRI will be compared to CT and FDG-PET. 
 
Project 3:  DW- and DCE-MRI will be evaluated as potential biomarkers for predictive 
imaging during and early after CRT for HNSCC. The project aims to determine the most 
optimal strategy for treatment prediction by comparing both techniques to volumetric 
measurements or morphological criteria. 
The predictive value of DW- and DCE-criteria at these early time points will be correlated 
to LRC, and compared with known predictive parameters, such as initial tumour stage and 
tumour volume. 
 
Project 4: DW- and DCE-MRI rely on quantitative measurements based on manually drawn 
regions of interest (ROI) for  differentiation of tissue composition, respectively vascularity.  
Variability of measurements between different readers may thus influence imaging results 
which may be highly dependent of observer training. 
The aim of this study is to determine the inter- and intra-observer variability in quantitative 
analysis of DWI. 
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Chapter 2: 
Rationale for using functional magnetic resonance 
imaging: probing the tumoral microenvironment 
 
2.1 Diffusion-weighted MRI 
Water molecules are in constant motion, also called Brownian motion (Figure 1). These 
thermal motions lead to random rotations of the water molecules that produce fluctuations of 
the magnetic field. These fluctuations, felt by the hydrogen atoms, result in relaxation. 
Additionally to the random rotations of the molecules, these thermal motions also produce 
random molecule displacements or diffusion (1). 
 
 
Figure 1: Illustration of process of diffusion. Considering a large number of protons in the centre at the start of 
the diffusion time (top left), the random Brownian motion will induce a spread out of the protons over time (top 
right). The bottom left image shows a random path of one proton, while the bottom right indicates the 
mathematical spread function induced by the diffusion in the given time T. 
 
Contrary to water outside the body where the random movement is free, water molecules in 
biological tissues are variably restricted in their motion, inversely correlated to tissue 
cellularity and cell membrane integrity. In biological tissue water molecule displacements 
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occur in and between three major compartments: the intracellular space (IS), the extravascular 
extracellular space (EES) and the intravascular space (IVS).  In solid malignant lesions, the 
EES will be relatively diminished compared to the IS, due to the  high microstructural density, 
consisting of an increased number of cells, cellular pleomorphism, large cell volume and neo-
angiogeneic vessels disorganized in a chaotic structure. This increased microstructural density 
will lead to a restriction of the Brownian or random water molecule movement, due to their 
interaction with the intact cellular membranes and macromolecules. 
Contrary, tissue with low cellularity, like benign lesions or tissues with more pronounced 
necrosis, the EES will be relatively enlarged compared to the IS due to the lower density of 
cells and membranes, or in case of necrosis, the complete absence of any organized tissue 
structures. As such, the lesser interaction with cell membranes will lead to a facilitation of 
random water molecule movement (2) (Figure 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: (a) Low cellularity allows for larger interstitial space, facilitating Brownian movement of water 
molecules (black line represent random trajectory of a water molecule). (b) High cellularity in tumoral tissue 
decreases the interstitial space and increases the surface of cell membranes for interaction with water molecules. 
This leads to a restriction of Brownian or random water molecule movement (black line represent random 
trajectory of a water molecule). 
 
The DWI sequence is made susceptible to the differences in water mobility by pairing two 
equally large but opposite gradient pulses around the 180° refocusing gradient of a standard 
T2-weighted spin-echo (SE) sequence (Figure 3).  
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Figure 3: schematic drawing of echo-planar diffusion weighted sequence. The effects of the paired diffusion 
gradients (blue) are opposed to each other due to the application of a 180° refocusing gradient (red). 
 
The first gradient pulse induces a phase shift of water molecules proportional to its initial 
location while the second gradient pulse rephases the water molecules. If water molecules 
would be static, the rephasing would be complete and not result in a significant loss of SI. 
However, due to the variable random water movement, the rephasing will always be 
incomplete in biological tissues and result in a net signal loss dependent of microstructural 
density  and diffusion sensitivity (2). The diffusion sensitivity to water motion can be changed 
by modulating the gradient amplitude, the duration of the gradient or changing the duration 
between both gradients. However, in practice, the diffusion sensitivity is modulated by the b-
value, which represents the effect of gradient strength on diffusion sensitivity (3).  In standard 
DWI-sequences, consecutive native images with increasing b-values ranging from 0 to 1000 
seconds per square millimetres (s/mm
2
) are used. 
When using low b-values, water molecules with a great diffusion distance are preferably 
depicted (mostly intravascular space), while the application of high b-values allows to 
perceive small diffusion distances and thus restricted water movement in the EES and IS (4). 
By repeating the sequence with consecutive and increasing b-values, the progressive signal 
decay over the images with increasing b-value loss can be quantified using the apparent 
diffusion coefficient (ADC). By plotting the logarithm of the SI on the Y-axis relative to the 
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b-values on the x-axis a slope line can be fitted through the plots (exponential function) from 
which the ADC is calculated using a least squares solution of the following equation: 
 
SIi=SI0 x exp(-bi x ADC) 
 
where SIi is the signal intensity measured on the i‟th b-value image and bi is the     
corresponding b-value. SI0 is a variable that estimates the exact (without noise induced by the 
MR measurement) signal intensity for b = 0 s/mm
2
. As such, the ADC indicates the amount 
of water molecule mobility present in the tissue and in a simplified model shows an inverse 
correlation with tissue cellularity (5). 
Hypercellular tissue, characterized by a limited EES and diffusion restriction, will only show 
limited signal decay with increasing b-value (more complete rephasing due to limited water 
mobility) with a persistent high SI on the native DWI images with high b-value (1000s/mm
2
) 
resulting in a low ADC (Figure 4). Contrary, areas of low cellularity, showing a large EES 
and facilitation of water movement, will show rapid signal decay with increasing b-value 
(incomplete rephasing due to pronounced water mobility) with low or absent SI on the native 
DWI images with high b-value (1000s/mm
2
) resulting in a high ADC (Figure 4). As such 
malignant tissue can potentially be differentiated from benign tissue, or in case of treatment 
follow-up, from necrosis or inflammation based on high b-value SI combined with ADC-
calculation. 
However, as low b-values (0-100 s/mm
2
)
 
are usually included in routine ADC-calculation, 
there will always be an additional but variable influence of microperfusion (flow-sensitive 
ADC) (1,4). A possible solution lies in excluding low b-values (0-300 s/mm
2)
 from the 
calculation for which the non flow-sensitive ADC would more closely reflect true cellularity 
(6,7). However, the exclusion of low b-value factors may not go without penalty as a more 
unfavourable signal-to-noise ratio (SNR) would be introduced, which cannot always be 
sufficiently compensated on currently used clinical MRI-systems at 1.5 Tesla. As benign 
lesions usually show a lack of sufficient SI in the high b-value range, the resulting ADC will 
be decreased due to the low SNR, which is difficult to discriminate from a low ADC caused 
by diffusion restriction in  malignancy. This is of particular importance for head and neck 
DWI where the high amount of air-tissue interfaces and movement may lead to suboptimal 
signal generation. 
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Figure 4: (a) Necrotic centre of rodent rabdomyosarcoma shows substantial  loss of signal (logarithmic curve) 
over consecutive b-values correlating to a high apparent diffusion coefficient (represented by vertical double 
arrow). (b)  Intact tumoral tissue in the peripheral area of the tumour shows only limited loss of signal over the 
consecutive b-values, correlating to a low apparent diffusion coefficient. 
 
Furthermore, signal generation on DWI images does not solely depend on water diffusion but 
also on T2 relaxation time.  An area with very long T2 - usually fluid, possibly in necrosis – 
may show persistent hyperintensity on high b-value images difficult to distinguish from 
hyperintensity related to diffusion restriction. This is called the T2 shine-through effect and 
can hamper qualitative interpretation of DWI images (8). As in head and neck imaging, image 
interpretation routinely consists of lesion detection on a high b-value image in combination to 
ADC quantification, this should  hardly have any influence on diagnostic accuracy (9). 
Potential limitations for application of DWI in the head and neck are artifacts related to 
physiological motion, susceptibility and chemical shift artifacting, which could restrict 
diagnostic accuracy. Improved echo-planar imaging (EPI) technology, use of dedicated coils 
and dedicated sequence optimization enables a maximal reduction of EPI-related artifacts. 
The reduction of these artifacts, in combination with high gradient strength available on 
current MRI-systems, substantially increases the SNR, necessary for the detection of small 
lesions (10). 
A major advantage of DWI, compared to other biological imaging methods, is the lack of 
radiation exposure and the absent need for an extrinsic contrast agent. 
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2.2 Dynamic contrast-enhanced MRI 
The vascular structural changes related to intratumoral angiogenesis lead to a highly altered 
vascular functionality resulting in a heterogeneous and sometimes insufficient transtumoral 
blood flow, increased capillary permeability and increased interstitial pressure compared to 
normal tissue (11). DCE-MRI is acquired by repetitive imaging with high temporal resolution 
over a predefined lesion or anatomical region prior to and during the injection of a low-
molecular gadolinium-based contrast agent (Figure 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Time intensity curve respectively in artery (blue region of interest), metastatic adenopathy (purple 
region of interest) and muscle (red region of interest) at separate time points during the dynamic contrast-
enhanced: (A) prior to contrast injection, (B) early arterial phase, (C) early washout phase, (D) late washout 
phase. 
 
In the arteries, the concentration rises after contrast agent injection and falls back to a steady 
state value before being washed out by the kidneys. In normal tissue and tumoral lesions, the 
contrast agent will leak into the interstitial space at a variable rate and will only be washed out 
when the vessel concentration is very low. The rate of contrast agent leakage into the 
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interstitial space depends on tissue perfusion, vessel wall permeability and the total vessel 
surface area (12). 
The resulting SI‟s acquired by the consecutive sequences over time, or the signal intensity 
curve, hold information about tissue perfusion, tracer uptake and blood volume. Typically, the 
signal intensity curve will show 3 distinct phases: the upslope or rapid arterial enhancement, 
the point of maximum enhancement and delayed washout (Figure 6). 
 
 
 
 
 
 
 
 
 
 
Figure 6: (A) Visualisation of tumoral mass (arrow) in the lower oesophagus consistent with biopsy-proven 
adenocarcinoma. (B) Concentration-time-curve for (full line) arterial input function (AIF) and (dotted line) 
tumour is shown. The typical components of the concentration-time-curve of the tumoral mass consist of (1) 
steep upslope indicating rapid arterial enhancement (initial slope), (2) high point of maximum enhancement 
(contrast-peak) and (3) rapid washout of contrast agent in the delayed phase. 
 
In general, the rate of upslope will predominantly be influenced by tissue perfusion secondary 
to the high blood volume and high first pass extraction. The maximum enhancement will 
predominantly be influenced by the total uptake of contrast agent in the interstitial space and 
the washout will be largely determined by extraction of contrast agent out of the interstitial 
space and will be strongly related to vessel permeability and vessel surface area. 
The dynamic signal enhancement on T1-weighted DCE-MRI can be assessed by semi-
quantitative evaluation of the signal intensity curve or by quantification of the change of 
contrast agent concentration based on pharmacokinetic modelling techniques (13,14). Semi-
quantitative parameters attempt to quantify a certain aspect of the signal intensity-curve, while 
ignoring the information in the rest of the curve. These parameters include the maximal 
contrast enhancement (contrast-peak/c-peak), time to maximal contrast enhancement (time to 
peak/TTP) and the speed of arterial contrast enhancement (arterial slope/AS). They are very 
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robust and easily implemented, facilitating their use in clinical routine. However, semi-
quantitative parameters do not accurately reflect contrast agent concentration in tissues and 
may show variability due to scanner settings and differences in interpatient cardiovascular 
physiology (12). In order to decrease intra- and interpatient variability during treatment 
follow-up, normalization of contrast agent uptake is done by analyzing contrast enhancement 
in a feeding artery and normalizing the tissue measurements to this arterial input function 
(AIF) (15). 
Quantitative analysis is performed on the contrast-time-curves instead of on the signal 
intensity curves. These contrast-time-curves are calculated from the signal intensity curves 
through normalization to the baseline signal intensity, keeping in mind the non-linearity of the 
signal intensity increase with increasing contrast agent concentration. For quantitative 
analysis, the entire contrast-time-curve is fitted by a curve model based on biological 
assumptions, such as blood volume, blood flow or permeability. In most cases, a modified 
two compartment model correlating the tissue tracer concentration to the difference between 
arterial plasma and interstitial fluid concentrations is used (16). Quantitative parameters that 
are increasingly researched include the volume transfer constant of the contrast agent (K
trans
) 
and the rate constant (kep). These parameters provide information that can be linked to 
underlying biologic processes of the vasculature, such as the permeability surface area and 
flow (12). Thus, next to clinical applications, these parameters are more suited than semi-
quantitative parameters for scientific or clinical evaluation of the efficacy of antivascular 
treatment (17). 
However, quantified models are more complex to derive, less robust to noise and more 
susceptible to artifacting secondary to patient or physiological movement, making 
interpretation of the results more difficult. Also, the contribution of intravascular flow to the 
MRI-signal remains unclear and may have variable influence to the accuracy of the models 
depending on the tumour type. For a diffusible tracer, the contribution of the intravascular 
component may be neglected due to the low proportion compared to its distribution volume 
(18). However, this assumption is less accurate for an extracellular tracer as the distribution 
volume will be substantially lower and intravascular flow may possibly contribute more to the 
tissue signal. As such, estimates of kinetic parameters may be less reliable. 
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An intermediate solution to quantify perfusion is the use of the initial area under the signal 
intensity curve (IAUC) or contrast agent concentration curve (12). Using these semi-
quantitative parameters, estimations can be made of the K
trans
 or the leakage space (ve), 
without the difficult calculations inherently linked to fitting biophysical curve models to the 
data. This parameter combines the robustness of the semi-quantitative parameters with the 
easier inter- and intrapatient comparison and lower scanner hardware dependence of the 
quantitative parameters and is currently one of the more promising parameters for clinical 
routine (12,19,20) 
Although DCE-MRI shows value in treatment follow-up and prognosis for several tumour 
types and different non-surgical treatment regimens (21,22,23), one of the major limitations of 
the technique is that it can only act as an indirect marker for tumour tissue viability and may 
have difficulties to depict small residual viable tumoral deposits early after the end of therapy 
(4). 
For perfusion imaging with MRI, different sequences can be used and the type of sequence 
employed will influence the techniques‟ reliability and quality. In extracranial tumours, 
perfusion measurements are usually acquired using a T1-weighted gradient-echo sequence 
with injection of a low-molecular weight Gadolinium based contrast agent. This is in part 
attributable to its robustness, anatomical image quality and relative resistance to image 
artifacting compared to T2*-based perfusion-MRI, whose use is mostly limited to brain 
imaging (24,25). Although T2*-based perfusion imaging has the advantage that it allows 
absolute quantification of perfusion, its sensitivity to motion and susceptibility artifacts (e.g.: 
patient motion, air-tissue boundaries in the bowel) can decrease the reliability of the technique 
substantially for extracranial applications. Other advantages of T1-weighted DCE-MRI are 
the lower amount and injection-rate of contrast agent required and the possibility for coverage 
of sufficiently large scan volumes (such as the entire head and neck) in acceptable time 
resolution. Also, the positive contrast enhancement used in the T1-weighted DCE-MRI is 
more beneficial in the relatively low SNR areas outside of the brain, compared to the negative 
contrast enhancement of the T2*-weighted DCE-MRI. 
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Chapter 3:  
Standardized methodological aspects common to the 
consecutive studies 
 
3.1 Imaging techniques 
 
3.1.1 MRI  
The studies were performed on a 1.5T SONATA Vision MRI-scanner (Siemens, Erlangen, 
Germany) combining a standard head coil and two-channel dedicated surface neck coil. All 
sequences covered the entire head and neck ranging from the skull base to the thoracic inlet in 
order to allow the evaluation of the primary tumour and all nodal stations. The anatomical, 
DCE- and DWI sequences were scanned with identical geometry to allow for identification 
and comparison of corresponding primary tumours and lymph nodes. A transverse T2-
weighted Turbo Spin-Echo (TSE)-sequence was acquired with 44 slices, 4 millimetre (mm) 
slice thickness, 0.4 mm intersection gap, Field of View (FoV) of 20x25 square centimetre 
(cm²), matrix of 291x512, repetition time/echo-time (TR/TE) = 3080 milliseconds (ms)/106 
ms, 2 averages, an echo-train length of 19 and a pixel resolution of 0.7x0.5x4.0 cubic 
millimetre (mm³). The acquisition time was 5‟42”. A transverse T1-weighted TSE-sequence 
was acquired with 44 slices, 4 mm slice thickness, 0.4 mm intersection gap, FoV of 
20x25 cm², matrix of 250x512, TR/TE = 775 ms/8.3 ms, 3 averages, an echo-train length of 9 
and a pixel resolution of 0.8x0.5x4.0 mm³. The acquisition time was 4‟55”. EPI DWI was 
acquired prior to contrast-injection in the transverse plane with 44 slices, bandwidth of 1502 
(Hertz) Hz/pixel, 4 mm slice thickness, 0.4 mm intersection gap, FoV 20x25 cm², matrix of 
104x128, TR/TE = 7100 ms/84 ms, 3 averages and a pixel resolution of 2.0x2.0x4.0 mm³. Six 
b-values were applied (b=0, 50, 100, 500, 750 and 1000 s/mm²). The acquisition time was 
5‟19”. All diffusion-sensitizing gradients were applied in 3 orthogonal directions, combined 
to create a 3-scan trace. An ADC-map was calculated using the built-in manufacturer‟s 
software. 
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Critical to optimize image quality of the DWI; manual shimming was applied in an identical 
way in all patients. The inclusion of moving or air containing anatomical structures within the 
shim box was obviated. As such, the shim box was placed over the spine and muscles of the 
neck (Figure 1). 
 
 
Figure 1: The effect of manual shim-optimization is shown in a representative patient with a large necrotic 
adenopathy in left level 2 (arrows): (A) the shim-box (green grid) is positioned in the area of the spine and 
posterior muscles of the neck, with (B,C) only limited artifacting visible on the b0 and b1000 images. (D) The 
shim-box is erroneously placed on the larynx, resulting in severe fat-shift and distortion artifacts. (E,F) The large 
necrotic adenopathy (arrows) is barely visible on the native b0 images and not visible on the b1000 images. 
 
DCE-MRI was acquired using a three-dimensional T1-weighted gradient-echo sequence with 
fat saturation and consisted of 44 slices, 4 mm slice thickness, 0.4 mm intersection gap, 
22.5x30 cm FoV, TR/TE of 4.3/1.6 ms. Twenty-five runs, each lasting 8.4 s were dynamically 
performed prior to, during and after the injection of a single-dose Gadolinium-
benzyloxypropionictetra-acetate (Gd-BOPTA) (Multihance®, BRACCO, Milan, Italy). The 
T1-weighted sequence was repeated after intravenous administration in all  patients with or 
without fat-suppression. Coronal and/or sagittal T1-weighted sequences with identical 
imaging parameters were applied after contrast agent administration, depending on the 
51 
 
localization of the primary tumour. All TSE-sequences were acquired by means of a partial 
Fourier factor of 5/8. 
 
3.1.2 CT scan 
Contrast-enhanced CT studies of the head and neck were performed, using a multidectector 
scanner (Sensation 16, Siemens, Erlangen, Germany). Collimation was 16x0.75 mm, 
feed/rotation 9.9 mm/s, tube voltage 120 (kilovolt) kV and output (mAseff) of 250. The 
effective slice thickness was 1.5 mm, the reconstruction interval 0.75 mm; adjacent axial and 
coronal slices were reformatted with a thickness of 3 mm parallel to and perpendicular on the 
true vocal cords. 
 
3.1.3 FDG-PET/CT 
Single-section, whole-body, spiral CT (85 mAs, 130 kV, slice
 
thickness 5 mm, table feed 
12 mm/rotation) was performed after
 
intravenous injection of 120 millilitre (ml) of a contrast 
agent containing 300 milligram (mg) iodine/ml. PET-CT images were acquired 60 minutes 
after the intravenous
 
administration of FDG at a dose of 305 millibecquerel (mBq). PET was 
performed with an in plane resolution of 4.6 mm and an axial field of view of 15.5 cm for 
each bed position. PET images were corrected for attenuation using the CT-data. 
 
3.2 Image analysis 
 
3.2.1 DWI 
For all studies, DWI analysis was done on a PACS-workstation (Agfa-Gevaert, Mortsel, 
Belgium). The DWI images were analyzed in a first step by visual inspection of the native 
DWI-images with b-value 0 and 1000 s/mm² (b0- and b1000-images), in order to localize 
lesions at the primary site and lymph nodes. For quantitative assessment, regions of interest 
(ROI) were placed over lesions at the primary site and lymph nodes on the images with b-
value of 0 s/mm² and automatically copied to the other b-value images by the software.  As 
HNSCC has a high propensity for developing necrosis, quantitative assessment should be able 
to assess intralesional  tissue heterogeneity. Therefore, ROI-delineation was guided by SI on 
the b1000 images. Native high b-value images allow to identify the separate tissue 
components. Currently, there is no agreement as to which b-value best delineates intact 
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tumoral tissue from necrosis or background tissue. Therefore, for this study, the native b1000 
images were chosen to identify solid tumoral areas from background or necrosis as it is most 
likely that the suppression of T2 shine through effects in necrosis or fluid containing regions 
is most effective and that the volume of solid tumoral tissue cannot be overestimated due to 
remnant signal in necrotic areas. 
For solid lesions at the primary site and solid sub- and supracentimetric lymph nodes, the 
ROIs were placed over the entire lesion (Figure 2). In the case of obvious solid and necrotic 
components on the DW images, ROIs were placed on the solid tumoral components according 
to their signal heterogeneity on the images acquired by a b-value of 1000 s/mm
2
 (1,2) 
(Figure 3). 
 
 
Figure 2: Regions of interest covers the entire lesion on the b0 image in a solid adenopathy and is 
automatically copied to the consecutive b-value images. 
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Figure 3: Region of interest covers the solid part of the lesion on the b0 image, guided by the hyperintensity 
on the b1000 image in a centrally necrotic adenopathy, and is automatically copied to the consecutive b-value 
images. 
 
To reduce the effect of partial volume artifacts, the lowest size limit for ADC-calculation in a 
lesion was set to a minimal axial diameter of 4 mm. For each lesion, all ROIs were combined 
into a single ROI per lesion for each b-value and the average SI was then calculated for each 
b-value per delineated lesion  (SI of b=0, 50, 100, 500, 750 and 1000 s/mm
2
). The  ADC was 
calculated from this range of b-values as described in paragraph 2.1 with an online calculator 
(Figure 4) developed in our department. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Online calculator used for standardized ADC-calculation in the study 
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3.2.2 DCE-MRI 
The DCE-MRI was analyzed on an off-line workstation using dedicated software (BioMAP, 
Novartis Pharma AG, Basel, Switzerland). 
DCE-MRI images were analyzed in a first step by visual inspection of the fifth scan run 
(arterial enhancement phase), in order to localize primary lesions and lymph nodes.  For 
quantitative assessment, regions of interest (ROI) were placed over primary lesions and lymph 
nodes in these images and were automatically copied by the software to the other dynamic 
runs. Similar as for the DWI-images, in case of obvious solid and necrotic component 
identified by differences in contrast enhancement on the native DCE-MRI images, ROIs were 
placed on the separate tissue portions and the multiple ROIs were analyzed separately in order 
to study the influence of intralesional tissue heterogeneity on the acquired DCE-MRI signal. 
Viable tumoral tissue was identified based on arterial enhancement on the native dynamic 
images. Solid tumoral parts were characterized as arterial enhancing tissue on the fifth scan 
run (arterial enhancement phase) while necrotic tumoral parts did not show early arterial 
enhancement. In case of solid lesions, ROIs were drawn over the entire lesion. For all ROIs, 
the SI on the separate dynamic runs were calculated and evaluated by semi-quantitative 
parameters: AS or  wash-in ratio, washout ratio and c-peak or maximum enhancement. In 
order to normalize the data between the patients, the AIF was calculated out of a ROI on the 
common carotid artery. 
 
3.2.3 CT scan – conventional MRI 
In the studies involving lesion characterization, anatomical imaging data on CT studies and 
conventional MRI were interpreted by qualitative assessment. The CT scans were evaluated 
for tissue changes at the primary site such as tissue asymmetry, presence of a mass and/or 
pathologic contrast enhancement. The nodal status was determined using nodal diameter, 
nodal morphology and contour and the presence of intranodal in homogeneity (3). 
In the studies involving per-treatment follow-up and –prediction, anatomical imaging data 
were analyzed by volumetric assessment. For each identified lesion, contours were drawn 
around the lesion border at each slice position (Figure 5). Subsequently, the volume of each 
lesion was calculated with the following equation: 
(∑surface at each slice position)*(slice thickness+interslice gap) 
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Figure 5: Region of interest delineation in volumetric assessment of primary tumour in the right base of 
tongue. 
 
In the studies involving early post-treatment assessment, primary tumour site and nodal 
analysis was based on scoring systems accepted by literature. For primary lesions, anatomical 
imaging variables included tissue asymmetry or mass (grade 0: no detectable focal 
abnormality, grade 1: anatomic asymmetry or discrete mass < 10 mm, grade 2a: mass > 
10 mm, or 2b, <50% reduction of largest dimension), T2-weighted SI and contrast 
enhancement. CT imaging variables consisted of tissue asymmetry or mass and contrast 
enhancement (4). 
Lymph nodes were evaluated based on diameter (1 cm short axis respectively 1.5 cm long 
axis threshold), presence of intranodal focal defects, focal contrast enhancement or 
calcifications (5,6). 
 
3.2.4  FDG-PET/CT 
In the current setting of the thesis, the clinical FDG-PET/(CT) was only used in the studies 
involving lesion characterization. PET images were qualitatively evaluated. Standard uptake 
value (SUV) is not routinely used at our institution and was not applied for determination of 
PET results. Focal areas of increased FDG-uptake were correlated to the co-registered CT and 
increased uptake of FDG, not related to physiological uptake or treatment effects, was 
interpreted as positive for tumour. 
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3.3 Reference standard 
 
3.3.1 Historadiological correlation and histopathological analysis 
After surgery, the resection specimens of primary lesions were oriented and tagged in the 
craniocaudal and were subsequently sectioned in macroslides oriented along the plane of the 
transverse MRI images. Histopathological analysis of the primary lesions was done by 
haematoxylin and eosin (HE) staining. 
In the neck dissections, the borders of each nodal neck level in the fresh neck dissection 
specimens were carefully delineated and tagged by the surgeon according to the AAO-HNS 
criteria (7) (Figure 6). 
 
 
Figure 6: Separation of nodal stations in different levels according to Standardized neck dissection 
terminology. According to the official report of the Academy's Committee for Head and Neck Surgery and 
Oncology. 
 
This additional orientation of the neck dissection aimed to facilitate the identification of 
separate lymph nodes by means of the borders of each separate neck level. To allow 
identification of small lymph nodes by palpation, the neck dissection specimens were 
subsequently fixated in 5% formaldehyde for 24 hours, which enables palpation of small 
lymph nodes as a firmly consistent structure while surrounding fatty tissue can easily be 
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compressed. Subsequently, the fixated neck dissection specimen was attached to a hardboard 
in order to approach its anatomical configuration. First, the different lymph nodes were 
localized in correlation to adjacent anatomical structures, being the submandibular gland, the 
sternocleidomastoid muscle and the jugular vein. Then, the specimens were axially transected 
in 4 mm transverse sections corresponding to the plane of the T1-weighted images. Per slice, 
the lymph nodes were palpated and progressively dissected from the resection specimen while 
being matched to their corresponding position on the T1-weighted images. Subsequently, each 
lymph node was put in a separate small plastic container, to allow for precise historadiological 
correlation with the co-registered conventional MRI and DWI sequences per lymph node. The 
remaining specimens were then scrutinized by the pathologist for remaining lymph nodes not 
clearly identified on the imaging studies. All lymph nodes were sectioned with 5 μm slice 
thickness every 3 mm. 
Next to HE staining, prekeratine immunohistochemical staining was applied to improve the 
detection of micrometastases, defined as nodal tumour deposits smaller than 3 mm (8). 
 
3.3.2 Follow-up and correlation to long-term treatment outcome 
In case no histopathological specimen could be obtained, imaging results were correlated to 
long-term follow-up. As the majority of locoregional tumour recurrences occur within the first 
2 years after the end of treatment, the 2-year clinical LRC was chosen as primary endpoint. 
Clinical follow-up of the patients was done by radiation oncologists and head and neck 
surgeons in a joint clinic. The first year after irradiation, the patients were seen clinically 
every 2 months; the second to third year every 3 to 4 months; from the third year on, once a 
year. A baseline CT study was performed at 4 months post-CRT. Thereafter, in the absence of 
signs of persistent or recurrent tumour, a CT study was done yearly or at the discretion of the 
treating clinician. As such, 2-year LRC as endpoint was defined by the routinely implemented 
CT study and simultaneous clinical evaluation. Patients did not receive routine neck 
dissections after treatment, although surgery was considered in patients suspect of residual 
nodal disease or primary tumour recurrence. 
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In case of negative biopsy in persistent lesions, clinical and imaging follow-up was continued 
to evaluate lesion evolution and determine further patient management. Complete remission 
(CR) was defined as a persistent clinical complete regression of the primary lesion and 
adenopathies for 2 years follow-up. 
Tumour recurrence was defined as a persisting or recurrent primary lesion or adenopathy 
within the first two years after the end of CRT, consisting of 1) a diameter increase of more 
than 30% or volume increase of ≥ 65% (9) on serial imaging and 2) histopathological proof of 
HNSCC on biopsy and/or surgical specimen. 
 
 
3.4 Estimation of study population size and number of 
patients included 
 
Study 1: lymph node staging –  total included: 33 patients 
Sample size estimation was based on preliminary data (10). The sample size estimations were 
based on a significance level of 0.05 and a power of 0.8, and on the mean differences and 
standard deviations found in the pilot studies. For an average ADC value of 1.20 x 10
-3
 mm
2
/s 
for benign nodes and 0.80 x 10
-3
 mm
2
/s for malignant nodes,  with a standard deviation of 
0.40 x 10
-3
 mm
2
/s, a sample size of 16 patients per group (malignant versus non-malignant) 
was required, or 32 patients in total. 
 
Study 2: Post-chemoradiotherapy tissue differentiation – total included: 26 
patients 
For the unpaired Student‟s t-test, sample size estimation was based on a published small data 
set of our group regarding DWI for the evaluation of the larynx for tumour recurrence after 
radiotherapy (11). The reported ADC values averaged to 0.90±0.09 x 10
-3
 mm
2
/s for 
recurrences and 1.64±0.25 x 10
-3
 mm
2/s for benign tissue alterations. Using α of 0.05, a power 
of 0.8, and a standard deviation of 0.50 x 10
-3
 mm
2
/s, to avoid sample size underestimation 
from the low standard deviation of the small test dataset, at least 8 patients should be included 
in each group (tumour recurrence versus inflammation/necrosis), or 16 patients in total. 
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For the DCE-MRI parameters, no data were available prior to study inclusion. Therefore, a 
difference of 30% between recurrence and benign tissue alterations with a standard deviation 
of 20% was estimated for the DCE-MRI parameters (c-peak, AS, washout). With a 
significance level of 0.05 and power of 0.8 this leads to an sample size estimation of 8 
patients per group (tumour recurrence versus inflammation/necrosis), or 16 in total. 
 
Study 3: Imaging during treatment  – total included: 30 patients 
Study 4: early post-treatment imaging – total included: 29 patients 
For the Mann-Whitney test between lesions with CR and those with later recurrence, sample 
size estimation was performed using an average ADC increase of 50% (50% decrease on 
DCE-MRI) for CR lesions, and 0% change of functional parameters for lesions with later 
recurrence, always compared to their baseline values. For α = 0.05, power = 0.8, and a 
standard deviation of 40% (of baseline value) a sample size of 11 patients per group (CR 
versus later recurrence) was required, or 22 patients in total. 
  
60 
 
3.5 References 
 
1. Razek A, Soliman N, Elkhamary S, Alsharaway M, Tawfik A. Role of diffusion-
weighted MR imaging in cervical adenopathy. Eur Radiol 2006;16:1468-1477 
2. Wang J, Takashima S, Takayama F, et al. Head and Neck lesions: Characterization with 
Diffusion-weighted Echo-planar MR Imaging. Radiology 2001;220:621-630 
3. Castelijns JA, van den Brekel MW. Imaging of lymphadenopathy in the neck. Eur Radiol 
2002;12:727-738 
4. Ljumanovic R, Langendijk JA, Hoekstra OS, Knol DL, Leemans CR, Castelijns JA. Pre- 
and post-radiotherapy MRI results as a predictive model for response in laryngeal 
carcinoma. Eur Radiol 2008;18:2231-2240 
5. Liauw SL, Mancuso AA, Amdur RJ, et al. Postradiotherapy neck dissection for lymph 
node-positive head and neck cancer: the use of computed tomography to manage the 
neck. J Clin Oncol 2006;24:1421-1427 
6. Castelijns JA, van den Brekel MW. Imaging of lymphadenopathy in the neck. Eur Radiol 
2002;12:727-738 
7. Robbins KT, Medina JE, Wolfe GT, et al. Standardizing neck dissection terminology. 
Official report of the Academy's Committee for Head and Neck Surgery and Oncology. 
Arch Otolaryngol Head Neck Surg 1991;117:601-605 
8. van den Brekel MW, van der Waal I, Meijer CJ, Freeman JL, Castelijns JA, Snow GB. 
The incidence of micrometastases in neck dissection specimens obtained from elective 
neck dissections. Laryngoscope 1996;106:987-991 
9. Padhani AR, Ollivier L. The RECIST (Response Evaluation Criteria in Solid Tumors) 
criteria: implications for diagnostic radiologists. Br J Radiol 2001;74:983-986 
10. Vandecaveye V, De Keyzer F, Vander Poorten V, Nuyts S, Hermans R. Diffusion-
weighted magnetic resonance imaging for discrimination of malignant and benign lymph 
nodes in primary head and neck squamous cell carcinoma: preliminary results. 
Radiological Society of North America, RSNA 2005, Chicago, USA; abstract 
11. Vandecaveye V, De Keyzer F, Vander Poorten V, et al. Evaluation of the larynx for 
tumour recurrence by diffusion-weighted MRI after radiotherapy: initial experience in 
four cases. Br J Radiol 2006;79:681-687 
  
61 
 
Chapter 4: 
DWI for differentiation of benign and metastatic 
lymph nodes in HNSCC 
 
4.1 Introduction 
Nodal metastases are an adverse prognostic factor in patients with HNSCC requiring accurate 
detection for optimization of treatment (1). The ability to allow tissue differentiation based on 
changes in T2 or T1 relaxation has been explored for its potential additional value to 
anatomical criteria for lymph node differentiation (3). However, differences in T1 and T2 
relaxation do not allow for reliable differentiation of benign and metastatic lymph nodes. This 
is most likely due to the lack of a straightforward relationship between tissue cellularity and 
T1 or T2 relaxation and technical factors that increase T2- or T1-SI like arbitrary scaling and 
dependence of coil position (4). Therefore, similarly as CT, MRI needs to rely on size-related 
and morphological criteria for nodal differentiation and the technique has generally shown 
similar or slightly inferior results compared to CT (5). 
Efforts are ongoing to increase the accuracy of MRI, by using USPIO or by exploiting 
tumour-induced metabolic, vascular or microstructural changes (6,7,8). A number of prior 
studies have reported on DWI to detect nodal metastases in HNSCC but have mainly focused 
on enlarged lymph nodes while the therapeutic impact lays in the additional detection of 
subcentimetric adenopathy. Moreover, the results of these studies are conflicting regarding 
ADC-values attributed to benign respectively metastatic lymph nodes (9,10,11). 
The aim of this study is to evaluate the value of DWI for the detection of nodal metastases in 
HNSCC. Additionally, DWI will be compared to conventional MRI and FDG-PET in order to 
evaluate the additional value of DWI, especially for the differentiation of subcentimetric 
lymph nodes. 
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4.2 Materials and Methods 
 
4.2.1 Patient selection and study design 
The study was approved by the local ethics committee and all patients gave written informed 
consent prior to inclusion.  From July 2004 to May 2006, 36 patients (age ranging from 48 to 
81 years) scheduled for surgical treatment of biopsy-proven HNSCC were prospectively and 
consecutively included. Patients were included irrespective of clinical T-stage, N-stage, or 
tumour localization (Table 1). The criteria for T-staging of HNSCC depend on the anatomical 
subsite from where the primary tumour originates; it is mainly determined by the size of the 
tumour, depth of invasion and involvement of critical structures, such as the carotid artery. 
The N-staging of HNSCC is determined by the size, number and localisation of the 
adenopathies (12). Two patients had  to be excluded due to conversion to non-surgical 
treatment and one patient because of diagnostic excision of a neck node prior to surgical 
treatment. None of the patients had previously been diagnosed with or treated for head and 
neck cancer. Thirty-three patients underwent conventional MRI and DWI. Additionally, 11 
patients of this group underwent FDG-PET-CT. In none of the patients did major artifacts 
occur in the DWI-sequence requiring exclusion.  
Conventional or TSE-MRI was read blinded from the DWI-images at the time of patient 
inclusion. The time delay between the reading of conventional imaging, topographic 
correlation of the neck dissection specimens and the later blinded reading of the DWI images 
was 18 ± 6 months on average. Similarly to conventional MRI, the FDG-PET-CT 
examinations were read blinded from the other examinations at the time of patient inclusion. 
Histological analysis was performed blinded from patient identity 3 months prior to the 
blinded reading of the DWI images. Historadiological correlation was done after all image 
analysis had been completed. Histopathology, with prekeratine-immunohistochemical staining 
was used as a standard reference. A detailed timeline shows the different methodological 
steps (Figure 1). 
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Patient Primary tumour Histopathology TSE-MRI DWI PET-CT 
Patient 1 Nasal cavity/T2 N2b N2a N2b N2a 
Patient 2 Supraglottis/T3 N2b N2b N2b N2a 
Patient 3 Floor of mouth/T4a N0 N1 N0  
Patient 4 lateral oropharyngeal wall/T3 N2c N2b N2c N2b 
Patient 5 Glottis/T3 N1 N0 N1  
Patient 6 Glottis/T3 N0 N2b N2b  
Patient 7 Supraglottis/T4a N2c N2b N2c  
Patient 8 Oral tongue/T2 N2b N0 N2b  
Patient 9 Glottis/T3 N0 N0 N0  
Patient 10 Glottis/T4 N0 N0 N1 N0 
Patient 11 Base of tongue/T3 N2c N2b N2c N2b 
Patient 12 Glottis/T3 N0 N0 N0  
Patient 13 Oral tongue/T3 N0 N0 N1  
Patient 14 Floor of mouth/T2 N0 N0 N0  
Patient 15 Floor of mouth/T2 N1 N1 N1  
Patient 16 Base of tongue/T2 N2b N2b N2b N2b 
Patient 17 Glottis/T3 N0 N0 N0  
Patient 18 Glottis/T4 N1 N0 N1  
Patient 19 Floor of mouth/T3 N2c N2b N2c  
Patient 20 Oral tongue/T3 N2b N2b N2b N2b 
Patient 21 Oral tongue/T2 N0 N1 N1  
Patient 22 Glottis/T4a N1 N0 N0  
Patient 23 Hypopharynx/T4 N0 N2b N0 N0 
Patient 24 Supraglottis/T3 N1 N0 N1  
Patient 25 Oral tongue/T2 N0 N0 N0  
Patient 26 unknown/TX N2b N2b N2b N2b 
Patient 27 Floor of mouth/T2 N0 N0 N0  
Patient 28 Oral tongue/T4 N2b N2b N2b N2b 
Patient 29 Oral tongue/T2 N2b N0 N2b  
Patient 30 Oral tongue/T4 N2b N2b N2b N2b 
Patient 31 Lateral oropharyngeal wall/T3 N2b N1 N2c  
Patient 32 Floor of mouth/T2 N2b N0 N1  
Patient 33 Floor of mouth/T4a N2c N2c N2c  
 
Table 1: Localization, clinical T-classification and N-staging respectively based on histopathology, turbo-spin 
echo (TSE)-MRI, diffusion-weighted MRI (DWI), and in the patient subgroup for PET-CT of included patients, 
according to the guidelines of the International Union Against Cancer. 
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Histopathology, with prekeratine-immunohistochemical staining was used as a standard 
reference. A detailed timeline shows the different methodological steps (Figure 1). 
 
 
 
 
 
 
 
 
 
 
Figure 1: Timeline detailing the exact set-up of study inclusion and data processing used in this study. 
 
4.2.2 Imaging technique 
All patients underwent the standardized anatomical and DWI-sequences as described in 
chapter 3. MRI imaging covered the entire head and neck ranging from the base of skull to the 
thoracic outlet, and included all regional nodal stations (retropharyngeal space and neck 
levels). 
The 12 patients undergoing FDG-PET-CT were scanned with the standard clinical protocol, 
described in chapter 3. The imaging protocol consisted of a whole body protocol. 
 
4.2.3 Image analysis 
The images of the TSE-MRI, DWI and FDG-PET-CT were interpreted in a blinded fashion. 
The TSE-MRI was interpreted by a head and neck radiologist with 15 years of experience, 
prior to surgery as described in chapter 3.3.3. Lymph nodes were differentiated based on the 
standardized criteria for pretherapeutic nodal characterization as described in chapter 3.3.3. 
The cut-off point for nodal diameter between benign and malignant lymph nodes was set to 10 
mm, according to literature (13,14). Definite diagnosis was made based on the combined 
findings of plain T1-weighted, T2-weighted and contrast-enhanced T1-weighted images. 
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The DWI images were quantitatively interpreted by two radiologists in consensus (both 
4 years of experience in head and neck DWI)  as described in chapter 3.3.1. Nodal status was 
differentiated solely based on the ADC. 
FDG-PET-CT images were qualitatively interpreted by an experienced nuclear medicine staff 
physician as described in chapter 3.3.4. 
 
4.2.4 Topographic correlation and histopathological analysis 
Topographic correlation and histopathological analysis was performed according to the 
standardized methodology as described in chapter 3.4.1. 
 
4.2.5 Historadiological correlation and comparison of different 
imaging modalities 
Historadiological correlation was done after all image interpretation had been concluded. 
Historadiological correlation of DW- and conventional MRI was done per lymph node. The 
optimal threshold for ADCb0-1000 between benign and malignant lymph nodes was obtained 
with receiver-operating-characteristics (ROC). The imaging appearance of benign and 
metastatic lymph nodes on conventional MRI was documented in correlation to nodal size, 
internal contrast enhancement and nodal contour. Subsequently, sensitivity, specificity and 
accuracy of conventional MRI and DWI were calculated. For historadiological correlation, the 
PET-CT images were correlated per level seen the lower spatial resolution and the suboptimal 
settings of full-body CT for detailed evaluation of the head and neck. Levels with pathologic 
lymph nodes were documented and sensitivity, specificity and accuracy were calculated. 
Accuracy per  lymph node for DWI and conventional MRI was compared for all  lymph 
nodes and for supra- and subcentimetric  lymph nodes separately. Accuracy of both 
techniques was compared per level for lymph nodes. Finally, the N-stage obtained with DWI 
and the N-stage obtained by TSE-MRI were compared with the histopathological N-stage. 
In a subpopulation of 11 patients where FDG-PET-CT was performed, FDG-PET-CT, 
conventional MRI and DWI were compared per level and per hemi-neck. The N-stage 
obtained with the three techniques was also compared with the histopathological N-stage. 
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4.2.6 Statistical analysis 
Statistical analysis was done with Microsoft Excel 9.0 (Microsoft Corporation, Washington, 
US) and SPSS 11.0 for Windows (SPSS Inc., Chicago, Illinois, US). Numerical data are 
reported as means
 
 standard deviation (SD). An unbalanced two-way analysis of variance 
(ANOVA) was used to compare the ADC-values of metastatic with benign lymph nodes, with 
ADC-values as the dependent variable, benign/metastatic as independent variable, and the 
patient identifier as blocking factor. The different imaging modalities were compared using 
paired observations and McNemar‟s test. 
 
4.3 Results 
 
4.3.1 Histopathology 
The localization and clinical T-stage of the primary tumours as well as the histopathological 
N-stage per patient is shown in Table 1. There were 13 unilateral neck dissections and 20 
bilateral neck dissections. In total 650  lymph nodes were dissected. Of these 650, 301  lymph 
nodes were identified by DWI, all larger or equal to 4 mm in size. The total number of 
metastatic  lymph nodes was 76 (74 larger or equal to 4 mm and 2 smaller). Ten  lymph 
nodes, all smaller than 8 mm, contained micrometastases. The distribution of metastases per 
nodal size is shown in Table 2. 
 
4.3.2 Historadiological correlation 
 
4.3.2.1 Conventional MRI 
The imaging appearance of metastatic and benign lymph nodes in correlation to nodal size is 
shown in Figure 2. The majority of nodal metastases detected by TSE-MRI were larger than 
1 cm. Three subcentimetric nodal metastases were detected based on aberrant contrast 
enhancement. An irregular nodal contour was only apparent in enlarged metastatic  lymph 
nodes, as well as in a limited number of enlarged benign  lymph nodes. The majority of 
subcentimetric metastatic lymph nodes showed no distinct morphological abnormalities 
indicative of malignancy. TSE-MRI showed 34 true positives (TP), 10 false positives (FP), 
217 true negatives (TN) and 40 false negatives (FN), yielding a sensitivity of 46%, a 
specificity of 96% and an accuracy of 83% per  lymph node. 
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4.3.2.2 DWI 
The ADCb0-1000 was significantly lower for metastatic than for benign  lymph nodes. The 
ADCb0-1000 for benign  lymph nodes was 1.19 0.22 x 10
-3 
versus 0.85 0.27 x 10
-3 
mm
2
/sec for 
malignant (p<0.0001) (Figure 3.a). The optimal threshold of 0.94 x 10
-3 
mm
2
/sec based on 
ROC-analysis (Figure 3.b), resulted in 62 TP, 14 FP, 213 TN and 12 FN, yielding a sensitivity 
of 84%, a specificity of 94% and an accuracy of 91%. 
 
Nodal diameter Number of LN number of metastatic LN Prevalence* 
> 10 mm 42 32 76% 
    
4-9 mm 259 42 16% 
    
< 4mm or undetected on MRI 349 2 0.6% 
* Prevalence calculated as the ratio of metastatic lymph nodes versus total number of lymph nodes in the same 
size category 
Table 2: Pathological distribution of metastases according to nodal size. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Correlation of histologically proven metastatic and benign lymph nodes to their imaging appearance 
on turbo-spin echo (TSE)-MRI. The criteria are: nodal size larger than or equal to 1cm, heterogeneous contrast 
enhancement (CE+) and irregular nodal contour (NC+). Note that the majority of subcentimetric nodal 
metastases does not show any morphological changes indicative of  malignancy. The benign enlarged lymph 
nodes show a variable internal contrast enhancement and nodal contour. 
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Figure 3: Box-whisker plots of apparent diffusion coefficient (ADCb0-b1000) (a) for all lymph 
nodes, (c) lymph nodes larger or equal to 10 mm and (e) lymph nodes ranging from 4 to 9 mm 
between metastatic and benign lymph nodes. ADC-values were significantly lower for metastatic 
than for benign lymph nodes. Box-whisker plots are presented with median (-), interquartile range 
(box) and minima/maxima. Receiver operator curves are shown for ADCb0-1000 (b) for all lymph 
nodes, (d) lymph nodes larger or equal to 10 mm and (f) lymph nodes ranging from 4 to 9 mm. 
Results of turbo-spin echo (TSE)-MRI using a combination of nodal size, morphology and contrast 
enhancement are indicated with a point. Note the markedly higher specificity of DWI for enlarged 
lymph nodes, while the sensitivity is substantially higher for lymph nodes ranging from 4 to 9 mm. 
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4.3.2.3 FDG-PET 
In the subgroup of 12 patients, sixteen levels showed an FDG-avid lymph node corresponding 
to a histologically proven metastasis. Twelve of sixteen lymph nodes were supracentimetric, 
while 4 were subcentimetric, without any internal morphological alterations. Eight levels 
containing histologically proven lymph nodes could not show any FDG-avid lesions. All 
these  lymph nodes were subcentimetric. One level showed an FDG-avid  lymph nodes, which 
was negative on histopathology. Per level, FDG-PET-CT  showed a sensitivity of 67%, 
specificity of 98%, accuracy of 86%, positive predictive value (PPV) of 94% and NPV of 
83%. Additionally, PET-CT indicated 4 lesions suspect for tumour in four separate patients, 
respectively 1 in a mediastinal lymph node, 1 in the lung 2 and 2 in the large intestine. Neither 
of the lesions could be confirmed as a progressive tumoral location after additional 
examinations or during imaging follow-up (colonoscopy, chest CT). 
 
4.3.3 Comparison of DWI and conventional MRI 
 
4.3.3.1 DWI and TSE-MRI per  lymph node and per level 
Overall sensitivity, specificity, accuracy, PPV and NPV per node and per level for both 
techniques are shown in Table 3.  Sensitivity per  lymph node and per level is significantly 
higher for DWI than for conventional MRI (p<0.0001), while no significant difference in 
specificity is found per  lymph node (p=0.66) and per level (p=1). 
 
Per node ADCb0-1000 MRI Per level ADCb0-1000 MRI 
True positive 62 34 True positive 44 27 
False positive 14 10 False positive 6 10 
True negative 213 217 True negative 212 208 
False negative 12 40 False negative 3 20 
      Sensitivity 84% 46% Sensitivity 94% 57% 
Specificity 94% 96% Specificity 97% 95% 
Accuracy 91% 83% Accuracy 97% 89% 
PPV* 82% 77% PPV 88% 73% 
NPV
#
 95% 84% NPV 99% 91% 
* Positive predictive value; 
#
 Negative predictive value 
Table 3: Comparison of apparent diffusion coefficient (ADCb0-1000) with conventional MRI per node  
and level for all lymph nodes with historadiological correlation (size >= 4mm) 
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The differences in N-stage are shown in Table 1. Compared to TSE-MRI, DWI led to a 
correct change in nodal staging in 13/33 patients (39%). Two patients were downstaged from 
N1 to N0. In 4 patients a contralateral metastasis was diagnosed, initially undetected on pre-
operative imaging (Figure 4). 
 
 
Figure 4: (a) Gadolinium-enhanced T1-weighted turbo-spin echo (TSE) images show large left-sided tumoral 
mass (*), centred on the piriform sinus involving the supraglottis and crossing the midline on the posterior 
pharyngeal wall (arrowhead). (b) A small oval-shaped lymph node is seen in level two on the right side, having a 
shortest transverse diameter of 0.6 cm (arrow); this lymph node was considered negative on TSE-MRI. (c) The 
lymph node is hyperintense on the b0 diffusion-weighted image (arrow) and (d) shows only limited loss of signal 
on the b1000 image (arrow), (e)  corresponding  to  an  apparent  diffusion  coefficient  (ADC)  of                  
0.71 x 10
-3
 mm
2
/sec (arrow); these findings are suspect for metastatic adenopathy. (f) Histopathological slice 
with prekeratine staining (magnification factor=150) shows intranodal metastatic deposit (#). 
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Six patients with a pre-operative N0-neck were upstaged: three patients with laryngeal cancer 
to N1 or N2b, two patients with tongue cancer to N2b and one patient with a floor of mouth 
cancer to have an ipsilateral metastasis. In one patient with floor of mouth cancer, a 
contralateral lymph node in level 2 suspect on TSE-MRI was correctly diagnosed as benign 
on DWI, limiting the extent of the  contralateral neck dissection (Figure 5). DWI led to a 
wrong nodal staging in 4/33 patients (12%). Two patients were falsely upstaged from N0 to 
N1. DWI failed to downstage one patient correctly from N1 to N0. One patient was falsely 
upstaged as having a contralateral metastasis. 
 
 
Figure 5: (a-b) Gadolinium-enhanced T1-weighted turbo-spin echo (TSE)-images depict large anterior floor 
of the mouth tumour involving the mandibular symphysis (*). (b) A small, round lymph node (shortest 
transverse diameter of 0.9 cm) with heterogeneous contrast enhancement is noted in level three on the right, 
suspect for small metastatic lymph node (arrow). (c) This lymph node is hyperintense on the b0 diffusion-
weighted image and shows substantial loss of signal (d) on the b1000 image, (e) corresponding to an apparent 
diffusion coefficient (ADC) of 1.4 x 10
-3
mm
2
/sec. These findings indicate a non-tumoral lymph node. 
Histopathological slice with prekeratine staining (magnification factor=120) shows normal nodal architecture 
and absence of metastatic deposits. 
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4.3.3.2 ADCb0-1000 and TSE-MRI in correlation to nodal diameter 
The ADCb0-1000 showed similar sensitivity (p=0.5 per lymph node, p=1 per level) for detection 
of enlarged adenopathies as TSE-MRI but enabled better differentiation of benign enlarged  
lymph nodes, resulting in a higher specificity (p=0.0078 per  lymph node, p=0.5 per level) 
(Table 4, Figure 3.d). For subcentimetric  lymph nodes, DWI showed a significantly higher 
sensitivity than conventional MRI p<0.0001 per  lymph node and per level), at the cost of a 
diminished specificity (p=0.0063 per  lymph node, p=0.125 per level) (Table 4, Figure 3.f). In  
lymph nodes smaller than 4 mm, none of the 2 metastatic nodes were detected, neither by 
conventional nor by DWI. An example of a subcentimetric nodal metastasis, detected by DWI 
is shown in Figure 6. 
 
 
 
ADC >= 10mm TSE-MRI >= 10mm ADC 4-9mm TSE-MRI 4-9mm 
True positive 30 31 32 3 
False positive 2 9 12 1 
True negative 8 1 205 216 
False negative 2 1 10 39 
sensitivity 94% 97% 76% 7% 
specificity 80% 10% 94% 99.5% 
accuracy 90% 76% 92% 85% 
PPV 94% 78% 73% 75% 
NPV 80% 50% 95% 85% 
 
Table 4. Comparison of ADC and TSE-MRI per lymph node size (size >= 4mm). 
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Figure 6: (a) Gadolinium-enhanced T1-weighted turbo-spin echo (TSE)-images show large tumour (*) in the 
left side of the oral tongue, extending over the midline. (b) A normal shaped lymph node with regular contours, 
shortest transverse diameter of 0.8 cm and homogeneous contrast enhancement in ipsilateral level 2 on the left 
(arrow) is considered normal by TSE-MRI. (c) This lymph node is hyperintense on b0 and (d) b1000 diffusion-
weighted image (arrows), corresponding to (e) an apparent diffusion coefficient (ADC) of 0.73 x 10
-3
 mm
2
/sec, 
suspect for metastatic adenopathy. (f) Histopathological slice with prekeratine immunostaining (magnification 
factor=100) shows large solid metastatic deposit diffusely infiltrating in the centre of the lymph node (#). 
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4.3.4 Comparison of DWI, conventional MRI and FDG-PET in 
patient subgroup 
 
Sensitivity, specificity, accuracy, PPV and NPV per level and per  hemineck are shown for the 
three different imaging techniques in Table 5. 
 
 
Per level ADCb0-1000 MRI PET-CT Per Hemineck ADCb0-1000 MRI PET-CT 
True positive 23 18 16 
 
12 10 10 
False positive 1 0 1 
 
1 1 0 
True negative 54 55 54 
 
5 5 6 
False negative 1 6 8 
 
0 2 2 
Sensitivity 96% 75% 67% 
 
100% 83% 83% 
Specificity 98% 100% 98% 
 
84% 84% 100% 
Accuracy 97% 90% 86% 
 
94% 83% 89% 
PPV* 96% 100% 94% 
 
92% 91% 100% 
NPV
#
 97% 87% 83% 
 
100% 83% 83% 
 
* Positive predictive value; 
#
 Negative predictive value 
Table 5: Comparison of apparent diffusion coefficient (ADCb0-1000) with conventional MRI and FDG-PET-
CT per level and hemineck in the subgroup of 11 patients. 
 
Per level, DWI showed higher sensitivity than conventional MRI (p=0.062) and FDG-PET-
CT (p=0.0078). Specificity showed no significant differences among the different techniques.  
DWI correctly upstaged two patients to N2c, staged as N2b by conventional MRI. 
Furthermore, DWI correctly staged 3 patients as N2b of which 2 were staged as N1 by MRI 
and 3 staged as N1 by PET-CT (Figure 7). 
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Figure 7: (a) T2-weighted turbo-spin echo (TSE) image shows heterogeneous adenopathy in level 3 left, 
which shows heterogeneous contrast uptake on the (b) Gadolinium-enhanced T1- TSE image. (c) The lymph 
node is hyperintense on the b1000 diffusion-weighted image and corresponds to an (d) an apparent diffusion 
coefficient (ADC) of 0.84 x 10
-3
 mm
2
/sec, suspect for metastatic adenopathy. (e,f) the lymph node is not visible 
nor shows any FDG-uptake on the inline PET-CT (arrowhead shows streaking artifacts on the CT-image). 
Histological examination showed the lymph node to be obliterated by a partially necrotic metastasis (not shown) 
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4.4 Discussion 
To date, the assessment of neck nodal metastases in HNSCC remains a difficult issue. 
Due to the lack of reliable morphological criteria, anatomical imaging modalities like CT and 
MRI mainly rely on nodal size for detection of metastatic neck disease (15). It should be 
noted that several size criteria for detecting neck nodal disease have been reported, with each 
cut-off value constituting a compromise between sensitivity and specificity. The criterion of 
10 mm for the short axis diameter, as proposed by van den Brekel et al, has now gained 
widespread acceptance and was therefore used in this study (14). 
Morphologically malignant features, such as necrosis or indistinct margins indicating 
extranodal spread, are rather infrequent findings, especially in small (< 10 mm) metastatic  
lymph nodes (4). In our patient group, intranodal heterogeneity and indistinct nodal margins 
were of minimal or no use in the identification of subcentimetric nodal metastases, as these 
were mostly present in enlarged  lymph nodes. Consequently, the high number of small  
lymph nodes most likely accounts for the low sensitivity of TSE-MRI in this study compared 
to literature (16). 
Only a limited number of reports have studied DWI to characterize head and neck lesions and 
discriminate malignant and benign lymph nodes (10,11,17,18). DWI has been shown to 
differentiate malignant from benign lymph nodes with reported sensitivities ranging from 52 
to 98% and specificities ranging from 88% to 97%, be it with different ADC-thresholds 
(10,11). Remarkably and contrary to findings of other studies, Sumi et al found higher ADC-
values for metastatic than for benign  lymph nodes (10). These differences can not solely be 
explained by different b-value settings used for ADC-calculation. Probably, a contributing 
factor for the discrepancy was the high number of necrotic metastatic  lymph nodes included 
in Sumi‟s study. On the other hand, so far, DWI has only been used for characterization of 
enlarged  lymph nodes, while the clinical impact relies mainly in the identification of 
metastases in subcentimetric  lymph nodes. In this study, DWI using the ADCb0-1000 showed 
higher accuracy for detection of metastatic  lymph nodes than TSE-MRI, mainly by 
improving the detection of subcentimetric nodal metastases. The technique also improved the 
identification of benign enlarged  lymph nodes. In the subcentimetric size group, DWI 
showed a sensitivity of 76% for  lymph nodes ranging from 4 to 9 mm, while the sensitivity 
of TSE-MRI dropped to 7%. 
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Several factors allow for detection of small nodal metastases by DWI. Improved EPI 
technology, use of dedicated coils and dedicated sequence optimization enables a maximal 
reduction of EPI-related artifacts at relatively high spatial resolution (19). The reduction of 
these artifacts, in combination with high gradient strength available on current MRI-systems, 
substantially increases the SNR, propagating sufficient signal generation in small lymph 
nodes and reducing the influence of noise in the ADC-calculation. The application of a higher 
number of b-values is likely to reduce the influence of noise propagation on the ADC-
calculation and reduce the risk of motion-related artifacting. 
Moreover, as background tissue is usually suppressed on the native DWI images, the 
conspicuity of small lymph nodes is markedly improved compared to conventional sequences, 
which enables their depiction and subsequent ROI-delineation (20). Finally, the low 
prevalence of necrosis in small nodal metastases makes the inverse correlation with intranodal 
cellularity in a more straightforward way, potentially diminishing the variability of ADC-
values in metastatic lymph nodes. This is likely to decrease the overlap of ADC-values of 
metastatic with benign lymph nodes and improve ADC-based nodal differentiation. 
In our study, metastatic lymph nodes showed a significantly lower ADC than benign lymph 
nodes, corroborating the results of prior investigators (11,17). The decreased ADC most likely 
correlates to the tumoral microstructure, demonstrating a high number of cells, cellular 
polymorphism and increased mitosis. These features probably diminish the EES and decrease 
the ADC (21). However, the equally low ADC seen in partially invaded  lymph nodes 
suggests the presence of additional mechanisms. For instance, keratinisation and peritumoral 
nodal reactivity, may have contributed to the diffusion-restriction (22,23). Although these 
tumour-related changes were seen in a number of histological specimens we did not further 
analyze or quantify them in this study setting. From literature, it is known that keratin impairs 
water movement and therefore this feature – specific for metastases of SCC - may intensify 
the ADC decrease in metastatic lymph nodes (22). Peritumoral reactive changes, as an 
immune response to the tumoral tissue, lead to an increase of peritumoral lymphocytes, 
additionally reducing the EES and further decreasing the ADC (11,17). However, as the 
extent or presence of peritumoral reactivity was highly variable on histopathology, it is very 
likely that this is subordinate to the effect of the tumoral microstructure itself. (23). 
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Nevertheless, as previously described by Wang et al, in benign lymph nodes, falsely 
decreased ADC may correlate with the presence of nodal reactive changes showing multiple 
germinal centres and fibrotic stroma, which act as microstructural barriers (17). In this study, 
this was most apparent in subcentimetric lymph nodes in the proximity of metastatic 
adenopathies, probably as part of a tumour-induced immunological response. Therefore, the 
overall influence on diagnostic accuracy and treatment impact was only minor when the neck 
was staged per level. Nevertheless, falsely decreased ADC due to nodal reactive changes may 
lead to an overestimation of the metastatic burden. This was, in our study, reflected by the 
lower specificity of DWI compared to TSE-MRI in the subcentimetric nodal range. 
Combining DWI with anatomical features indicative of benign nature may help decrease the 
false positive rate (24). Other false positive readings may be due to diffusion restriction in 
recent haemorrhage or hematoma (25,26). Therefore, DWI should probably not be performed 
directly after biopsy. 
In our study, false negative findings in the majority of enlarged lymph nodes were associated 
with diffuse intranodal necrosis, evidently characterized by lack of microstructural barriers as 
reported in prior literature, (9,27). However, the impact on diagnostic accuracy was low as 
native DWI sequences were able to identify small solid metastatic from necrotic depositions 
in most patients (11,28). Although we did not assess the impact on diagnostic accuracy of 
combining DWI with TSE-MRI, the combined use of both imaging techniques should be able 
to avoid the majority of necrosis induced false negative findings, in view of the high 
sensitivity of conventional sequences to depict necrosis (29). Another cause of false negative 
ADC, mainly in small lymph nodes, was an insufficient intranodal metastatic volume. 
Dispersed small deposits in the otherwise normal nodal architecture are less likely to build up 
sufficient tissue boundaries to restrict water diffusion and probably explain the lower 
detection rate of intranodal micrometastatic deposits. 
It might be premature to speculate on the relevant clinical impact of nodal staging with DWI 
in HNSCC as the technique needs to be further refined before it can be used in routine clinical 
practice. The interpretation of DWI in the head and neck is not always straightforward and 
requires training and expertise. Both benign and malignant lymph nodes are hyperintense on 
high b-value images necessitating the use of ADC for nodal characterization (30). As ADC-
maps are difficult to interpret, a quantitative – and possibly more complicated - assessment 
with ROI-analysis is necessary. Therefore, the further development of DWI into clinical 
routine will likely depend on an improved standardization of imaging technique and image 
interpretation (31). 
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Nevertheless, the findings indicate that the degree in which DWI changed the accuracy of 
nodal differentiation by detecting subcentimetric nodal metastases, compared to conventional 
MRI and in the smaller group compared to PET-CT, the technique shows additional value in 
nodal staging and may impact clinical management in specific indications. In tumours 
growing close to the midline or with extensive ipsilateral nodal metastatic involvement, the 
detection or exclusion of metastatic spread to the contralateral neck is pivotal for treatment 
(13,32). The high sensitivity of DWI for contralateral metastases, combined with the high 
NPV allowed for reliable detection or exclusion of contralateral neck disease in mainly small 
lymph nodes. As such, the technique harbours potential value as an ancillary tool to determine 
the required extent of neck dissection in advanced disease stage, but also for radiotherapy 
planning. The increasing ability of functional imaging techniques such as DWI to detect small 
volume disease, raises the question whether remaining tumoral deposits too small for 
characterization may not be effectively treated with de-escalated doses. In this setting, the 
high NPV of DWI appears promising and warrants further research. An improved 
differentiation of nodal metastases may lead to closer conformity between the radiation target 
volume and the regional tumour extent, potentially decreasing the treatment-induced side-
effects. As such, the technique may show future use in the selection and treatment planning 
for unilateral or parotid sparing 3 dimensional conformal RT or IMRT (33,34,35). 
The detection of subclinical skip metastases in nodal level IV by DWI in two patients with 
tongue cancer supports the general reluctance of surgeons in the application of 
supraomohyoid neck dissection in patients with oral cancer, even with clinically N0-neck 
(36). However, given the high sensitivity and high NPV per lymph node and per level seen in 
this study, DWI may help in the selection of patients eligible for limited neck dissection, 
evidently in correlation to the appropriate clinical risk factors and tumoral T-stage (37). 
Whether the technique will enable surgeons to avoid neck dissection in all patients with 
clinically N0-neck is unclear. Although the high NPV may help to decrease the risk of nodal 
metastases to an acceptable level, DWI currently lacks sufficient sensitivity - similar to 
anatomical or metabolic imaging modalities - to avoid elective neck dissections (38). Further 
studies on larger patient groups with N0-neck are therefore warranted. 
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The main – and clinically most relevant - advantage of DWI in this study was the improved 
detection of subcentimetric metastatic lymph nodes compared with conventional MRI and – 
in the smaller subgroup of patients – with PET-CT. The large majority of false negative 
findings on PET-CT consisted of small lymph nodes ranging between 4 and 8 mm for which 
no clear morphological alterations were visible on the inline PET-CT images. As conventional 
MRI showed slightly higher sensitivity than PET-CT, it is likely that part of the lower 
detection rate of smaller lymph nodes could be attributed to the suboptimal CT parameter 
settings of the CT-component of the combined PET-CT studies, hampering the adequate 
detection of subtle morphological alterations suggesting metastatic nodal involvement. The 
sensitivity of PET-CT for small nodal metastases may be improved by using a dedicated PET 
protocol, with a coverage limited to the head and neck region, which may show additional 
value in cases where standard PET is inconclusive (39). However, the accuracy of this 
approach may be diminished by a non-uniform radionuclide uptake in lesions and 
background, potentially diminishing lesion conspicuity, patient movement, which decreases 
lesion detection and causes misregistration with the CT-acquisition. Also, the increased 
sensitivity of dedicated PET-CT may be gained at the cost of a decreased specificity 
compared to standard PET-CT due to the better visualization of FDG-uptake in inflammatory 
lymph nodes (39). 
The findings of the study indicate that DWI could be of complementary value to FDG-PET 
for the detection of small nodal metastases. The high lesion-to-background contrast, ultrafast 
imaging properties which make the technique relatively insensitive to movement are likely to 
facilitate the detection and characterization of small lesions. DWI may help compensate the 
lower sensitivity to small volume disease of FDG-PET. Therefore, the technique may be used 
in conjunction with FDG-PET offering a microstructural correlate to the metabolic findings. 
Evidently comparison of both imaging techniques in larger patient groups will be necessary to 
further compare and elucidate a potential synergistic role of microstructural and metabolic 
imaging in this setting. 
Nevertheless, the application of advanced imaging techniques in the head and neck should be 
judiciously outweighed against clinical indication and relevance. Despite the previously 
reported higher sensitivity of FDG-PET/CT -  not confirmed in this limited study population - 
for detection of non-palpable nodal metastases compared to anatomical imaging modalities, 
its added clinical value has not unambiguously been proved in the pre-operative assessment of 
HNSCC and the same may account for DWI (40,41,42). This is in part reflected by the similar 
accuracy of DWI, PET-CT and conventional MRI for nodal staging per hemineck; although it 
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should be outlined that DWI correctly identified subcentimetric contralateral metastatic lymph 
nodes.  These findings underscore the need of developing advanced imaging techniques, 
either molecular or microstructural, in respect to proper clinical indications and in close 
cooperation with clinicians involved in the treatment of HNSCC. 
There are some limitations to this study. Not all patients received a bilateral neck dissection. 
As such a number of micrometastases in the contralateral neck may have remained undetected 
and eradicated by post-operative radiotherapy. However, in none of the patients receiving a 
unilateral neck dissection did the tumour come near the midline, or was there any indication 
of extensive nodal involvement, nor signs of extranodal spread, which minimized the 
likelihood of contralateral metastases (32). Additionally, potential bias in the image 
interpretation cannot be entirely excluded as 1 radiologist reviewed both conventional MR- 
and DWI images and 1 radiologist performed histological imaging correlation and evaluation 
of the DWI. However, as indicated above and illustrated on the included timeline, careful 
precautions were undertaken to minimize the effects of double reading. Moreover, the results 
of the study suggest that DWI analysis was not biased by the results of conventional MRI as 
DWI detected the majority of metastases in anatomically apparently normal lymph nodes and 
showed a lower false positive ratio in enlarged lymph nodes than TSE-MRI. 
 
 
4.5 Conclusion 
The higher accuracy of DWI based on ADC-calculation for detection of nodal metastases 
compared to conventional MRI -and in a smaller subpopulation- compared to PET-CT, was 
most beneficial for the detection of subcentimetric metastatic lymph nodes. 
This suggests that DWI can be of complementary use to conventional MRI; as size-related 
and morphological criteria lack sufficient reliability for differentiation of small nodal 
metastases in patients with HNSCC, and to PET-CT, for which the lower spatial resolution 
potentially hampers the detection of small nodal metastases. Further studies reproducing the 
promising results on a wider scale and focusing on standardization of imaging technique and 
image interpretation are required before DWI can be used in the routine clinical setting. 
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Chapter 5:  
DW- and DCE-MRI for differentiation of recurrent 
head and neck squamous cell carcinoma after 
chemoradiotherapy: a correlative study to 
histopathology 
 
5.1 Introduction 
At the time of diagnosis, HNSCC usually presents as locoregional disease, for which both 
surgery and CRT are primary treatment options (1,2,3). 
Treatment failure in the head and neck after CRT is mainly related to locoregional tumour 
recurrence, while distant metastases less frequently occur as an isolated event (4).  At the time 
of follow-up, however, clinical or imaging findings are sometimes not straightforward due to 
the difficult differentiation of tumour recurrence and complications like necrosis or severe 
inflammatory alterations. 
The obvious microstructural differential properties between CRT-induced non-tumoral tissue 
changes such as oedema, inflammation, fibrosis, and necrosis and tumour recurrence can be 
expected to produce different imaging properties on DWI and DCE-MRI based on differences 
in tissue cellularity and vascularisation (5,6,7). The purpose of this study was to evaluate DWI  
and DCE-MRI for differentiation of recurrent or persistent tumour from post-radiotherapeutic 
alterations and necrosis, in comparison to routine imaging methods and histopathology of the 
resected specimens. 
 
5.2 Materials and Methods 
 
5.2.1 Patient selection 
Twenty-eight patients (ranging from 49 to 83 years old) with a suspected tumour recurrence 
after CRT for HNSCC (median time of suspected recurrence: 8 months after end of treatment, 
interquartile range (IQR): 6-21) were prospectively included. CRT had been applied 
according to a standardized treatment protocol. Chemotherapy consisted of Cisplatinum, 
100 mg/ml at week 1 and 4 . Radiotherapy was delivered to a total dose of 72 Gray (Gy) 
according to a hybrid fractionation schedule in 28 patients: 20 daily fractions of 2 Gy, 
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followed by 20 fractions of 1,6 Gy twice daily (32 Gy), to a total dose of 72 Gy. Two patients 
were excluded from the study due to lack of histopathological correlation. These two patients 
suffered concurrent metastatic disease and were therefore treated non-surgically. The initial 
tumour localization, staging and treatment are summarized in Table 1. 
 
 
primary tumour prior to therapy Initial treatment 
Patient 1 T4N2bM0 - piriform sinus CRT (70Gray) 
Patient 2 T2N0M0 - left vocal cord RT (70Gray) 
Patient 3 T2N1M0 - supraglottis CRT (72Gray) 
Patient 4 T2N0M0 - supraglottis RT (70Gray) 
Patient 5 T1bN0M0 - glottis RT (55Gray) 
Patient 6 T2N2bM0 - left posterior hypopharynx RT (72Gray) 
Patient 7 T2N0M0 - right glottis RT (70Gray) 
Patient 8 T1N1M0 - left nasal cavity RT (70Gray) 
Patient 9 T2N1M0 - tonsil right RT (72Gray) 
Patient 10 T1N2bM0 - right piriform sinus CRT (70Gray) 
Patient 11 T2N2cM0 - right lateral oropharynx surgery - RT (60Gray) 
Patient 12 T2N2cM0 - right lateral oropharynx RT (60Gray) 
Patient 13 T4N2M0 - right piriform sinus surgery - RT (50Gray) 
Patient 14 T3N1M0 - supraglottis CRT (70Gray) 
Patient 15 T3N1M0 - left base of tongue CRT (70Gray) 
Patient 16 T1N2aM0 - right tonsil neck dissection - RT (50Gray) 
Patient 17 T1N0M0 - right glottis RT (55Gray) 
Patient 18 T1N0M0 - right glottis RT (55Gray) 
Patient 19 T2N0M0 - right tonsil RT (72Gray) 
Patient 20 T3N0M0 - right tonsil RT (72Gray) 
Patient 21 T2N2bM0 - right base of tongue CRT (70Gray) 
Patient 22 T2N0M0 - left glottis RT (70Gray) 
Patient 23 T1N2M0 - right base of tongue neck dissection - CRT (66Gray) 
Patient 24 T2N0M0 - right soft palate RT (72Gray) 
Patient 25 T3N2bM0 - right hypopharynx RT (72Gray) 
Patient 26 T3N2bM0 - left supraglottis CRT (70Gray) 
CRT: Chemoradiotherapy 
RT: Radiotherapy 
Table 1: Initial tumour localization, TNM-staging and treatment in all 26 patients 
 
The remaining 26 patients were selected for salvage surgery based on clinical and radiological 
findings. Routine diagnostic examinations included contrast-enhanced CT in all patients; in 1 
patient, contrast agent injection was not possible because of diabetic nefropathy. FDG-PET 
was performed in 17 patients, and pre-operative panendoscopy with biopsy in 7 patients. A 
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conventional MRI examination with additional DCE-MRI and DWI was added the day before 
surgery in these 26 patients. 
Eighteen patients were primarily investigated for a suspect lesion in the primary tumour bed, 
and 8 for a persistent or recurrent neck adenopathy. One of these 8 patients also underwent an 
endoscopic examination for a clinically suspect supraglottic lesion in the primary tumour bed. 
The result of the histopathological examination of the surgical specimens in 23 patients 
(including one patient with an additional biopsy of the supraglottic lesion during the 
scheduled neck dissection procedure), and bioptic material obtained in three patients 
constituted the reference standard. None of the patients received postoperative re-irradiation 
nor chemotherapy. All patients were followed for at least one year after salvage surgery by 
clinical examination and CT to exclude sampling error or to exclude occult tumour 
localizations in the non-resected areas. After correlation with the histopathological results, the 
sensitivity, specificity and accuracy of DCE- and DW-MRI was calculated. The additional 
value of DWI and DCE-MRI was compared with CT and FDG-PET. 
This study was approved by the local ethics committee, and all patients gave informed 
consent prior to inclusion. 
 
5.2.2 Imaging technique 
All patients underwent the standardized anatomical (CT and TSE-MRI), DWI- and DCE-MRI 
sequences as described in chapter 3. MRI imaging covered the entire head and neck ranging 
from the base of skull to the thoracic outlet, and included all regional nodal stations 
(retropharyngeal space and neck levels). 
The 17 patients undergoing FDG-PET were scanned with a standard clinical protocol, 
described in chapter 3. The imaging protocol consisted of a whole body protocol without co-
registered CT-images. 
 
5.2.3 Image analysis 
The images of the TSE-MRI, CT studies, DWI, DCE-MRI and FDG-PET  were interpreted in 
a blinded fashion. The TSE-MRI and CT studies were interpreted by a head and neck 
radiologist with 15 years of experience, prior to surgery as described in chapter 3.3.3. Primary 
lesions and lymph nodes were differentiated based on clinically accepted criteria for 
characterization with morphologic imaging modalities. The cut-off point for nodal diameter 
between benign and malignant lymph nodes was set to 10 mm, according to literature (8,9). 
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Definite diagnosis was made based on the combined findings of plain T1-weighted, T2-
weighted and contrast-enhanced T1-weighted images. 
The DWI images were quantitatively interpreted by two radiologists in consensus (both 
4 years of experience in head and neck DWI)  as described in chapter 3.3.1. Primary lesions 
and lymph nodes were differentiated solely based on the ADC. 
DCE-MRI images were interpreted by two radiologists in consensus (both 4 years of 
experience in head and neck DWI) with the semi-quantitative parameters as described in 
chapter 3.3.2. FDG-PET images were qualitatively interpreted by an experienced nuclear 
medicine staff physician as described in chapter 3.3.4. 
 
5.2.4 Topographic correlation and histopathological analysis 
Topographic correlation and histopathological analysis was performed according to the 
standardized methodology as described in chapter 3.4.1. 
 
5.2.5 Historadiological correlation and comparison of different 
imaging modalities 
Historadiological correlation was done by one radiologist and pathologist in consensus. For 
DWI, the ADC-values were correlated to the presence of viable tumour, tumour necrosis 
without remaining viable tumour cells, or radiotherapy-induced tissue changes for the 
separate delineated tissue subsites. The same was done for DCE-MRI where the values of AS, 
washout and c-peak were compared to histopathology. 
First an optimal threshold for DWI and DCE-MRI parameters was determined to differentiate 
between HNSCC, tissue necrosis, and post-radiotherapeutic tissue changes, based on ROC-
analysis. Based on these thresholds, sensitivity, specificity, accuracy, PPV and NPV of DWI 
and DCE-MRI using the most accurate parameter for detection of tumoral recurrence at the 
separate delineated tissue subsites were compared. 
Finally, DWI and DCE-MRI were compared with CT and conventional MRI for the entire 
group and with FDG-PET in 17 patients, in order to determine potential additional value. 
For comparison with the anatomical and metabolic imaging results, the DWI- and DCE 
images were averaged per lesion. 
  
91 
 
5.2.6 Statistical analysis 
Statistical analysis was done with Microsoft Excel 9.0 (Microsoft Corporation, Washington, 
US) and SPSS 11.0 for Windows (SPSS Inc., Chicago, Illinois, US). Numerical data are 
reported as means
 
 SD. To compare DWI and DCE-MRI parameters between all tumoral 
ROIs and all non-tumoral ROIs, an unpaired two-tailed Student‟s t-test was used. The same 
was done to compare the results between lymph nodes and primary site. As ADC-values 
cannot be considered as independent, a Bonferroni correction for multiple testing was applied. 
P-values <0.05 were considered as significant. 
 
5.3 Results 
 
5.3.1 Histopathology 
Histopathological material consisted of 10 laryngectomies (with  2 pharyngolaryngectomies), 
2 pharyngectomies, 4 hemiglossectomies, 16 unilateral neck dissections and 6 bilateral neck 
dissections. For one floor of mouth lesion and 2 supraglottic lesions, only histological 
material obtained during endoscopic examination was available. 
Fifteen of 19 suspect primary lesions proved to be positive for cancer; 4 lesions contained 
only post-radiotherapeutic non-tumoral or necrotic tissue. The surrounding tissues showed 
radiotherapy-induced tissue changes or necrosis in all resection specimens without tumour. Of 
all performed neck dissections, eight were performed for a persisting or recurrent lymph node. 
The other neck dissections (11 unilateral and 6 bilateral) were elective dissections performed 
during the resection of a recurrent lesion at the primary site. In total, 16 metastatic lymph 
nodes were found on histopathology in nine different patients. 
At the primary site, the maximal tumour diameter ranged between 5 mm to 30 mm. The nodal 
diameter ranged from 6 mm to 18mm; six metastatic lymph nodes were smaller than 10 mm. 
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5.3.2 Historadiological correlation 
 
5.3.2.1 DWI 
No DWI examinations failed due to artifacting and all examinations were included in the 
analysis. In total 165 ROIs were delineated over tissue subsites, including all target lesions at 
the primary site and nodal stations. 
ADC-values were significantly lower for HNSCC than for non-tumoral post-radiotherapeutic 
tissue (0.00111±0.00029 mm²/s versus 0.00185±0.00035mm²/s; p<0.0001) (Figure 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Comparison of ADC-values between recurrent or persistent HNSCC and post-radiotherapeutic 
benign alterations (post-RT); ADC-value in SCC was significantly lower than in post-CRT normal tissue. ADC-
value shows minimal overlap between SCC and post-RT. Box-whisker plots are presented with median (-), 
interquartile range (box) and minima/maxima (x). 
 
No significant difference was found for the ADC-values and threshold between lymph nodes 
and the primary sites when comparing similar tissue types (HNSCCprimary site versus 
HNSCClymph node ; Post-RT changesprimary site versus Post-RT changeslymph node). The calculated 
optimal threshold for the ADC-value and resulting sensitivities, specificities, accuracies, PPV 
and NPV for all delineated tissue subsites at the primary site and lymph nodes separately are 
reported in Table 2. 
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DWI ADC primary ADC lymph nodes 
True positive at tissue subsite 41 22 
False positive at tissue subsite 3 4 
True negative at tissue subsite 60 32 
False negative at tissue subsite 1 2 
Sensitivity 96% 92% 
Specificity 97% 85% 
Accuracy 97% 88% 
PPV 94% 85% 
NPV 98% 92% 
Threshold 0.0013 0.0013 
Table 2: Comparison of diagnostic performance for ADC based DWI for all delineated tissue 
subsites and for subsites at lymph nodes and primary sites separately. 
 
5.3.2.2 DCE-MRI 
In 3 patients, DCE-MRI examinations were non-diagnostic due to movement artifacting and 
were subsequently excluded from further analysis. 
In total 145 ROIs were delineated over tissue subsites, including all target lesions at the 
primary site and lymph nodes. The AS was significantly higher for HNSCC than for non-
tumoral post-radiotherapeutic tissue at the primary site and in lymph nodes (19.45±18.81 
versus 14.41±10.2; p=0.04), as well as the c-peak (5.07±4.8 versus 2.89±4.9; p=0.008), 
washout ( 0.57±2.02 versus -0.024±1.19; p= 0.03). A significant difference was found 
between the thresholds of all DCE-MRI parameters between lymph nodes and the primary 
sites when comparing similar tissue types (HNSCCprimary site versus HNSCClymph node ; Post-RT 
changesprimary site versus Post-RT changeslymph node)  (p< 0.0001 all DCE-MRI parameters). 
The calculated optimal thresholds for the separate DCE-MRI values and resulting 
sensitivities, specificities, accuracies, PPV and NPV for all delineated tissue subsites at the 
primary site and lymph nodes separately are reported in Table 3. 
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DCE-MRI 
 
Primary site 
 
 
c-peak arterial slope washout 
True positive at tissue subsite 29 34 24 
False positive at tissue subsite 11 9 26 
True negative at tissue subsite 40 42 25 
False negative at tissue subsite 11 6 16 
Sensitivity 73% 83% 60% 
Specificity 78% 82% 49% 
Accuracy 76% 82% 54% 
PPV 73% 79% 48% 
NPV 78% 86% 61% 
Threshold 3.15 14.79 -0.44 
    
    DCE-MRI 
 
          Lymph nodes 
 
c-peak arterial slope washout 
True positive at tissue subsite 14 16 12 
False positive at tissue subsite 9 15 14 
True negative at tissue subsite 25 19 22 
False negative at tissue subsite 6 4 8 
Sensitivity 70% 80% 60% 
Specificity 74% 56% 59% 
Accuracy 72% 65% 59% 
PPV 61% 52% 46% 
NPV 81% 83% 71% 
Threshold 2 7.5 -0.01 
 
Table 3: Comparison of diagnostic performance for the separate DCE-MRI parameters for the  
delineated subsites at lymph nodes and primary sites separately. 
  
95 
 
5.3.3 Comparison of DWI with CT/conventional MRI and FDG-
PET 
When compared with CT and TSE-MRI in all patients (Table 4), DWI correctly characterized 
two persistent enlarged lymph nodes in two different patients and one enlarged lymph node 
(13 mm) in one patient with a tumour recurrence at the primary site as non-tumoral. 
Consequently, these patients were downstaged to N0 (Figure 2). 
 
 
 
 
 
 
 
Figure 2: (a) CT scan shows lymph node short axis diameter of 1.2 cm in level II in the right neck; (b) on 
DW-MRI this node shows no substantial signal on the b1000-image, (c) while on ADC-map this node is 
hyperintense (ADC = 0.00180 mm²/sec) suggesting absence of tumour tissue; (d) histology showed presence of 
lymphoid tissue (*) and partially necrotic and sclerotic stroma (#) and excluded tumour. 
 
DWI detected an additional contralateral subcentimetric nodal metastasis (6, 8 and 8 mm 
diameter, respectively on CT/conventional MRI) in 3 different patients (Figure 3), and two 
additional nodal metastases (7 and 9 mm diameter, respectively on CT/conventional MRI) at 
the ipsilateral site in one other patient. 
A persistent contrast-enhancing ulcer in the base of tongue, visualized on CT/conventional 
MRI, was correctly identified as non-tumoral by DWI (Figure 4). 
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Figure 3: (a) CT scan shows supraglottic tumour recurrence after (chemo)radiotherapy (small arrows); (b) no 
enlarged lymph nodes were visible, however a lymph node (arrowheads) with a diameter of 6 mm is visible in 
level III on the right, possibly showing subtle rim enhancement; (c) this node shows no tracer uptake on FDG-
PET; (d) Contrast-enhanced MRI confirms the presence of the small lymph node; (e) on DW-MRI the node is 
hyper-intense on the b0-image and shows nearly no signal loss on the b1000-image; (f) low signal is seen on the 
ADC-map; (g) corresponding to an ADC of 0.00089 mm²/sec, indicating diffusion restriction, suggestive for 
lymphatic metastasis; (h) histology confirmed the presence of metastatic SCC in this subcentimetric lymph node 
(arrowheads). 
 
In one case of laryngeal necrosis, depicted as an enhancing ulcerated mass on conventional 
MRI, DWI correctly predicted absence of tumour. 
When compared with FDG-PET (Table 4) (17 patients), DWI correctly excluded tumour in 2 
hypermetabolic lymph nodes in two different patients. In one patient, DWI correctly excluded 
tumour in a hypermetabolic lymph node and a concurrent hypermetabolic spot in the 
ipsilateral piriform sinus. DW-MRI correctly identified a subcentimetric contralateral nodal 
metastasis which showed no FDG-uptake, in 2 different patients (Figure 3). 
Also, tumour was excluded in two isolated hypermetabolic lesions at the primary site, in the 
base of tongue (Figure 4) and larynx respectively, in 2 different patients. 
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Figure 4: (a) Increased FDG-uptake in the base of tongue on the left side, corresponding to persisting left 
glossotonsillar ulcer on (b) post-contrast T1-weighted TSE-image suspect for persisting tumour 6 weeks after 
end of CRT; on DW-MRI, no substantial signal is visible on the (c) b1000-image, while the (d) ADC-map shows 
a hyperintense appearance of the ulcer (ADC = 0.00167 mm²/sec) excluding the presence of restrictive tissue 
such as HNSCC. (e) Histology confirmed the absence of HNSCC on the histological macroslide. (f) 
Magnification view shows limited necrosis (arrows) in the ulcer with adjacent inflammatory cells (arrowheads). 
 
DWI showed false positive findings in 4 subcentimetric nodes adjacent to a metastatic node in 
two separate patients, and in one subcentimetric lymph node in another patient. CT, TSE MR-
images, and FDG-PET were negative for these lymph nodes. Histologically, these lymph 
nodes showed reactive changes, with loss of normal follicular structure and presence of giant 
cells. DW-MRI showed no false positive findings at the primary sites. 
DWI failed to identify 2 lymph nodes containing micrometastases (< 3 mm); none of these 
adenopathies were identified by the other imaging modalities. 
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5.3.4 Comparison of DCE-MRI to CT/conventional MRI and 
FDG-PET 
When compared with CT and TSE-MR (Table 4) (23 of 26 patients) DCE-MRI correctly 
characterized 2 persistent enlarged lymph nodes in 2 separate patients as non-tumoral. A 
persistent contrast-enhancing ulcer in the base of tongue, visualized on CT/conventional MRI, 
was correctly identified as non-tumoral by DCE-MRI. In one case of laryngeal necrosis, 
depicted as an enhancing ulcerated mass on conventional MRI, DCE-MRI correctly predicted 
absence of tumour. In one patient with a recurrence at the primary site DCE-MRI correctly 
detected an ipsilateral nodal metastasis (Figure 5). 
Compared to FDG-PET (Table 4), (15 patients), DCE-MRI correctly excluded tumour in 
2 hypermetabolic lymph nodes in two different patients and correctly downstaged one patient 
with a primary tumour recurrence FDG-avid ipsilateral adenopathy to N0. Also, tumour was 
excluded in two isolated hypermetabolic lesions at the primary site, in the base of tongue and 
larynx respectively, in 2 different patients (Figure 6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: (a) T1-weighted TSE-image, (b) T2-weighted TSE-image and (c) Gadolinium-enhanced T1-
weighted TSE-image shows non-enhancing 8 mm lymph node within level II left (arrows). (d) Perfusion map 
depicting the arterial slope show increased arterial enhancement,  suspect for metastasis. Metastatic involvement 
of the lymph node was histologically confirmed. 
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Figure 6: (a) Transverse CT image shows diffuse thickening and contrast enhancement of the false vocal 
cords, without focal nodular mass. Small air bubble adjacent to the right arytenoid can be appreciated (arrow). 
(b) Transverse FDG-PET image shows tracer uptake at the laryngeal level (arrow). (c) Contrast-enhanced T1 
weighted MR image show diffuse thickening and contrast enhancement of the false vocal cords, without focal 
nodular mass. (d)  Perfusion map depicting the arterial slope  shows no focal areas of accelerated arterial contrast 
uptake. (e) No asymmetric hyperintensity is revealed by b1000 and (f) the ADC map shows diffuse 
hyperintensity of the soft tissues at the same level. Histological examination showed granulation tissue and 
inflammatory infiltrate (image not shown). 
 
Contrary, DCE-MRI was false negative for three necrotic recurrent tumour at the primary site. 
Furthermore, DCE-MRI failed to detect subcentimetric nodal metastases in 4 separate 
patients, including metastatic disease at the contralateral neck. DCE-MRI falsely upstaged the 
ipsilateral neck in two separate patients with a recurrence at the primary site. 
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Patient CT/MRI FDG-PET DWI DCE-MRI Histology Lesion size 
Patient 1 4 months      
primary NA NA NA NA NA NA 
lymph nodes 1(+) 1(+) 1(+) 1(+) SCC > 1.5 cm 
Patient 2 6 months      
primary + + + - SCC 0.4x0.5 cm 
lymph nodes right - - - - post-RT < 1.5 cm 
lymph nodes left - - - 1 post-RT < 1.5 cm 
Patient 3 6 months      
primary NA NA NA NA NA NA 
lymph nodes 1(+) 1(+) - - post-RT >1.5 cm 
Patient 4 12 years      
primary + + + + SCC 3x4 cm 
lymph nodes NA NA NA NA NA NA 
Patient 5 13 years      
primary + + + + SCC 2.1x1 cm 
lymph nodes right - - - - post-RT <1.5 cm 
lymph nodes left - - - - post-RT <1.5 cm 
Patient 6 7 months      
primary NA NA NA NA NA NA 
lymph nodes 1(+) NA 2(+) 1(+) SCC (4) >1.5 cm 
Patient 7 4 months      
primary - + - - post-RT 1.5x1.5 cm 
lymph nodes NA NA NA NA NA NA 
Patient 8 8 months      
primary NA NA NA NA NA NA 
lymph nodes 1(+) 1(+) 3(+) 2(+) SCC (1) >1.5 cm 
Patient 9 7 years      
primary NA NA NA NA NA NA 
lymph nodes 1(+) NA 1(+) - SCC (1) 1-1.5 cm 
Patient 10 10 months      
primary - + - NA post-RT 0.9x0.9 cm 
lymph nodes 1(+) 1(+) - NA post-RT >1.5 cm 
Patient 11 3 months      
primary + + + + SCC 0.9x1 cm 
lymph nodes NA NA NA NA NA NA 
Patient 12 6 months      
primary NA NA NA NA NA NA 
lymph nodes 1(+) 1(+) 1(+) - SCC (1) 1-1.5 cm 
Patient 13 7 years      
primary + + + + SCC 3.2 x 1.8 cm 
lymph nodes - - - - post-RT <1.5 cm 
Patient 14 12 months      
primary + + + - SCC 2.7x1.6 cm 
lymph nodes right - - 1(+) - SCC (1) <1 cm 
lymph nodes left 2(+) 2(+) 2(+) 2(+) SCC (2) > 1.5 cm 
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Patient 15 7 months      
primary + + - - post-RT 1.4x1.2 cm 
lymph nodes - - - - post-RT < 1cm 
Patient 16 4 years      
primary + + + + SCC 0.9x0.9 cm 
lymph nodes NA NA NA NA NA NA 
Patient 17 3 months      
primary + NA + + SCC 1.5x2 cm 
lymph nodes - NA - 1(+) post-RT < 1 cm 
Patient 18 7 months      
primary + NA + + SCC 1.7x0.9 cm 
lymph nodes - NA 1(+) 4(+) post-RT < 1 cm 
Patient 19 11 months      
primary + + + + SCC 2.3x2.4 cm 
lymph nodes - - - - post-RT < 1 cm 
Patient 20 6 weeks      
primary + NA + + SCC 1.1x1 cm 
lymph nodes - NA - - post-RT < 1cm 
Patient 21 9 months      
primary + + + - SCC 4.1x3.2 cm 
lymph nodes - - - - post-RT < 1 cm 
Patient 22 10 months      
primary + NA - NA post-RT 2x1.5 cm 
lymph nodes right - NA - NA post-RT <1cm 
lymph nodes left - NA - NA post-RT <1cm 
Patient 23 4 years      
primary + + + + SCC 2.5x2.8 cm 
nodes - 1 - - post-RT < 1cm 
Patient 24 10 months      
primary NA NA NA NA NA NA 
nodes 1(+) 1(+) 1(+) 1(+) SCC <1.5 cm 
Patient 25 8 months      
primary + + + NA SCC 1.3x1.8 cm 
lymph nodes right 1(+) 1(+) 1(+) NA SCC (1) < 1.5 cm 
lymph nodes left - 1(+) 1(+) NA SCC (2) < 1 cm 
Patient 26 6 months      
primary + + + + SCC (1) 2.1 x 2.1 cm 
nodes right - - 3(+) - SCC (1) < 1 cm 
nodes left - - -                 -  post-RT < 1 cm 
SCC: tumour recurrence; Post-RT: post-radiotherapy benign changes 
+: scored as tumour recurrence by imaging modality 
-: scored as benign by imaging modality 
NA: not applicable 
Table 4: Comparison of CT/TSE-MRI, FDG-PET and DW-MRI and DCE-MRI in correlation to 
histopathology. 
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5.4 Discussion 
In this study, recurrent HNSCC at the primary site and in lymph nodes showed a significantly 
lower ADC and significantly higher AS, c-peak and washout than post-CRT non-tumoral 
tissue. 
Similarly as for other tumour types, the significant difference in ADC between recurrent 
HNSCC and non-tumoral post-CRT tissue is most likely attributable to differences in tissue 
cellular density and volume of the interstitial space. This is confirmed by the 
histopathological findings in our study. In the resection specimens, HNSCC consisted of large 
cells, ordered in girdle-like hypercellular microstructures. Similar to previous animal and 
clinical studies, the presence of HNSCC correlated significantly with low ADC-values 
(10,11). This low ADC is thought to be caused by the restriction of proton movement in the 
EES secondary to tumour hypercellularity (12). 
Contrary, the non-tumoral post-CRT areas showed higher ADC which correlated 
histologically to necrosis, fibrosis and inflammation which correlated to an increased 
interstitial space and low cell density on histological slices (13). These changes diminish the 
number of microstructural barriers and, thus, facilitate the tissue free water movement, 
leading to an increased ADC when compared with tumoral tissue. 
DCE-MRI aims to distinguish malignant from benign or normal tissue by exploiting 
differences in contrast agent behaviour in their respective microcirculations. Of all used semi-
quantitative parameters, the AS showed highest accuracy for differentiation of lesions at the 
primary site and lymph nodes. The AS or rate of upslope is predominantly influenced by 
blood volume and first pass extraction of contrast agent (14). The higher accuracy of the AS 
appears to be in agreement with a prior study that showed early arterial phase enhancement  in 
HNSCC (7). 
Nevertheless, the underlying microstructural substrate for differences in dynamic 
enhancement patterns are not entirely clear. A variable correlation of T1-kinetic parameters 
with MVD has been found in several tumour types (15,16). For HNSCC, only limited data are 
available. In a study performed by Guckel et al, a correlation was found between dynamic 
enhancement patterns of nodal metastatic HNSCC, with a higher micro vessel density (MVD) 
for nodal metastatic HNSCC compared to non metastatic lymphoid tissue (17). Vessel 
permeability and vascular endothelial growth factor (VEGF) may have an additional role in 
determining the MRI signal enhancement as a correlation has been shown between VEGF-
expression and vascular permeability estimated by the kep (18). Other factors that have been 
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correlated with enhancement patterns include the degree of stromal cellularity, fibrosis and 
tissue oxygenation (7,19). Ultimately, the significant difference in enhancement between 
tumoral and non-tumoral sites in this study may reflect differences in tissue cellularity. As 
such, the absence of tumoral tissue in non-tumoral post-CRT tissue will lead to vascular 
compromise due to insufficient neo-angiogeneic acitivity. 
When compared, DWI showed higher accuracy than DCE-MRI for differentiation of tumour 
recurrence from post-CRT non-tumoral tissue. Several factors may attribute to the observed 
differences in diagnostic accuracy. One of the major limitations of DCE-MRI is that it does 
not enable direct visualisation of viable and necrotic tumoral tissue portions (20). Although 
the tissue perfusion correlates to a certain degree with the presence of malignancy, the overlap 
with perfusion rates in non-tumoral tissue changes, such as inflammation, may cause loss of 
specificity of the technique. Especially in the early post-CRT phase, inflammation and nodal 
reactivity may be responsible for an accelerated arterial perfusion, making the differentiation 
with post-treatment recurrence particularly difficult (7). Similarly as in this study, this may 
generate false positive findings in persistent lesions after the end of CRT, but may also lead to 
failed detection of  small tumoral remnants, masked by the early and strong enhancement in 
the surrounding inflammatory tissue. Contrary, in highly necrotic lesions, vascularity may be 
compromised related to insufficient tumoral load, leading to erroneously low perfusion 
values. In this study,  this led to false negative findings in 3 large recurrent primary tumours. 
On the other hand, the evaluation of partially necrotic or small lesions by DCE-MRI may be 
difficult due to the lower lesion-to background contrast and the inability to adequately 
differentiate small solid from necrotic intratumoral areas. This may lead to inaccurate ROI-
delineation with the potential inclusion of surrounding normal tissue or necrotic areas in the 
ROI, which may adversely affect imaging results (21). 
Contrary, for DWI, as inflammation is expected to increase expansion of the interstitial space 
due to tissue congestion, the contrast with diffusion restrictive or tumoral areas is likely to be 
more pronounced and intensify differences in ADC between tumoral and non-tumoral tissue 
areas. This may in part explain the higher accuracy of DWI in this study and the higher mean 
ADC-values for non-tumoral lesions, when compared with previous DWI studies in the head 
and neck, which were performed on non-irradiated patients (11,12,22). 
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Furthermore, the ability of DWI to asses spatial tissue heterogeneity and separate intratumoral 
viable and necrotic tumoral areas as small as 4 mm, combined with the signal suppression of 
the surrounding non-tumoral tissue normal, may also have contributed to the higher accuracy 
of DWI (23).  The subsequent improved  conspicuity of small solid tumoral lesions, as seen in 
prior studies, may have improved lesion detection and ROI-delineation compared to DCE-
MRI and probably explains the lower false negative ratio for partially necrotic tumoral lesions 
and small nodal metastases. 
Finally, another issue that may explain the lower sensitivity for small nodal metastases by 
DCE-MRI is the variability in blood flow and size of extravascular extracellular space 
between normal lymphoid tissue and metastatic HNSCC, which may result in considerable 
overlap between semi-quantitative perfusion parameters of benign and metastatic lymph 
nodes (24,25). It remains important to note however, that despite the high accuracy of DWI 
for differentiation of post-CRT nodal HNSCC, nodal reactivity was the main cause of false 
positive findings of DWI and correlation with anatomical nodal features may be necessary to 
improve proper differentiation. Similarly as in the prior study of this thesis, these lymph 
nodes occurred mainly adjacent to metastatic lymph nodes, which limited the impact on 
diagnostic accuracy. 
When compared to CT/TSE-MRI and/or FDG-PET, both DWI and DCE-MRI decreased the 
false positive ratio rate for persistent lesions at the primary site and persistent nodal disease in 
the post-RT period. DWI and to lesser extent DCE-MRI provided additional information to 
more correctly characterize non-tumoral persistent ulcers, persistent enlarged lymph nodes or 
hypermetabolic lesions caused by inflammation. On FDG-PET examinations, inflammatory 
cells contribute substantially to the uptake of FDG, making them a major cause of false 
positive findings in the early post-RT phase (26). The presence of inflammatory cells, as 
histopathologically identified, did not correlate with decreased ADC-values. Most probably 
their small cell size, compared to HNSCC, cannot compensate for the increased water 
mobility in inflammatory tissue or oedema. 
Additionally, unlike DCE-MRI, DWI improved the detection of subcentimetric nodal 
metastases compared to CT/TSE-MRI and FDG-PET. At our institution, in case of a local 
recurrence, an ipsilateral neck dissection is routinely performed, to eradicate potential 
micrometastases (27). Nevertheless, DWI may be of clinical interest by limiting the extent of 
neck dissection in such patients, or by selecting patients more adequately for contralateral 
neck dissection. Further studies in a larger population are needed to address this specific 
issue. 
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Persistent lesions at the primary site, the difficult differentiation of laryngeal necrosis from 
recurrence or the presence of a persistent adenopathy after radiotherapy may cause a 
diagnostic and therapeutic dilemma. While invasive procedures – potentially leading to 
iatrogenic complications - and unnecessary surgery should be avoided, delay of treatment 
holds the risk of disease progression, eventually depriving the patient from salvage treatment. 
DW-MRI, showing a high accuracy for tissue differentiation in the post-RT phase 
independently from inflammatory or necrosis-induced tissue distortions, can provide 
complementary diagnostic information in the non-invasive assessment of the post-RT head 
and neck. As such DWI may help in the timely selection of patients towards surgery or 
conservative treatment. Although DCE-MRI may show additional value in the correct 
differentiation of persistent non-tumoral lesions at the primary site and persistently enlarged 
non-tumoral lymph nodes, the false negative findings in partially necrotic tumours and the 
inability to detect subcentimetric nodal metastases probably limits the value of the technique 
as a single modality in the post-CRT setting. 
 
5.5 Conclusion 
 
In this patient group, DWI showed additional value for detecting or excluding persistent or 
recurrent HNSSC after CRT and for detection of subcentimetric nodal metastases. Although 
DCE-MRI helped in the correct differentiation of persistently enlarged non-tumoral lesions, 
the lower accuracy for differentiation of partially necrotic tumours and subcentimetric nodal 
metastases limits the additional value and excludes its role as a standalone diagnostic tool in 
the post-CRT evaluation of the head and neck. 
The ability to investigate the tissue micro-structure non-invasively, based on proton 
movement, opens a potential novel approach in the evaluation of the post-radiotherapeutic 
neck, complementary to currently used imaging modalities. The applied DWI technique 
allows a comprehensive evaluation of the entire head and neck region. Further studies are 
required to evaluate this technique for treatment monitoring during and after radiotherapy and 
its potential to influence patient management. 
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Chapter 6:  
Value of DW- and DCE-MRI as imaging biomarkers 
during chemoradiotherapy of head and neck 
squamous cell carcinoma 
 
6.1 Introduction 
Currently, bio-adaptive treatment strategies such as IMRT, the addition of radio-sensitizers or 
targeted agents are increasingly researched and introduced in clinical applications (1,2,3). 
Cure rates and patient survival may be further improved by adapting the non-surgical 
treatment scheme to the individual patients treatment response. Therefore, early diagnostic 
biomarkers are warranted (4). 
Studies in abdominal, breast and brain tumours have shown a correlation of pre-treatment 
ADC, DCE-parameters and ADC- and DCE-changes early after non-surgical treatment with 
final treatment response (5,6). In a study in an orthotopic HNSCC mouse model, DWI 
allowed early evaluation of treatment response during chemoradiation (7). The aim of this 
prospective study in locally advanced HNSCC was to evaluate DWI and DCE-MRI during 
CRT for early response assessment and prediction of LRC at two years after end of treatment, 
in comparison with volumetric tumour measurements. 
 
6.2 Materials and Methods 
 
6.2.1 Study design 
Thirty-one patients (29 men, 2 women, mean age: 53 years, range: 38 to 66 years) with 
histologically proven  HNSCC, were consecutively included in this prospective study. One 
patient was excluded due to detection of metastatic disease. The primary tumour localization 
and clinical stage of the remaining 30 patients are summarized in Table 1. 
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Patient primary tumour localization Staging 
Patient 1 tonsil T2N3 
Patient 2 tonsil T2N2a 
Patient 3 piriform sinus T4a2b 
Patient 4 supraglottic T3N1 
Patient 5 piriform sinus T4aN2b 
Patient 6 supraglottic T4aN2c 
Patient 7 glottic T1N0 
Patient 8 base of tongue T3N1 
Patient 9 lateral oropharynx T4aN2c 
Patient 10 supraglottic T3N2b 
Patient 11 posterior hypopharynx T4aN2c 
Patient 12 supraglottic T3N2b 
Patient 13 base of tongue T3N2b 
Patient 14 lateral oropharynx T4N1 
Patient 15 piriform sinus T2N1 
Patient 16 supraglottic T4aN2c 
Patient 17 glottic T3N0 
Patient 18 supraglottic T4aN2c 
Patient 19 lateral oropharynx T2N1 
Patient 20 lateral oropharynx T3N2c 
Patient 21 piriform sinus T1N2b 
Patient 22 lateral oropharynx T4aN2c 
Patient 23 tonsil T3N0 
Patient 24 piriform sinus T4aN1 
Patient 25 base of tongue T3N2c 
Patient 26 lateral oropharynx T4 
 
piriform sinus T3N1 
Patient 27 supraglottic T3N2b 
Patient 28 piriform sinus T3N2c 
Patient 39 tonsil T2N2b 
Patient 30 tonsil T4aN1 
Table 1: Initial tumour localization, and TNM-staging in 
the included patient group 
 
Treatment consisted of concomitant CRT in 27 patients and radiotherapy 3 patients, for which 
diagnosis, staging and treatment planning was done according to current international 
standards. Radiotherapy was delivered to a total dose of 72 Gray (Gy) according to a hybrid 
fractionation schedule in 28 patients: 20 daily fractions of 2 Gy, followed by 20 fractions of 
1.6 Gy twice daily (32 Gy), to a total dose of 72 Gy. In the patient with a T1 glottic cancer, a 
total dose of 55Gy was delivered. All patients completed the planned treatment scheme. 
Chemotherapy consisted of Cisplatinum, 100 mg/ml at week 1 and 4. 
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A timeline shows the different methodological steps in the study (Figure 1). Routine pre-
treatment examinations included diagnostic contrast-enhanced CT, FDG-PET-CT in 14 
patients, and panendoscopy with biopsy in all patients. MRI with anatomical, DCE- and DWI-
sequences was added just prior to and at 2 and 4 weeks after the start of CRT. All MRI-
studies were of sufficient technical quality to allow analysis. The study was approved by the 
local ethics committee and all patients gave written informed consent prior to inclusion. 
 
 
 
 
 
 
 
 
Figure 1: Timeline detailing the exact set-up of study inclusion and data processing used in this study. 
 
6.2.2 Imaging technique 
All patients underwent the standardized anatomical TSE-MRI, and functional DWI- and 
DCE-MRI sequences as described in chapter 3. MRI imaging covered the entire head and 
neck ranging from the base of skull to the thoracic outlet, and included all regional nodal 
stations (retropharyngeal space and all neck levels). 
 
6.2.3 Image analysis 
 
6.2.3.1 Lesion identification and correlation 
The primary tumours and nodal metastases were identified on the baseline TSE-MRI and 
DWI in correlation to the clinical information and the pre-therapeutic routine imaging 
results. Primary tumours were topographically annotated by their slice position and 
anatomical position in the upper aerodigestive tract. Adenopathies were topographically 
annotated by their position in correlation to anatomical structures in the neck - the 
submandibular gland, the sternocleidomastoid muscle and the jugular vein and level position 
according to the AAO-HNS classification (8). The primary tumours and metastatic 
adenopathies were identified on the 2 and 4 weeks follow-up TSE-MRI and DWI 
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examinations by visual correlation and correlation of slice positions with the baseline 
examination. 
 
6.2.3.2 Image analysis 
The images of the TSE-MRI, DWI and DCE-MRI were quantitatively interpreted in a blinded 
fashion as described in chapter 3.2. 
For both DWI, DCE-MRI and TSE-MRI lesion ADC, respectively lesion perfusion and lesion 
volume at 2 and 4 weeks after the start of CRT  were correlated to the baseline values for 
treatment assessment and correlation to treatment outcome. 
The ADC changes (∆ADCN ) in % for each lesion between the baseline and the 2 and 4 weeks 
time point were calculated using the formula: 
∆ADCN=[(ADCN -ADCB)/ADCB]*100 
Where ADCB represents pre-treatment ADC-value and ADCN represents the ADC on the N
th 
time point after the start of CRT. 
The changes of the perfusion parameter (∆PERFN) in % in for each lesion between the 
baseline and the 2 and 4 weeks time point was calculated using the formula: 
∆PERFN=[(PERFN -PERFB)/PERFB]*100 
Where PERFB represents pre-treatment ADC-value and PERFN  represents the PERF on the 
N
th 
time point after the start of CRT. 
The volume changes (∆VN) in % for each lesion between the baseline and the 2 and 4 weeks 
time point were calculated using the formula 
∆VN=[(VN -VB)/VB]*100 
Where VB represents pre-treatment lesion volume and VN represents the volume on the N
th 
time point after the start CRT. 
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6.2.4 Correlation to treatment outcome 
As in our institution neither routine biopsies nor routine elective neck dissections are 
performed after CRT, the imaging findings were primarily correlated to post-treatment patient 
follow up as described in chapter 3.4.2. 
 
6.2.5 Statistical analysis 
The software package Statistica 8
®
 (StatSoft Inc, Tulsa, OK, USA) was used for the statistical 
analysis. A p-value < 0.05 was considered statistically significant. 
The ∆ADCN, ∆PERFN  and the ∆VN of primary lesions and adenopathies showing CR versus 
those with later tumour recurrence were compared with a Mann-Whitney test. ROC analysis 
with the area under the curve (AUC) was employed to investigate the discriminatory 
capability of the ∆VN, ∆PERFN and ∆ADCN. For calculation of the sensitivity, specificity, 
accuracy, PPV and NPV for of the ∆VN, ∆PERFN and ∆ADCN, the optimal threshold was 
determined as the point giving equal weighting to sensitivity and specificity on the ROC 
curve. 
Cumulative LRC was estimated with the Kaplan-Meier product-limited (actuarial) method 
and the statistical significance of differences between curves were compared with the log-rank 
test. In the univariate analysis the following clinical variables were entered: tumour 
localization (laryngeal versus pharyngeal), age, T-stage (T1-2 vs. T3-4), N-stage (N1-2a vs. 
N2b-3), initial primary tumour volume and initial nodal volume. All clinical variables with a 
p-value < 0.1 were included in a multivariate analysis comparing the predictive value of the 
separate imaging variables; the ∆VN, ∆PERFN and ∆ADCN. 
 
6.3 Results 
 
6.3.1 Treatment outcome 
Complete LRC at 2 years after the end of treatment was achieved in 15 of 30 patients (50%). 
Six of 30 patients (20%) developed an isolated local recurrence (at a median of 129 days post-
CRT, range: 27 to 189 days) for which salvage surgery could be performed in 5 patients. 
Seven of 30 patients (23%) developed a regional recurrence without primary tumour 
recurrence (at a median of 224 days post-CRT, range: 91 to 364 days), of whom 4 were 
eligible for neck dissection at time of diagnosis. Two of 30 patients (7%) developed a 
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simultaneous locoregional tumour recurrence (at 126 and 161days after CRT, respectively); 
one patient received salvage surgery with bilateral neck dissection, the other was inoperable 
because of the extent of disease. Nine of 30 patients (30%) deceased during the 2 years 
follow-up: 7 patients because of a tumour recurrence.  The death of two patients was 
unrelated to the HNSCC. 
 
 
6.3.2 Clinical variables and volumetric tumourassessment: lesion 
based assessment and correlation with locoregional control 
The univariate analysis of clinical pre-treatment variables showed a substantial correlation 
between nodal volume and N-stage and 2-year LCR (p=0.06 respectively 0.08), no correlation 
was found for the other variables (p>0.2) (Table 2). In the multivariate analysis, the N-stage 
and nodal volume no longer showed any correlation with LCR (p>0.5). 
The ∆V2weeks was significantly lower for primary tumours with post-CRT recurrence than with 
CR (in %, -2.8.1±34.5 versus 31.3±32.1, p=0.03) but no significant difference was found for 
adenopathies (-15.4±58.9 versus 19.9±39.7, p=0.1). The ∆V4weeks showed no significant 
difference for either lesions (in %, primary tumour: 46.4±27.0 vs. 56.3±30.8; adenopathies: 
15.1±67.4 vs. 49.3±41.3, both p>0.1). The ∆V2weeks and ∆V4weeks showed no significant 
correlation with the LRC ( p>0.05) in the multivariate analysis. 
 
Pre-treatment parameter Locoregional control 
Volume primary tumour p=0.23987 
(≥ 12.31 cc vs. < 12.31 cc) 
Volume adenopathy p=0.06463 
(≥ 18.612 cc vs. < 18.612 cc) 
T-stage p=0.21938 
(T1-2 vs. T3-4) 
N-stage p=0.08019 
(N0-1-2a vs. N 2b-2c-3) 
age p=0.92106 
(≥ 53 jr vs. < 53 jr) 
Tumour localization p=0.66 
(Laryngeal versus pharyngeal)   
Table 2: The univariate analysis of tumour-specific properties prior to 
treatment. N-stage and volume of adenopathies showed a p-value smaller than 
0.1 and were included in the subsequent multivariate analysis. 
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6.3.3 Tumour diffusion: correlation with locoregional control 
The ∆ADC2weeks was significantly lower for primary tumours and adenopathies with  post-
CRT recurrence than CR  (in %, primary tumour: -1.6±9.7 vs. 40.5±25.6, p<0.0001; 
adenopathies: 10.9±26 vs. 52.4±36.1, p<0.0001). The ∆ADC4weeks was significantly lower for 
primary tumours and adenopathies with  post-CRT recurrence than with CR (in %; primary 
tumour: -1.0±24.6 vs. 65.1±36, p<0.0001; adenopathies: 15.8±25.6 vs. 67.6±41.4, p<0.0001). 
In the multivariate analysis, the ∆ADC2weeks  and ∆ADC4weeks  correlated significantly to 2-year 
LRC; (∆ADC2weeks  ; p=0.003, ∆ADC4weeks  ;p<0.0001) (Figure 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Multivariate analysis shows significant correlation of ∆ADC with locoregional control (Y-axis) at  
(A) 2 and (B) 4 weeks. 
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6.3.4 Tumour perfusion assessment and correlation with 
locoregional control 
Changes in the AS showed highest AUC and accuracy compared to the c-peak and washout at 
all time points and was chosen for further assessment and comparison. Changes in the AS will 
be further referred to as ∆PERF. 
The ∆PERF2weeks showed no significant difference between  primary tumours or adenopathies 
with post-CRT recurrence than with CR (in %, primary tumour: 73.5±86.6 vs. 
9.9±52.4,p=0.08; adenopathies: 29.8±66.85 vs. -1.1±50.5,p=0.11). For primary tumours, non-
responding lesions showed tendency to have higher ∆PERF than responding lesions. 
The ∆PERF4weeks showed no significant difference between  primary tumours or adenopathies 
with post-CRT recurrence than with CR (in %, primary tumour: 46.8±46.8 vs. 
41.1±113.6,p=0.8; adenopathies: 36.8±84.2 vs. 37.5±121.9,p=0.9). 
After multivariate analysis, the ∆PERF2weeks and ∆PERF4weeks showed no significant 
correlation with the LRC (p>0.1). 
 
6.3.5 Comparison of different tumour imaging methods 
The sensitivity, specificity accuracy, PPV and NPV of DWI, DCE-MRI and TSE-MRI are 
shown in Table 3. 
At 2 and 4 weeks during CRT, the ∆ADC showed highest AUC and accuracy for prediction of 
treatment outcome compared to the ∆V and ∆PERF. Except for primary tumours at 4 weeks 
during CRT, where the ∆PERF showed slightly higher accuracy than the ∆V, the ∆PERF had 
lowest accuracy at 2 and 4 weeks during CRT. 
Examples of early response assessment at 2 weeks for primary lesions and 4 weeks during 
CRT for lymph node metastases are shown in Figure 3 – 6. 
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Threshold (%) 14 20 60 Threshold (%) 14 33 18 
Primary lesion ∆ADC ∆V ∆PERF Nodal metastases ∆ADC ∆V ∆PERF 
        True positive 7 7 5 True positive 8 9 6 
False positive 2 10 1 False positive 5 23 20 
True negative 21 13 22 True negative 39 21 24 
False negative 1 1 3 False negative 2 1 4 
        Sensitivity 88% 88% 63% Sensitivity 80% 90% 60% 
Specificity 92% 57% 96% Specificity 89% 48% 55% 
Accuracy 94% 65% 87% Accuracy 87% 56% 56% 
PPV 78% 41% 83% PPV 62% 28% 23% 
NPV 96% 93% 88% NPV 95% 96% 85% 
 
 
       Threshold (%) 25 65 45 Threshold (%) 19 50 25 
Primary lesion ∆ADC ∆V ∆PERF Nodal metastases ∆ADC ∆V ∆PERF 
        True positive 7 6 6 True positive 8 7 5 
False positive 2 10 7 False positive 2 17 17 
True negative 21 13 17 True negative 42 27 27 
False negative 1 2 2 False negative 2 3 5 
        Sensitivity 88% 75% 75% Sensitivity 80% 70% 50% 
Specificity 92% 57% 71% Specificity 95% 61% 61% 
Accuracy 94% 61% 72% Accuracy 93% 63% 59% 
PPV 78% 38% 46% PPV 80% 29% 23% 
NPV 96% 87% 89% NPV 95% 90% 84% 
PPV: positive predictive value 
NPV: negative predictive value 
Table 3: Comparison of accuracy of ∆ADC versus ∆V versus ∆PERF at (upper table) 2 weeks and (bottom 
table) 4 weeks. 
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Figure 3: Upper row shows tumoral mass in the right base of tongue on (a) contrast-enhanced T1-weighted      
turbo-spin echo (TSE) MRI, (b) b1000 diffusion-weighted image, (c) ADC-map and (d) arterial slope perfusion 
map. Middle row: tumour at 2 weeks during chemoradiotherapy (e) is unchanged in tumour dimensions, (f) 
shows unchanged signal intensity on the b1000 diffusion-weighted image, (g) ∆ADC (in %) < 15 and ∆PERF 
(in %) < 18, indicative of treatment failure. Bottom row shows tumour recurrence on (i) CT study and (j) FDG-
PET at 4 months after completion of chemoradiotherapy. Recurrent SCC was confirmed by (k) histopathology 
after surgical excision. 
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Figure 4: Upper row: Left supraglottic ulcerated tumoral mass on (a) contrast-enhanced T1-weighted turbo-
spin echo (TSE) MRI, (b) b1000 diffusion-weighted image, (c) ADC-map and (d) arterial slope perfusion map. 
Middle row: (e) The supraglottic tumour shows unchanged volume at 2 weeks during chemoradiotherapy. (f) the 
tumour shows substantial decrease of signal intensity on the b1000 diffusion-weighted image, corresponding to 
(g) a ∆ADC (in %) > 40 and ∆PERF (in %) > 50. These findings are indicative of good treatment response. (i) 
Follow-up CT scan after 2 years shows complete remission of the primary tumour site. 
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Figure 5: Patient with left tonsillar cancer shows two subcentimetre nodal metastases in left level 2 of the 
neck prior to treatment on (a) contrast-enhanced T1-weighted turbo-spin echo (TSE) MRI, (b) b1000 diffusion-
weighted image and (c) ADC-map (arrow, arrowhead). At 4 weeks during chemoradiotherapy, (d) the posterior 
adenopathy has completely regressed (arrowhead), while the more anterior lymph node has partially regressed 
(arrow).  (e) Persistent hyperintensity is present in the anterior lymph node correlating to (f) a ∆ADC (in %) < 5, 
indicative of bad treatment response (arrows). (g) Follow-up CT scan shows nodal tumour recurrence at 
8 months after completion of chemoradiotherapy (arrow). 
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6.4 Discussion 
In this study group, DWI allowed prediction of 2-year LRC at 2 and 4 weeks during CRT and 
showed a substantially higher accuracy than serial volumetric assessment for differentiation 
between responding and non-responding lesions. 
During CRT, the ∆V2weeks was only significantly different between responding and non-
responding primary tumours. Although no significant correlation with LRC was found, the 
∆V2weeks with a threshold of 20% and ∆V4weeks with 65% allowed a high NPV.  In a study of 
Jaulerry et al, tumour volume regression of 25% at 2 weeks during RT was predictive for CR 
after RT (9). However, in the current study, a high number of primary tumoral and nodal 
metastatic lesions, including eventually responding lesions, showed no substantial volume 
regression early during CRT. Therefore, the resulting poor PPV of volumetric measurements 
hampered the identification of non-responding lesions and is a probable reason why 
volumetric assessment lacks sufficient reliability to select lesions for treatment intensification, 
such as dose escalation. 
The ability to probe the tissue microstructure and the high sensitivity of DWI for low levels of 
intratumoral cell destruction may explain the high accuracy of DWI for early response 
assessment (10,11). Tumoral lesions with CR after CRT showed a significantly higher ∆ADC 
than tumoral lesions that recurred. Historadiological correlation during treatment follow-up in 
prior studies showed a relation between the ADC increase and necrosis and apoptosis, in 
response to cytotoxic and radiation treatment (12,13). The loss of tissue cellularity in 
apoptosis and necrosis will increase the ADC (14,15). Contrary, absent ADC increase in 
primary tumours or adenopathies during CRT corresponded to lesions with a high likelihood 
of recurrence post-CRT, which is probably related to diffusion restriction in the dense 
microstructure of persistent tumour (11,16). These findings are in agreement with the results 
in a recent study by Kim et al, which also found a significant ADC increase in responding 
compared to non-responding metastatic adenopathies (17). Moreover, using similar thresholds 
a near identical accuracy is found in this study for nodal metastases at the 2 weeks‟ time 
point, compared to the 1 week time point during CRT in the study of Kim et al (17). These 
similar findings demonstrate the robustness of DWI as a potential biomarker for early 
prediction of treatment response. 
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In addition to the findings of the study of Kim et al (17), our findings indicate that the 
∆ADC2weeks and ∆ADC4weeks  correlate  significantly to 2-year LRC. Recently, DWI was shown 
to predict at 2 weeks during CRT the final imaging and clinical response in uterine cervical 
cancer (18). In patients with primary cerebral neoplasms, the combination of DWI before and 
at three weeks after the initiation of treatment has been demonstrated to accurately predict 
later radiographic response, time to progression and overall survival (16,19,20). The 
underlying causative link between ADC-changes during CRT and later LRC  remains unclear 
due to lack of historadiological correlation in our study. The relation between the observed 
signal changes on DWI and the underlying pathophysiological processes, such as apoptosis, 
hypoxia, proliferation index or tumour grade, are to be further investigated (21). 
Unlike DWI, DCE-MRI with semi-quantitative perfusion parameters was only of limited 
value for the early differentiation of responding and non-responding lesions. Compared to the 
other perfusion variables, the ∆PERF based on the AS showed highest accuracy, but also 
failed to show significant differences at 2 and 4 weeks during CRT between lesions with later 
CR and lesions with later tumour recurrence. 
So far, the role of DCE-MRI as an imaging biomarker during chemoradiation has mainly been 
investigated in uterine cervical cancer. In this tumour type, different studies have shown a 
positive correlation between either pre-treatment enhancement or initial enhancement rate, 
2 weeks during chemoradiation, and local tumour control (22,23). A recent pilot study in a 
limited number of patients investigating DCE-MRI during radiotherapy of HNSCC showed a 
significant correlation between increased blood volume and local control while no substantial 
change was found in blood flow or blood volume in adenopathies (24). 
In our study, the lack of statistically significant differences of perfusion variables between 
responding and non-responding lesions may reflect the complexity of intratumoral 
physiological changes that occur during fractionated CRT. Usually, changes in tissue contrast 
enhancement relate to changes in vascular supply, capillary permeability and cell density (25). 
The dynamic contrast enhancement patterns in tumours during CRT may be averaged out by 
the simultaneous physiological processes known to occur during radiation treatment. 
Radiation-induced cell loss may lead to a decrease of dynamic tissue enhancement, due to 
direct radiation-induced vascular damage and decrease of intralesional tumour load with loss 
of angiogeneic activity. However, simultaneously, the increase of leakage space secondary to 
cell loss may lead to an increased tissue enhancement. Finally, the variable occurrence of 
tumour hypoxia prior to and during CRT is usually associated with decreased tumour 
perfusion as measured by DCE-MRI. 
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In a previous study in head and neck cancer, an increased tumour perfusion measured by 
DCE-MRI correlated to favourable tumour response to radiation treatment; it has been 
suggested that the increased tumour perfusion may indicate an increased tumour oxygenation 
which could lead to increased tumour cell radio-sensitivity (24). However, this hypothesis is 
in contradiction with a prior report in patients treated with induction chemotherapy (26) as 
well as the findings of our study. Moreover, although decreased perfusion has been related to 
tumour hypoxia (27,28), it is currently unclear to what extent DCE-MRI directly reflects 
fractions of radiobiologically hypoxic cells (29). 
Although not significantly different, non-responding primary tumours showed a tendency to 
increased tissue perfusion – as measured by the AS – during treatment. This may indicate 
persistent angiogeneic activity in non-responding compared to responding lesions. However, 
the large overlap with responding primary tumours in which the tissue AS increased during 
treatment, limits the diagnostic accuracy of DCE-MRI . This underscores the inability of the 
technique to directly assess tissue viability, but also raises the question to what extent the 
technique is hampered by treatment-induced inflammation. Inflammatory induced rapid tissue 
enhancement, initiated by CRT-induced tumour necrosis, is difficult to differentiate from 
tumour-related tumour enhancement (30,31). 
Part of the poorer results of DCE-MRI in this study may relate to the sole use of semi-
quantitative perfusion variables which do not accurately reflect contrast medium 
concentration in tissues. The K
trans
 and kep allow for quantitative evaluation of the tumoral 
vascular response to chemoradiation by depicting changes in tissue permeability as a marker 
for response. Permeability parameters have the advantage that they provide information that 
can be linked to underlying biologic processes of the vasculature, such as the permeability 
surface area and flow (25). However, quantified models are more complex to derive, less 
robust to noise and more susceptible to artifacting secondary to patient or physiological 
movement, making application and interpretation of quantitative DCE-MRI in the head and 
neck currently difficult. Further studies are required to further elucidate the potential role of 
these parameters in the treatment follow-up of HNSCC solely or in combination with other 
imaging modalities like DWI or PET with hypoxia markers (32). 
As a functional marker for the head and neck, DWI may be advantageous over other 
functional MR modalities, such as MR-spectroscopy and, as previously mentioned, DCE-
MRI. Unlike MR-spectroscopy, DWI is less restricted in its anatomical coverage and is, if 
appropriately optimized, able to comprehensively evaluate the primary tumour and all nodal 
stations in an acceptable scanning time. Also, being a quantification of signal loss, the ADC is 
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a robust imaging parameter as it will be less susceptible to variations induced by the magnetic 
field or tissue position in the coil (11). Moreover, the ADC-quantification is based on a 
relatively simple model and represents more directly tissue properties compared to DCE-MRI 
(17). Preferentially, a standardized ADC-calculation including at least 3 b-values with 
maximum b-values exceeding b500 sec/mm
2 
should be performed
 
(5,11,21). In order to 
optimize DWI for early treatment follow-up, time-dependable ADC thresholds may need to 
be defined (5). The ADC may falsely decrease if necrosis resolves. Contrary, the induction of 
liquefaction necrosis may interfere with DWI-measurements and falsely increase the ADC of 
small remnant solid tumoral components due to partial volume averaging (21). This may in 
part explain the lower PPV of the ∆ADC2weeks compared to the ∆ADC4weeks in adenopathies, 
often showing cystic necrotic degeneration prior to CRT. Early during CRT, necrosis may 
have been absorbed in a number of responding adenopathies, and may have led to an initial 
decrease of ADC, falsely suggesting poor response. As such, adenopathies may be preferably 
evaluated at a later time point during CRT compared to primary tumours. 
Contrary, the incorrect prediction of good treatment response in a primary tumour, 
respectively at 2 and 4 weeks during CRT, was probably secondary to extensive intratumoral 
necrosis obscuring small persistent solid tumour depositions. Although lesions were visually 
assessed on b1000-images for tumour heterogeneity, a more automated evaluation 
incorporating tumour heterogeneity may be needed to avoid interpretation error. A histogram-
based approach classifies different tumour diffusion environments but cannot depict spatial 
heterogeneity and may therefore fall short to guide topographically guided treatment like CRT 
(33). A voxel-wise approach incorporating registration of image data sets between treatment 
interval examinations, which allows to depict the topographical heterogeneity of tumour 
response to treatment between consecutive examinations may help to further develop DWI as 
a marker for bio-adaptive treatment (16). 
Despite the current limitations involving image interpretation and imaging standardization, 
the microstructural driven imaging properties of DWI may be advantageous over metabolic 
imaging modalities like FDG-PET for early response assessment during CRT. Brun et al 
found that metabolic response measured by FDG-PET early during CRT for HNSCC was 
associated with treatment outcome (34). In patients with a low metabolic response, 23 of 24 
obtained LRC, opposed to only 11 of 20 in patients with a high response. However, potential 
applications of FDG-PET remains unclear. The progressive inflammation of the normal 
surrounding tissues during CRT may obscure the tumoral lesion (4). Moreover, the 
association of FDG-uptake with tumour hypoxia and inflammation may increase the 
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variability of tracer uptake in tumoral and non-tumoral tissue and decrease the predictive 
value of the technique during fractionated RT (35). Alternatively, mid-treatment presence of 
hypoxia as depicted by [(18)
F
]-Misonidazole PET ((18)F-MISO)-PET has shown variable 
correlation with patient outcome (36,37). 
Contrary, as inflammation expands the extracellular space, it will increase the microstructural 
contrast with persistent tumoral or hypercellular areas, and is likely to improve the 
differentiation between responding and non-responding lesions on DWI (11). 
The higher microstructural contrast may lead to an improved conspicuity, detection and 
subsequent ROI-delineation of tumoral lesions on the native high b-value images due to a 
more pronounced signal suppression of the inflammatory tissues at higher b-values. 
Moreover, the increased microstructural contrast between inflammatory/necrotic and tumoral 
tissue, is likely to increase the differences in ADC between viable and non-viable tumoral 
tissue, facilitating their differentiation with DWI (11). 
 
6.5 Conclusion 
DWI with the ∆ADC at 2 and 4 weeks during CRT for HNSCC allow early response 
prediction, correlating significantly with LRC and DFS. DWI is more accurate than DCE-
MRI and serial volumetric assessment for prediction of treatment outcome. DCE-MRI with 
semi-quantitative assessment failed to show significant differences between responding and 
non responding tumours, and was of no additional value to the volumetric assessment for 
early prediction of treatment response. 
These findings indicate that DWI can be used as an early biomarker of treatment response in 
CRT of HNSCC. As such, the technique may be of value as a per-treatment response 
biomarker. 
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Chapter7: 
DWI and DCE-MRI for assessment of early post-
treatment tumour response in head and neck squamous 
cell carcinoma after (chemo)radiotherapy 
 
7.1 Introduction 
Previous studies have shown that DWI allows for differentiation of post-radiotherapeutic 
changes, necrosis and tumour recurrence at the time of diagnosis or clinical presentation (1,2). 
However, the imaging diagnosis of persistent or recurrent cancer, established at the time of 
clinical symptoms,  may come too late to allow successful tumour salvage. 
For instance, patients with T3 or T4 non-laryngeal cancers may only have a short window of 
opportunity to initiate successful salvage surgery and at the time that a tumour recurrence 
becomes clinically apparent, operability may be compromised. It has been shown that the 
addition of a planned clinical, pathological or imaging restaging (using CT) at 4 to 8 weeks 
after CRT may improve overall local control and overall survival rates (3). 
The aim of this study was to evaluate the potential value of DWI and DCE-MRI to anatomical 
imaging for prediction of treatment response in the early post-CRT phase. 
 
7.2 Materials and Methods 
7.2.1 Study design 
Thirty-one patients (mean age 54 years, range 39 to 67 years) with histologically proven  
HNSCC, were consecutively included in this prospective study. One patient was excluded due 
to detection of metastatic disease prior to treatment. Another patient refused MRI due to 
claustrophobia. The tumour localization, stage of the remaining 29 patients are summarized in 
Table 1. 
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Patient primary tumour localization Staging 
Patient 1 tonsil T2N3 
Patient 2 tonsil T2N2a 
Patient 3 piriform sinus T4a2b 
Patient 4 supraglottic T3N1 
Patient 5 piriform sinus T4aN2b 
Patient 6 supraglottic T4aN2c 
Patient 7 glottic T1N0 
Patient 8 base of tongue T3N1 
Patient 9 lateral oropharynx T4aN2c 
Patient 10 supraglottic T3N2b 
Patient 11 lateral oropharynx T4aN2c 
Patient 12 base of tongue T3N2b 
Patient 13 lateral oropharynx T4N1 
Patient 14 piriform sinus T2N1 
Patient 15 supraglottic T4aN2c 
Patient 16 glottic T3N0 
Patient 17 supraglottic T4aN2c 
Patient 18 lateral oropharynx T2N1 
Patient 19 lateral oropharynx T3N2c 
Patient 20 piriform sinus T1N2b 
Patient 21 lateral oropharynx T4aN2c 
Patient 22 tonsil T3N0 
Patient 23 piriform sinus T4aN1 
Patient 24 base of tongue T3N2c 
Patient 25 base of tongue T4 
 
piriform sinus T3N1 
Patient 26 supraglottic T3N2b 
Patient 27 piriform sinus T3N2c 
Patient 28 tonsil T2N2b 
Patient 29 tonsil T4aN1 
Table 1: Initial tumour localization, and TNM-staging in the 
included patient group 
 
Treatment consisted of concomitant CRT in 26 patients and radiotherapy in 3. Radiotherapy 
was delivered to a total dose of 72 Gray (Gy) according to a hybrid fractionation schedule in 
28 patients: 20 daily fractions of 2 Gy, followed by 20 fractions of 1.6 Gy twice daily 
(32 Gy), to a total dose of 72 Gy. Chemotherapy consisted of Cisplatinum, 100 mg/ml at week 
1 and 4. In one patient with a T1 glottic cancer, a total dose of 55 Gy was delivered in 25 
fractions of 2.2 Gy. All patients completed the planned CRT-scheme. Pre-treatment 
diagnostic examinations included contrast-enhanced computed tomography (CT), FDG-PET-
CT in 14 patients, and pre-operative panendoscopy with biopsy in all patients. MRI with 
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anatomical, DCE-MRI and DWI sequences was added prior to and 3 weeks after CRT. 
Routine follow-up CT was performed at 3±1 months after CRT  (CT3m). Clinical outcome 
after 2 years follow-up and histopathology served as reference standard. DWI was compared 
to conventional MRI at 3 weeks post-CRT (MRI3w) and the CT3m. A time line shows the 
different methodological steps in the study (Figure 1). 
 
 
Figure 1: Timeline detailing the exact set-up of study inclusion and data processing used in this study. 
 
The study was approved by the local ethics committee and all patients gave written informed 
consent prior to inclusion. 
 
7.2.2 Imaging technique 
All patients underwent the standardized anatomical TSE-MRI, and functional DWI- and 
DCE-MRI sequences as well as the CT study as described in chapter 3. Similar  as for the CT, 
MRI imaging covered the entire head and neck ranging from the base of skull to the thoracic 
outlet, and included all regional nodal stations (retropharyngeal space and all neck levels). 
 
7.2.3 Image analysis 
 
7.2.3.1 Lesion identification and correlation 
The primary tumours and nodal metastases were identified on the baseline TSE-MRI and 
DWI in correlation to the clinical information and the pre-therapeutic routine imaging 
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results. Primary tumours were topographically annotated by their slice position and 
anatomical position in the upper aerodigestive tract. Adenopathies were topographically 
annotated by their position in correlation to anatomical structures in the neck, including the 
submandibular gland, the sternocleidomastoid muscle and the jugular vein, and level position 
according to the AAO-HNS classification (4). The primary tumours and metastatic 
adenopathies  were identified on the  DWI examinations by visual correlation and correlation 
of slice positions with the baseline examination. 
 
7.2.3.2 Image analysis 
The images of DWI and DCE-MRI were quantitatively interpreted in a blinded fashion as 
described in chapter 3.2. 
For both DWI and DCE-MRI, ADC respectively perfusion parameters of the lesions at 3 
weeks after the end of CRT  were correlated to the baseline values for treatment assessment 
and correlation to treatment outcome. 
The ADC changes (∆ADCN ) in % for each lesion between the baseline and the 3weeks post-
CRT time point were calculated using the formula: 
∆ADCN=[(ADCN -ADCB)/ADCB]*100 
Where ADCB represents pre-treatment ADC-value and ADCN represents the ADC on the N
th 
time point after CRT. 
The changes of the perfusion parameter (∆PERFN) in % in for each lesion between the 
baseline and the 3weeks time point after CRT was calculated using the formula: 
∆PERFN=[(PERFN -PERFB)/PERFB]*100 
Where PERFB represents pre-treatment ADC-value and PERFN  represents the PERF on the 
N
th 
time point after CRT. 
 
7.2.3.3 Comparison with anatomical imaging criteria 
The findings of DWI and DCE-MRI were compared with currently accepted anatomical 
imaging criteria for post-CRT follow-up. The primary site and lymph nodes were evaluated 
by comparison of the MRI3w (Radiologist; 7 years of experience in head and neck radiology) 
and the CT3m (radiologist, 16 years of experience in head and neck radiology) with the 
baseline pre-treatment MRI. Both readers were blinded from all other imaging data. 
For evaluation of primary lesions, MRI imaging variables included tissue asymmetry or mass 
(grade 0: no detectable focal abnormality, grade 1: anatomic asymmetry or discrete mass < 
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10 mm, grade 2a: mass > 10 mm, or 2b, <50% reduction of largest dimension), T2-SI  and 
contrast enhancement. CT imaging variables consisted of tissue asymmetry or mass and 
contrast enhancement (5). 
Lymph nodes were evaluated based on diameter (1 cm shortest transverse diameter 
respectively 1.5 cm longest transverse diameter as described in literature), presence of 
intranodal focal defects, focal contrast enhancement or calcifications (6,7). 
 
7.2.4 Correlation to treatment outcome 
As in our institution, routine biopsies nor routine elective neck dissections are performed after 
CRT, the imaging findings were primarily correlated to post-treatment patient follow up as 
described in chapter 3.4.2. 
 
7.2.5 Statistical analysis 
The software package Statistica 8
®
 (StatSoft Inc, Tulsa, OK, USA) was used for the statistical 
analysis. A p-value < 0.05 was considered statistically significant. 
The ∆ADC and ∆PERF of primary lesions and adenopathies showing CR versus tumour 
recurrence were compared with a Mann-Whitney test.  Only the parameters with significantly 
different values were included for further analysis. ROC-analysis with the AUC was 
employed to investigate the discriminatory capability of the imaging parameters. For 
calculation of the sensitivity, specificity, accuracy, PPV and NPV, the optimal threshold was 
determined as the point giving equal weighting to sensitivity and specificity on the ROC-
curve. 
For evaluation of the MRI3w and CT3m, the appearance and size of the primary tumour site and 
lymph nodes were documented in correlation to post-CRT follow-up and histopathology. The 
sensitivity, specificity, accuracy, PPV and NPV were subsequently calculated. 
Finally, the selected DWI- and DCE-MRI parameters were compared per patient with the 
MRI3w and CT3m. 
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7.3 Results 
 
7.3.1 Treatment outcome 
At 2 years post-CRT, complete LCR was achieved in 15 of 29 patients (50%). 
Six of 29 patients (21%) developed an isolated local recurrence (at a median of 129 days post-
CRT, range: 27 to 189 days) for which salvage surgery was performed. Six of 30 patients 
(20%) developed a regional recurrence without primary tumour recurrence (at a median of 
224 days post-CRT, range: 91 to 364 days), of whom 3 were eligible for neck dissection at 
time of diagnosis. Two of 30 patients (10%) developed a simultaneous locoregional tumour 
recurrence (at 126 and 161days after CRT, respectively); one patient received salvage surgery 
with bilateral neck dissection, one was inoperable because of the extent of disease. Nine of 30 
patients (30%) deceased during the 2 years follow-up: 8 patients because of a tumour 
recurrence.  One patients death was non-tumour related. 
 
7.3.2 Primary tumour 
None of the perfusion parameters showed statistical difference between lesions with later 
post-CRT recurrence compared to lesions with CR (c-peak: recurrence : 0.59±2.1 versus CR : 
0.3±1.3 ; AS: recurrence : 0.02±0.59 versus CR : -0.28±0.71 ; washout : recurrence : 0.4±5.87 
versus CR : 4.02±27.27 ; p>0.1). 
The ∆ADCpost was significantly lower for lesions with  post-CRT recurrence than with CR   
(-2.25±0.3 versus 79.8±41;p<0.0001) (Figure 2). 
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Figure 2: Comparison of ∆ADCpost between primary tumours showing complete remission 2 years after the 
end of chemoradiotherapy and primary tumours showing recurrence during follow-up. The ∆ADCpost was 
significantly lower in lesions showing later recurrence. Box-whisker plots are presented with median (-), 
interquartile range (box) and minima/maxima (-). 
 
The imaging appearance of primary lesions at the MRI3w are shown in table 2. Primary site 
findings compatible with CR mostly showed a grade 0 or 1 and T2 hypo-intensity, while 
primary site findings compatible with later tumour recurrence mostly showed grade 2a or 2b 
and increased or mixed T2-SI. Contrast enhancement was of limited discriminatory value. 
The imaging appearance of  primary lesions at the CT3m are shown in Table 2. Primary site 
findings compatible with later CR mostly showed grade 0 or 1 and lack of contrast 
enhancement while primary site findings compatible with later tumour recurrence showed 
substantial correlation with grade 2a or 2b and contrast enhancement. 
Comparative sensitivity, specificity, accuracy, PPV and NPV for the ∆ADCpost at the optimal 
threshold of 25% and MRI3w and CT3m are shown in Table 3. Compared to the MRI3w, the 
∆ADCpost showed higher PPV and NPV. Compared to the CT3m, the ∆ADCpost showed higher  
PPV. DWI showed higher sensitivity for detection of persistent tumoral lesions that showed 
complete morphological regression (grade 0) and higher specificity by excluding persistent 
tumour that showed a persistent mass (grade 2a or b) or showed persistent mixed signal 
intensity of T2 weighted images. 
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MRI3w Primary site True negative True positive False positive False negative 
 
of 18 lesions of 6 lesions of 4 lesions of 2 lesions 
grade 0 4 0 0 1 
grade 1 10 0 0 1 
grade 2a or 2b 4 6 4 0 
     T2 hyperintense 3 0 3 1 
T2 mixed 0 6 1 0 
T2 hypo-intense 15 0 0 1 
     Contrast + 8 5 4 1 
Contrast - 10 1 0 1 
     
CT3m Primary site True negative True positive False positive False negative 
 
of 19lesions of 7 lesions of 3 lesions of 1 lesions 
grade 0 17 0 0 1 
grade 1 2 0 0 0 
grade 2a or 2b 0 7 3 0 
     Contrast + 2 7 2 0 
Contrast - 17 0 1 1 
Table 2: Imaging appearance of primary site lesions showing later tumour recurrence or remission  
at the MRI3w (upper table) and CT3m (lower table) 
 
 
Primary tumour ∆ADC MRI CT 
Time point 3 weeks 3 weeks 3±1 months 
TP 8 6 7 
FN 0 2 1 
FP 1 4 3 
TN 21 18 19 
    Sens 100% 75% 88% 
Spec 95% 81% 86% 
Acc 97% 80% 87% 
PPV 89% 60% 70% 
NPV 100% 90% 95% 
Table 3: Primary tumour: comparative accuracy between 
∆ADCpost, MRI3w and CT3m   
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7.3.3 Lymph node metastases 
None of the perfusion parameters showed a statistically different value between lesions with 
later post-CRT recurrence compared to lesions with CR and were excluded of further 
evaluation (c-peak: recurrence : -0.045±0.5 vs. CR : 0.24±1.35 ; AS: recurrence : 0.027±1.5 
vs. CR : -0.17±0.72 ; washout : recurrence : -1.26±1.51 vs. CR : 1.88±1.9 ; p>0.1). At 3weeks 
after the end of CRT, the ∆ADCpost was significantly lower for lesions with  post-CRT 
recurrence than with CR  (-2.25±0.3 vs. 79.8±41;p<0.0001) (Figure 3). 
 
 
Figure 3: Comparison of ∆ADCpost between adenopathies showing complete remission 2 years after the end of 
chemoradiotherapy and with recurrence. The ∆ADCpost was significantly lower in lesions showing later 
recurrence. Box-whisker plots are presented with median (-), interquartile range (box) and minima/maxima (-). 
 
For nodal differentiation at MRI3w, nodal size was the main discriminative variable while 
intranodal heterogeneity showed no additional value for detecting small adenopathies. 
Overall, 33 lymph nodes were smaller than 1 cm, 8 lymph nodes had a diameter range 
between 1 and 1.5 cm, 9 lymph nodes were larger than 1.5 cm. Comparative sensitivity, 
specificity, accuracy, PPV and NPV for the ∆ADCpost at the optimal threshold of 20% and 
MRI3w and CT3m per lymph node and neck side are shown in table 4. The ∆ADCpost showed 
higher PPV and NPV per lymph node and neck side than MRI3w and CT3m for both the 1 cm 
and 1.5 cm threshold, improving the detection of persistent subcentimetre nodal metastatic 
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disease and improving the exclusion of residual tumoral disease in persistently enlarged 
lymphadenopathy. 
 
Lymph node ∆ADC3w MRI3w - 1 cm MRI3w - 1.5*  CT4m – 1*  CT4m – 1.5 cm 
TP 7 6 3 5 3 
FP 5 11 6 5 3 
TN 36 30 35 36 38 
FN 2 3 6 4 6 
sens 78% 67% 33% 56% 33% 
spec 88% 73% 85% 88% 92% 
acc 86% 72% 76% 82% 82% 
PPV 58% 35% 33% 50% 50% 
NPV 95% 91% 87% 90% 86% 
 
 
     
Neck side ∆ADC3w MRI3w - 1 cm MRI3w - 1.5*  CT4m – 1*  CT4m - 1.5 cm 
TP 8 6 3 5 3 
FP 3 11 6 5 3 
TN 24 16 21 22 24 
FN 1 3 6 4 6 
sens 88% 67% 33% 56% 33% 
spec 89% 59% 77% 86% 89% 
acc 89% 61% 67% 80% 75% 
PPV 70% 35% 33% 50% 50% 
NPV 96% 84% 79% 89% 80% 
*Size threshold in cm – intranodal heterogeneity 
Table 4: Lymph nodes: comparative accuracy for post-treatment evaluation between ∆ADC, MRI3w 
and CT4m. Per lymph node (upper table) and per neck side (lower table). 
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Figure 4: Upper row: (a) right supraglottic tumour (arrowhead) and right level 2 metastatic adenopathy are 
shown on contrast-enhanced T1-weighted turbo-spin echo (TSE) image, (b) b1000 diffusion-weighted image, 
and (c) ADC-map prior to therapy. Middle row: (d) Three weeks after the end of chemoradiotherapy, the primary 
tumour (arrowheads) shows slight asymmetry (grade I), shows complete loss of signal on the b1000 diffusion-
weighted image and corresponds to (f) a ∆ADC (in %) of 60, indicating complete tumour eradication. The lymph 
node (arrows) (d) shows no intranodal heterogeneity and a diameter of 0.8 cm. (e) Visualized as a hyperintense 
lesion on the b1000 diffusion-weighted image, it corresponds to (f) a ∆ADC (in %) of 5, indicating persisting 
tumour. (g) CT scan at 8 months after completion of chemoradiotherapy shows necrotic adenopathy in right level 
2, corresponding to (h) a hypermetabolic lesion on FDG-PET. Subsequent histological examination after neck 
dissection confirmed the presence of a recurrent nodal metastasis (arrows). Bottom row: (i) follow-up CT scan at 
2 years after completion of chemoradiotherapy shows complete remission at the primary tumour site 
(arrowhead). 
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Figure 5: Upper row: patient with left tonsillar cancer (image not shown) presents with nodal metastasis in left 
level 2 on (a) contrast-enhanced T1-weighted TSE image, (b) b1000 diffusion-weighted image, and (c) ADC-
map prior to therapy. 
Bottom row: (d) Contrast-enhanced T1-weighted TSE image 3 weeks after completion of chemoradiotherapy 
shows persistent adenopathy > 1.5cm and with intranodal heterogeneity indicating necrosis. (e) the lymph node 
is hyperintense on the b1000 diffusion-weighted image and corresponds to a ∆ADC (in %) of 50, indicating 
tumour eradication. Watchful waiting during 2 years after chemoradiotherapy showed regression of the lymph 
node with persistent complete remission. 
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7.4 Discussion 
 
In this study, DWI with the ∆ADCpost allowed for treatment assessment of the head and neck 
as early as 3 weeks after the completion of CRT. Primary tumoral sites and lymph nodes that 
lacked a substantial increase in ADC 3 weeks after completion of CRT compared to the 
baseline scan (primary tumours: less than 25%, adenopathies: less than 20%) correlated 
significantly with later tumour recurrence. 
Prior studies have shown the value of DWI for detection of post-radiation or post-surgical 
tumour recurrence in the head and neck. At the time of clinical presentation or with suspect 
clinical examination, recurrent tumour showed a significantly lower ADC compared to post-
treatment inflammation or necrosis (1,2). This lower ADC was histologically correlated to the 
dense microstructure of HNSCC of residual or recurrent tumour (1). Moreover, a recent study 
has suggested the value of DWI for early response assessment prior to, during and early after 
CRT for nodal metastases of HNSCC in correlation to histology or short period of follow-up 
(7). 
In our study, DWI showed higher accuracy for both the evaluation of the treated primary site 
and nodal metastases, compared to conventional MRI at 3 weeks and the routinely 
implemented post-treatment CT, on average 3 months after CRT. 
Remarkably, no substantial difference in accuracy was found between the MRI3w and CT3m for 
the post-treatment evaluation of the head and neck. Usually, the first CT is routinely 
performed at 3 to 4 months after the end of treatment for the evaluation of the primary site, 
while CT studies earlier in the time course of follow-up rather aim at assessing nodal status 
before planned neck dissection (8). The findings of this study indicate that earlier 
implementation of routine imaging follow-up may be feasible. This in concordance with the 
findings of a prior study where imaging 4 to 8 weeks after RT was useful in the early 
identification of local treatment failure (3). However, despite the relatively high sensitivity for 
early detection of residual or recurrent tumour at the primary site the specificity and PPV was 
low, similarly as reported in earlier studies (9,10). In the first 3 to 4 months oedema, tumour 
necrosis and acute or chronic inflammation can lead to anatomical distortion and signal 
changes that may be difficult to distinguish from persistent or recurrent tumour or that may 
obscure small persistent tumoral lesions (11). The PPV for the early identification of lesions 
at risk of recurrence was markedly improved by DWI compared to the MRI3w and CT3m. 
Although the limited patient population in this initial study prohibits to draw definite 
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conclusions, a number of benefits of early post-CRT imaging for the post-CRT management 
of primary lesions in the head and neck may be postulated. The high NPV and PPV of DWI 
for assessment of the primary lesion site may aid in the stratification of patients for early 
salvage surgery in patients with failed CRT.  An increase in the success rate of early surgical 
salvage surgery may improve likelihood of survival (12). As previously shown, clinical 
evaluation and planned imaging or pathologic restaging of T3-T4 non-laryngeal primary 
tumours 1 to 2 months after RT may initiate early salvage surgery and improve local control 
and survival rates (3). The higher accuracy of DWI over anatomical imaging and the ability 
for early evaluation, may further increase the number of patients still eligible for salvage 
surgery.Additionally, the improved differentiation of persistent tumour from post-CRT 
inflammation and necrosis compared to anatomical imaging may help to obviate invasive 
diagnostic procedures in patients with a persistent suspect mass on serial imaging. 
For the evaluation of lymph nodes, DWI substantially improved both PPV and NPV 
compared to the MRI3w and CT3m for differentiation of persistent nodal disease. DWI 
improved the detection of persistent disease in subcentimetre lymph nodes and allowed 
exclusion of remnant tumoral disease in lymph nodes that were persistently enlarged or 
showed internal focal abnormalities. This underscores the potential limitations of size-related 
and anatomical criteria inherently used by CT and conventional MRI; DWI has the advantage 
that, being a microstructural imaging modality, it is not significantly influenced by lesion size 
or by treatment-induced tissue distortion (fibrosis, necrosis) or inflammation (1,2,7). 
The management of the post-radiotherapeutic neck remains controversial. Neck dissection 
performed 4 to 12 weeks after the completion of radiation treatment has been shown to 
improve regional control (13). Different studies have shown that patients with incomplete 
radiographic response on anatomical imaging showed higher neck control and cause-specific 
survival in patients when undergoing neck dissection (13,14). However, this improved 
survival comes at the cost of a high number of unnecessary performed surgical procedures 
and a significantly increased morbidity (15,16). In order to reliably avoid adjuvant neck 
dissection after CRT, imaging modalities need high sensitivity and high NPV. Liauw et al 
have reported a high NPV of CT performed at 4 weeks after the end of CRT for exclusion of 
persistent nodal metastatic disease and found only 1 neck recurrence in 32 necks with 
complete radiographic response (6). However, using the same imaging criteria, both MRI3w 
and CT4m did not achieve a similar NPV in this study. Moreover,  these criteria have the 
evident drawback that they do not allow to exclude patients from neck dissection who still 
have enlarged lymph nodes after CRT (17). 
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The high sensitivity and NPV of DWI may be of additional use for the post-CRT management 
of the neck. DWI showed a particularly high NPV for the exclusion of persistent neck disease, 
most importantly in patients with persistently enlarged adenopathies. DWI was able to 
correctly downstage 6 patients presenting with persistently enlarged adenopathies on post-
CRT conventional MRI at 3 weeks and in 5 patients at the time of the CT3m. In these patients 
careful follow-up was performed and none required neck dissection. 
Therefore, DWI may improve the risk assessment of patients and further safely reduce the 
number of elective post-CRT neck dissections. Nevertheless, it is currently unclear to what 
extent the early addition of DWI could decrease the number of imaging studies performed in 
the post-CRT phase. One persistent subcentimetric adenopathy was missed by both DWI and 
conventional imaging. A negative early DWI study should therefore not necessarily preclude 
further imaging follow-up during the first two years post-CRT in order to allow salvage 
surgery in initially missed metastatic adenopathies (6). 
Additionally, the high sensitivity combined with the improved PPV of DWI compared to the 
MRI3w and CT3m  for early nodal differentiation may aid in the timely selection of patients for 
neck dissection and maximize the chance for successful salvage neck dissection. DWI 
allowed for the additional detection of persistent nodal disease in 5 patients with complete 
radiological remission at repeated anatomical imaging. 
However, an issue for further improvement appears to be the false positive findings produced 
by DWI, which occurred in 3 patients with complete nodal regression on conventional 
imaging. This may be explained by a number of factors. First, in this study, all lymph nodes 
were included regardless of post-CRT size and a number of lymph nodes may have reached 
the lower resolution limit of DWI producing falsely lowered ADC-values as a result of 
inadequate ROI-delineation. Currently, DWI appears to be limited to the evaluation of lesions 
with a diameter of 4 mm or larger (18). Furthermore, DWI may have effectively detected 
residual nodal metastatic disease further regressing during follow-up secondary to late 
radiation effects. It is not always clear whether residual disease in the post-RT neck represents 
viable tumour at risk of progressive disease. In a prior study, not all histologically proven 
persistent nodal metastases after adjuvant neck dissection showed proliferative capacity by 
Ki-67 staining (19). Evidently, further studies are required to determine the post-CRT 
management in patients with DWI positive subcentimetric lymph nodes; intensified imaging 
follow-up or US-FNAB may be of use for further work-up of these patients. In this context, as 
interest in integrated PET/MRI is rising, it may be of value to evaluate the combined use of 
DWI with novel PET-tracers, such as 3-deoxy-3-[18F]fluorothymidine (FLT). FLT-PET 
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correlates with pathology based proliferation, including the Ki-67 score but is severely limited  
in its application in head and neck cancer due to false-positivity in areas of infection and 
inflammation (20,21). Although significant technical considerations have to be taken into 
account, FLT-PET may help to identify proliferation capacity in DWI positive lymph nodes, 
while DWI can reduce false positive findings of FLT by excluding inflammatory tissue areas 
(1). 
The time point where DWI allows for adequate post-CRT assessment  in this study appears to 
be in agreement with the expected optimal timing of adjuvant neck dissection between 4-8 
weeks after RT (22). Although further comparison with metabolic imaging is warranted in the 
future, FDG-PET has not been firmly shown to be reliable in this early post-treatment setting 
(23). Previous reports have shown optimal diagnostic results at 3 to 5 months after end of 
CRT for FDG-PET but this may be too late to adequately guide the management of the post-
CRT neck (24). 
 
7.5 Conclusion 
DWI with the ∆ADC is useful for early post-CRT assessment of the head and neck and shows 
higher accuracy than conventional MRI at 3 weeks and routine CT at 3 months after treatment 
for the detection of persistent HNSCC. A ∆ADC  higher than 20% for primary tumours and 
higher than 25% for nodal metastases is strongly indicative of tumour remission during the 
first 2 years of post-CRT follow-up and the high NPV may be useful to avoid invasive 
diagnostic procedures or exclude patients from adjuvant salvage surgery. 
The improved early identification of treatment failure by DWI may be beneficial for the 
timely selection of patients with persistent tumoral disease at the primary site or neck lymph 
adenopathy for salvage surgery. 
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Chapter 8:  
Challenges in apparent diffusion coefficient-based 
quantitative analysis: inter- and intra-observer 
variability of region-of-interest assessment 
 
8.1 Introduction 
Among the potential applications of DWI in the head and neck, the differentiation of lymph 
nodes is probably most affected by issues concerning image interpretation. Contrary to the 
primary lesion site, native high b-value DWI images do not allow for differentiation of benign 
and malignant lymph nodes, and therefore, nodal differentiation relies heavily on ADC 
calculation (1,2,3). In order to reliably use ADC-based differentiation in clinical practice, it is 
necessary that a high reproducibility is found in serial measurements or measurements 
between separate readers. This reproducibility will be affected by technical acquisition 
factors, but also by the region-of-interest-based analysis and the method of ADC calculation 
(4). 
The primary aim of this study was to determine intra- and interobserver variability of ADC 
values in the setting of ADC based differentiation of lymph nodes. Additionally, variability of 
ADC-quantification was compared between direct calculation of the ADC from the averaged 
ROIs on the native images and values calculated from the co-registered pixel-wise ADC-map, 
for delineations by the same observer. 
 
8.2 Materials and Methods 
 
8.2.1 Study design 
Of the patients scheduled for surgery of biopsy-proven HNSCC, 10 were randomly included 
irrespective of clinical T-stage, N-stage, or tumour localization. None of the patients had 
previously been treated for head and neck cancer. The interobserver study was performed 
6 months after completion of all prior studies of this thesis project, in order to avoid recall 
bias in the readers. A detailed timeline of the different steps is given in Figure 1. The DWI-
images were read in a blinded fashion by two readers (Reader 1: 7 years of experience in 
oncologic DWI, including head and neck tumour imaging – Reader 2: 15 years of experience 
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in head and neck imaging, 5 years of experience in head and neck DWI). Reader 1 repeated 
imaging analysis after a time delay of at least one month between the initial and second series 
of measurements. 
First, inter- and intra-observer variability was determined. Second, for the reader one 
delineations, the difference was compared between the direct calculation of the ADC from the 
averaged ROIs on the native images and values calculated from the co-registered pixel-wise 
ADC-map. 
 
 
 
Figure 1: Timeline detailing the study concept and data processing. 
 
 
8.2.2 Imaging technique 
All patients underwent the standardized anatomical TSE-MRI, and functional DWI- 
sequences as described in chapter 3. MRI imaging covered the entire head and neck ranging 
from the base of skull to the thoracic outlet, and included all regional nodal stations 
(retropharyngeal space and neck levels). 
 
8.2.3 Image analysis 
DWI analysis was done on a PACS-workstation (Agfa-Gevaert, Mortsel, Belgium). 
Observer 1 selected 10 study patients with histopathological confirmed neck nodal status and 
randomly indicated a maximum of 5 lymph nodes per patient for study analysis, irrespective 
of lesion size, level position in the neck and histological status (total 42 lymph nodes were 
selected, from which 6 were larger than or equal to 1 cm and 36 with a size range between 0.4 
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and 0.9 cm).  The location according to the AAO-HNS classification and slice position of the 
selected lymph nodes were recorded for further analysis. 
Quantitative analysis on the DWI was done as described in chapter 3.3.3. At first, quantitative 
analysis was done by a radiologist experienced for 7 years in head and neck DWI 
(observer 1), and by a subspecialty head and neck radiologist with 15 years of experience 
(observer 2). Both readers were blinded from each other and evaluated the recorded lesions. 
After a delay period of one month, observer 1 repeated the measurements in order to assess 
intra-observer agreement, using identical methodology. 
Additionally, for reader one, the ROIs copied on the native images were copied on the co-
registered pixel-wise ADC-map, in order to compare ADC calculations based on averaging 
native DWI signal intensities with averaging of pixel-wise calculated ADC values. 
 
8.2.4 Data analysis 
Mean ADC values ± SD were calculated for the lymph nodes for each single reader. Inter- 
and intra-observer variability of ADC calculations for lymph node measurements were 
determined as mean absolute difference (bias) and 95% confidence interval of the mean 
difference (limits of agreement), according to the method of Bland and Altman. Additionally, 
a spearman rank correlation and linear regression was used to correlate the inter- and intra-
observer agreement of nodal ADC-values in correlation to the ROI-delineation. To illustrate 
the effect of variations of ADC-calculation on nodal differentiation based on the arbitrary 
determined threshold, inter- and intra-observer agreement was determined based on the 
previously determined threshold in this study population (0.94x10
-3
; chapter 4) by means of 
agreement statistics (κ) (3). Linear-weighted kappa was used to determine inter- and intra-
observer variability of the readers in correlation to the reference standard. To  evaluate the 
difference between the co-registered pixel-wise ADC-map and the ADC calculated from the 
averaged ROIs on the native b-value images, the standard deviations of the difference 
between the 2 delineations in each setup were compared. 
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8.3 Results 
8.3.1 Inter- and intra-observer agreement 
Mean ADC of delineated lymph nodes were; for reader 1: 0.97 ± 0.17 x 10
-3 
(first 
interpretation session) and 0.97 ± 0.17 x 10
-3 
(second interpretation session). Mean ADC of 
delineated lymph nodes were; for reader 2: 0.99 ± 0.16 x 10
-3
. 
The mean biases and limits of agreement for inter- and intra-observer and corresponding 
Bland-Altman plots are depicted in Table 2 and Figure 2. Mean bias and limits of agreement 
for intra-observer comparison were slightly lower than for the inter-observer comparison. 
 
Measurement Mean bias (10-3 mm2/s) 95% Limits of agreement (10-3 mm2/s) 
   observer 1 vs. observer 2 0.011 -0.141 to 0.163 
 
  
observer 1 repeated  -0.003 -0.119 to 0.113 
Table 2: Inter-observer (upper row) and intra-observer (lower row) reproducibility of lymph node ADC values 
according to the Bland and Altman test. 
 
Linear regression showed a high correlation for both inter- and intra-observer agreement with 
the latter showing slightly higher agreement (inter-observer agreement: R
2 
= 0.79, slope=0.84; 
intra-observer agreement: R
2 
= 0.88, slope=0.97) (Figure 3). 
In correlation to the nodal characterization used in this study, the inter- and intra-observer 
variability showed excellent agreement (inter-observer: κ = 0.81, proportion of agreement = 
0.91; intra-observer: κ = 0.81, proportion of agreement = 0.91). 
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Figure 2: Upper plot shows inter-observer reproducibility, lower plot intra-observer reproducibility. The 
difference of ADC-measurements (y-axis) is plotted out against mean ADC measurement (x-axis), with 
depiction of mean absolute difference (bias) (continuous line) and 95% confidence interval of the mean 
difference (limits of agreement) (dashed lines). 
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Figure 3: Linear regression analysis plots of inter- (upper graph) and intra-observer (lower graph) agreement. 
The ADC measurements of reader 1 are plotted out against ADC measurements of reader 2, respectively the 
repeated measurements of reader 1. Points clouds are approximated with the optimal linear fit (continuous blue 
line) and confidence intervals (dashed lines); unity line is provided as reference. 
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8.3.2 Intra-observer variance in correlation to ADC-methodology 
The mean ADC of delineated lymph nodes, calculated from the averaged ROIs on the native 
b-value images (NATIVE group) were 0.97 ± 0.17 x 10
-3 
(first interpretation session) and 0.97 
± 0.17 x 10
-3 
(second interpretation session). Mean ADC of delineated lymph nodes, 
calculated from the co-registered pixel-wise ADC-map (ADCMAP group) were lower with  
0.91 ± 0.17 x 10
-3
 (first interpretation session) and 0.91 ± 0.17 x 10
-3 
(second interpretation 
session). The standard deviation of the difference between the repeat measurements was 5.9 x 
10
-5
 for the NATIVE group, while the standard deviation of the difference between the repeat 
measurements in the ADCMAP group was 39.6% higher (8.3 x 10
-5
). 
 
8.4 Discussion 
The value of DWI for nodal staging in the head and neck has already been shown in several 
studies (1,2,3). The body background suppression inherent in DWI imaging allows much 
easier detection of small lymph nodes (high signal) from the black background compared to 
conventional imaging sequences (5). However, both benign and malignant lymph nodes 
express a certain degree of diffusion restriction and will appear hyperintense on native DW 
images, and a b1000 image will therefore not allow for accurate nodal differentiation (6). 
Hence, nodal characterization remains dependent of ADC-calculation, for which the ROI-
analysis is likely to be influenced by observer related variations. 
In this study, good inter- and intra-observer agreement was found for ROI based ADC 
evaluation of both malignant and benign lymph nodes. Most likely, the high reproducibility of 
DWI in this study is attributable to the high degree of standardization of imaging technique 
(same scanner hardware, imaging sequence and patient positioning) and image interpretation 
(on the same PACS imaging system) but also the level of experience of the readers. 
The standardized analysis methodology in this study may have firmly contributed to the 
reproducibility. In our centre, ROI based analysis is performed on the native b-value images, 
with the ADC calculated only on the averaged signal intensities. A previous study in brain 
infarction has shown that native DWI-trace images were more reliable for quantification of 
final infarct volume compared to the pixel-wise ADC-map, anatomical sequences and 
magnetization transfer ratio (MTR) map (7). One of the possible reasons for this is the high 
image contrast on native DW images that might allow for improved lesion identification and 
delineation of lesion borders and probably facilitates a ROI-delineation with closer 
conformity to the true lesion volume compared to evaluation of ADC-maps alone. Also, 
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calculating ADC values based on the averaged native DWI-SI, instead of using the co-
registered ADC map may have increased reproducibility. In this limited study group, higher 
standard deviation of the difference between the repeat measurements was found when using 
the co-registered ADC maps. ADC calculations of a single or a few pixels are likely to be 
more prone to inflate noise influences, leading to higher stochastic variability in calculated 
ADC values. Additionally, variability in ADC calculation through the ADC map may be 
increased by artifacts due to susceptibility or eddy currents. Both may cause errors in the 
calculation or misregistration of the ADC map compared to the native DWI images (8). As 
such, ROIs drawn on the native DWI images may not show an exact positional match on the 
ADC map exactly match when copied and produce erroneous ADC values. 
In previous studies evaluating DWI for nodal staging in the head and neck, diverging results 
have been found for ADC values of benign and malignant lymph nodes (1,2,3,9,10,11). The 
most important cause for this variability in results can be attributed to the different choice of 
b-values to calculate the ADC. Other technical factors that influence the variability of ADC 
measurements, include, as previously mentioned susceptibility and eddy current related 
artifacts, and also movement artifacts, image noise, settings of diffusion gradient amplitudes, 
strength of the magnetic field and gradient calibration inaccuracy (8). Image artifacting is 
likely to be minimized by using combined head/neck coils as now routinely employed on 
most high-field MRI-systems, or by using more robust DWI-sequences such as Short Tau 
Inversion Recovery (STIR) DWI (5). Also, better gradients, or more optimal sequences with 
parallel imaging can be used to reduce sequence TE and reduce artifacts. 
In this study setting, parallel imaging could not be used as the combination of a head coil with 
a dedicated neck coil prohibits its use to suppress potential artifacting. However, as previously 
described, manual shimming should be considered as an important factor to obtain optimal 
image quality and reduce fat-shift and distortion artifacts. A shim should cover the spine and 
muscles of the neck while avoiding large areas of air appears to provide best image quality 
(12). 
So far, the lack of technical standardization has prohibited the routine application of DWI in 
the head and neck. However, as shown in recent studies investigating DWI for treatment 
follow-up, the stringent use of identical imaging protocols with identical technical parameters 
allowed for reproducible measurements and establishing fixed thresholds between different 
scanner types and field strengths (13,14). 
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This is reflected in three recent studies investigating DWI for nodal staging in HNSCC, where 
mainly subcentimetric lymph nodes were included (2,3,10). Similar ADC-values were 
reported for benign and malignant lymph nodes and the optimal thresholds for differentiating 
benign from malignant were similar. As these studies were performed using identical b-value 
settings, the slight variances may be explained by differences in the other technical 
parameters as detailed above, for which further standardization is probably required between 
different centres. 
In a recent study, doubt was cast on the reproducibility of ADC measurements for nodal 
stages. When comparing ranges of ADC in normal lymph nodes found in their study, large 
variability was found with other studies and between different body regions (4). 
While many discrepancies may be attributed to different settings of b-values and different 
method of ADC-evaluation, it can also be hypothesized that ADC-values and optimal 
thresholds may depend on the underlying tumour type and size of the lymph node. This could 
be important for the application of DWI in future studies incorporating several tumour tissue 
types and size thresholds. First, enlarged necrotic nodal metastases from HNSCC show high 
tendency for necrotic formation, which may falsely increase ADC-values. However, as 
reflected in the most recent papers, the consensus is to account for tissue heterogeneity when 
assessing necrotic adenopathies by delineating hyperintensities on native high b-value images 
to deal with this problem (1,2,3,10). Second, ADC-values for nodal characterization may vary 
according to the underlying histological subtype. As shown in previous studies, this may help 
to identify the underlying primary tumour type, thus helping in patient management (11). 
However, the development and implementation of DWI as a locoregional staging tool in head 
and neck tumours should probably be stratified according to the underlying primary tumour 
type. Therefore, for the further development of DWI, additional studies, including other head 
and neck tumour types like parotid tumours and thyroid cancers, may be required to further 
standardize image interpretation and characterization thresholds. 
  
160 
 
While interpreting the findings of this study, a number of limitations should be taken into 
account. First, the number of enlarged lymph nodes included for evaluation was limited. 
However, the inclusion of lymph nodes was done randomly and represents the ratio of sub- 
versus supercentrimetric lymph nodes in this patient group, in order to avoid selection bias. 
Also, as previously stated  the additional clinical value of DWI lays in the detection of 
subcentimetric lymph nodes, which justifies the inclusion of a majority of subcentimetric 
lymph nodes in this study. Second, the readers in this study are experienced in evaluating 
head and neck MRI and DWI and the presented intra- and inter-observer variability therefore 
reflects only variability in personal assessment of lymph node boundaries and ROI 
delineations, not in training level. Generalizing these conclusions to advocate the widespread 
use of DWI may thus be premature, as currently the technique requires training and a minimal 
degree of expertise, currently limiting its use to centres with sufficient exposure to head and 
neck oncology. However, as the technique is easy to integrate in standard imaging protocols, 
continuous progression into widespread research should lead to further standardization and 
simplification of imaging interpretation. 
 
8.5 Conclusion 
Good inter- and intra-observer reproducibility was found for DWI for nodal staging of 
HNSCC between two experienced readers. Additionally, initial findings indicate that ADC-
calculation from ROI-delineation on native b-value images may be more reproducible than 
values obtained from the pixel-wise ADC-map. 
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Chapter 9: 
Summary 
 
The overall aim of the thesis was to evaluate in head and neck squamous cell carcinoma the 
potential value of DCE-MRI and DWI in nodal characterization, the differentiation of post-
CRT necrosis and inflammation from tumoral recurrence, and early treatment prediction. 
While DWI was researched for nodal staging, differentiation of post-CRT recurrence and 
treatment prediction, DCE-MRI research was concentrated to its potential role in treatment 
follow-up and treatment prediction. 
For pre-treatment nodal differentiation, 33 patients were included in the study and DWI was 
primarily compared to TSE-MRI. DWI with ADC-calculation showed significantly higher 
sensitivity than TSE-MRI using size-related and morphological criteria (per level: 94% vs. 
57%, p<0.0001) with equal specificity (per level: 97% vs. 95%). Compared to TSE-MRI, 
DWI correctly changed nodal staging in 13 of 33 patients (39%). The main advantage of DWI 
was the detection of subcentimetric nodal metastases, as small as 4 mm in shortest transverse 
diameter, where DWI showed significantly higher sensitivity compared to TSE-MRI (per 
lymph node: 76% vs. 7%). In a smaller subpopulation (11 patients), DWI showed higher 
sensitivity than FDG-PET/CT for nodal characterization (per level: 96% vs. 67%). Although 
the main advantage of DWI is the detection of small nodal metastases, the spatial resolution 
limit of the technique did not allow to detect nodal micrometastatic deposits smaller than 
4 mm. In the pre-operative setting, the technique may show additional value for contralateral 
neck staging in large tumours close to the midline, in order to determine the necessity for 
contralateral neck dissection or for the detection of skip metastases in oral cancer. For 
radiotherapy planning, the improved detection of nodal metastases may lead to closer 
conformity between the radiation target volume and the regional tumour extent, potentially 
improving regional tumour control and decreasing the treatment-induced side-effects. 
In a second correlative study with histopathology in 26 patients, who underwent salvage 
surgery after chemoradiotherapy, DWI showed higher accuracy than DCE-MRI for the 
differentiation of tumour recurrence from necrosis and inflammation (primary tumour site: 
97% vs. 82%; lymph nodes: 88% vs. 76%). The higher accuracy of DWI over DCE-MRI was 
explained by the lower false positive ratio secondary to inflammation and higher sensitivity of 
DWI, as  the  higher  image  contrast  in  the latter technique allows detection of small volume  
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disease. DWI provided complementary information to CT/TSE-MRI and FDG-PET, by 
reducing false positive results and excluding recurrent tumour in persistent ulcers or 
persistently enlarged lymph nodes more than 4 months after completion of CRT. Moreover, 
confirming the results of the nodal characterization study, DWI improved the detection of 
subcentimetric nodal metastases. The high sensitivity and negative predictive value of DWI 
may allow to avoid invasive diagnostic procedures surgery in persistent lesions. Additionally, 
the technique may be useful in the pre-operative staging of patients with a recurrent tumour, 
in order to determine the extent of neck dissection required. 
Analysis with semi-quantitative parameters of DCE-MRI was less accurate in excluding 
recurrent tumour in persistent lesions after chemoradiotherapy. This limits the role of DCE-
MRI as a standalone functional diagnostic tool in the post-CRT evaluation of the head and 
neck. 
In the early treatment assessment, the value of imaging during treatment and imaging in the 
early post-treatment phase were separately investigated. Predictive imaging during CRT may 
help to tailor treatment to the individual patients response, while early post-CRT imaging 
mainly aims to timely select or exclude patients for salvage surgery. Thirty-one patients 
underwent DWI and DCE-MRI at 2 and 4 weeks during chemoradiotherapy for locally 
advanced HNSCC. DWI showed higher accuracy than serial volumetric measurements and 
DCE-MRI for the differentiation of responding and non-responding primary tumours and 
lymph nodes (primary tumour 2 weeks: DWI=94% vs. TSE-MRI=65% vs. DCE-MRI=87%; 
adenopathies 2 weeks: DWI=87% vs. TSE-MRI=56% vs. DCE-MRI=56%; primary tumour 4 
weeks: DWI=94% vs. TSE-MRI=61% vs. DCE-MRI=72%; adenopathies: DWI=93% vs. 
TSE-MRI=63% vs. DCE-MRI=59%). While volumetric measurements showed a relatively 
high negative prediction value, and thus can reliable exclude lesions at risk of treatment 
failure, the low positive predictive value did not allow selection of patients for treatment 
intensification. The main contribution of DWI is early recognition of treatment response in 
lesions initially lacking significant volume regression, and thus improving the positive 
predictive value of imaging. DWI also enabled identification of non-responding lesions that 
did show early volume regression. DCE-MRI did not provide additional information in the 
early response assessment, which may be in part caused by the inflammatory changes induced 
by CRT. 
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In the multivariate analysis, DWI findings at 2 and 4 weeks was an independent predictor of 
LRC 2 years after treatment, while volumetric measurements and DCE-MRI were not. If 
treatment strategies such as dose escalation or systemic targeted agents and radio-sensitizers 
become clinically available, DWI may help selecting patients for such bio-adaptive treatment. 
Further research in a larger patient population is ongoing to confirm these preliminary 
findings and to investigate a correlation between per-treatment DWI-results and overall 
survival and disease free survival. 
In a study on 29 patients, DWI and DCE-MRI were performed prior to and 3 weeks after 
completion of CRT and its accuracy was compared to TSE-MRI at the same time point, and a 
post-treatment CT study at 3 months after completion of CRT. 
DCE-MRI failed to show any significant difference between lesions showing later recurrence 
and lesions with CR 2 years after completion of CRT. 
DWI showed higher accuracy than TSE-MRI and CT for the assessment of treatment response 
at the primary tumour site (DWI=97% vs. TSE-MRI=80% vs. CT= 87%) and nodal disease 
(per neck side: DWI=89% vs. TSE-MRI=67% vs. CT=75%). For the primary tumour site, 
DWI mainly improved the positive predictive value compared to TSE-MRI and CT. DWI 
may be of use for the early identification of patients requiring salvage surgery. Timely 
selection for early salvage may improve local control and survival rates for T3-T4 non-
laryngeal primary tumours. For the evaluation of lymph nodes, DWI both improved the PPV 
and NPV compared to TSE-MRI and CT. DWI showed a particularly high NPV, allowing 
exclusion of persistent tumour, most importantly, in patients with persistently enlarged 
adenopathies. Therefore, DWI may aid in the timely selection of patients for adjuvant surgical 
intervention and maximize the chance for successful salvage neck dissection. However, 
although positive predictive value was substantially improved by DWI in this setting, further 
optimization is still required to decrease false positive findings in subcentimetric lymph 
nodes. 
In a final study, the inter- and intra-observer agreement regarding region of interest 
assessment for ADC-calculation was compared between two readers experienced in head and 
neck DWI. Statistical analysis showed a high correlation for both inter- and intra-observer 
agreement  (inter-observer agreement: R
2 
= 0.79, slope=0.84; intra-observer agreement: R
2 
= 
0.88, slope=0.97). 
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In addition, the direct calculation of ADC from the averaged ROIs on the native images 
(NATIVE group) was compared with the values obtained from the co-registered pixel-wise 
ADC-map (ADCMAP group), for variability of delineations by the same observer. In this 
limited group, the standard deviation of the difference between the repeat measurements was 
5.9 x 10
-5
 for the NATIVE group, while the standard deviation of the difference between the 
repeat measurements in the ADCMAP group was about 40% higher (8.3 x 10
-5
). This 
suggests that ADC-calculation from user-determined ROI‟s on native b-value images is more 
reproducible and reliable than values obtained from the pixel-wise calculated ADC-map. 
These findings indicate that, although high inter- and intra-observer agreement is reached 
between experienced readers, strict standardization of image analysis will be necessary to 
further  expand the use of DWI in the head and neck. Currently, DWI requires training and 
sufficient expertise, limiting its use to centres with a high throughput of oncologic head and 
neck pathology. As the technique can be integrated in standard imaging protocols without 
much burden for the patient, further research and standardization should permit easier 
interpretation and a more widespread application of this non-invasive imaging technique. 
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Hoofdstuk 10: 
Samenvatting 
 
Het globale doel van de thesis was om de waarde te evalueren van dynamische contrast- 
(DCE-MRI) en diffusiegewogen magnetische resonantie (DWI) in de karakterisatie van 
lymfeklieren, de differentiatie van post-radiotherapie necrose en inflammatie van 
tumorrecidief en de vroegtijdige voorspelling van het therapieresultaat in het spinocellulair 
carcinoom van het hoofd-halsgebied. 
Terwijl DWI onderzocht werd voor lymfeklierstadiëring, differentiatie van het post-
radiotherapie tumorrecidief en therapiepredictie, werd voor DCE-MRI de nadruk gelegd op 
therapie follow-up en -predictie. 
Voor de pretherapeutische studie met betrekking tot lymfeklierdifferentiatie werden 33 
patiënten geïncludeerd, voor wie DWI in de eerste plaats werd vergeleken met conventionele 
MRI. DWI, gekwantificeerd door de apparent diffusion coefficient (ADC), toonde een 
significant hogere sensitiviteit dan conventionele MRI voor de detectie van lymfeklier-
metastasen (per nekzone: 94% vs. 57%, p<0.0001) met een gelijkaardige specificiteit (per 
nekzone: 97% vs. 95%). Hierbij maakte conventionele MRI gebruik van lymfeklierdiameter 
en morfologische klierafwijkingen ter differentiatie. Vergeleken met conventionele MRI 
veranderde DWI correct de lymfeklierstadiëring in 13 van de 33 patiënten (39%). Het grootste 
voordeel van DWI lag in de detectie van subcentimetrische lymfekliermetastasen tot een 
minimale diameter over de kortste as van 4 mm, waarbij voor DWI een significant hogere 
sensitiviteit werd bekomen in vergelijking met conventionele MRI (per lymfeklier: 76% vs. 
7%). In een kleinere studiepopulatie van 11 patiënten toonde DWI een hogere sensitiviteit dan 
fluoro-deoxy-glucose positron emission tomography/computer tomografie (FDG-PET/CT) 
voor lymfeklierdifferentiatie (per nekzone: 96% vs. 67%). Hoewel DWI de differentiatie van 
kleine lymfeklieren als belangrijkste voordeel heeft, laat de spatiële resolutielimiet de detectie 
van metastatische deposities kleiner dan 4 mm - en dus micrometastasen - niet toe. De 
belangrijkste toegevoegde waarde van DWI in de pre-operatieve situatie lijkt de stadiëring 
van de contralaterale nek te zijn in tumoren die over of dicht op de midlijn uitbreiden en voor 
de detectie van “skip” metastasen in de lagere nekzones bij mondholtetumoren. In geval van 
radiotherapieplanning kan de verbeterde karakterisatie van lymfeklieren leiden tot een hogere 
conformiteit tussen het doelvolume van de bestraling en de regionale tumoruitbreiding. Dit 
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kan enerzijds leiden tot een verbeterde regionale tumorcontrole en anderzijds tot een daling 
van de therapie-geïnduceerde nevenwerkingen. 
In een tweede correlatieve studie met histopathologie in 26 patiënten die chirurgie 
ondergingen voor een mogelijk recidief na chemoradiotherapie toonde DWI een hogere 
accuraatheid dan DCE-MRI voor de differentiatie van tumorrecidief met necrose en 
inflammatie (primaire tumoursite: 97% vs. 82%; lymfeklieren: 88% vs. 76%). De hogere 
accuraatheid van DWI t.o.v. DCE-MRI kon teruggebracht worden op lagere vals positieve 
ratio secundair aan inflammatie, en aan de hogere sensitiviteit van DWI als gevolg van het 
hogere beeldcontrast dewelke de detectie van kleine letsels toelaat. DWI leverde 
complementaire informatie aan CT en conventionele MRI en FDG-PET door de vals positieve 
ratio te verlagen en persisterende of recidief tumor uit te sluiten in ulceraties of vergrote 
adenopathieën meer dan 4 maand na het beëindigen van de chemoradiotherapie. Evenals in de 
eerste studie, verbeterde DWI de detectie van subcentimetrische lymfekliermetastasen. De 
hoge sensitiviteit en negatieve predictieve waarde van DWI kan behulpzaam zijn om 
invasieve diagnostische procedures te vermijden in persisterende letsels en om de 
locoregionale stadiëring te vervolledigen, meer bepaald de identificatie van lymfeklier-
metastasen en dus het helpen bepalen van de uitbreiding van de geplande nekdissectie. Semi-
kwantitatieve analyse van de DCE-MRI was minder accuraat dan DWI, vooral in het 
uitsluiten van tumoraal weefsel in persisterende letsels. Dit beperkt de rol van DCE-MRI als 
diagnostische techniek in de post-chemoradiotherapeutische evaluatie van het hoofd-
halsgebied. Evenwel kan DCE-MRI nuttig zijn wanneer deze gebruikt wordt in combinatie 
met andere functionele technieken, zoals DWI. 
De waarde van functionele MRI-technieken voor vroegtijdige therapie follow-up werd 
arbitrair opgedeeld in beeldvorming gedurende, respectievelijk vroegtijdig na chemo-
radiotherapie. Predictieve beeldvorming gedurende chemoradiotherapie zou nuttig kunnen 
zijn om de therapie aan de individuele situatie van de patiënt aan te passen, terwijl 
beeldvorming vroegtijdig na chemoradiotherapie als doel heeft om vroegtijdig patiënten te 
selecteren die aanvullende chirurgie nodig hebben na het beëindigen van de 
chemoradiotherapie. 
Bij eenendertig patiënten met lokaal gevorderd hoofd-hals spinocellulair carcinoom werd een 
DWI en DCE-MRI uitgevoerd op 2 en 4 weken gedurende de chemoradiotherapie. DWI was 
accurater dan seriële volumetrische metingen en DCE-MRI voor de differentiatie van 
therapiegevoelige en therapieresistente primaire tumoren en lymfekliermetastasen (primaire 
tumor 2 weken: DWI=94% vs. conventionele MRI=65% vs. DCE-MRI=87%; adenopathieën 
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2 weken: DWI=87% vs. conventionele MRI=56% vs. DCE-MRI=56%; primaire tumor 
4 weken: DWI=94% vs. conventionele MRI=61% vs. DCE-MRI=72%; adenopathieën: 
DWI=93% vs. conventionele MRI=63% vs. DCE-MRI=59%). Terwijl volumetrische 
metingen een relatief hoge negatieve predictieve waarde vertoonden voor de exclusie van 
letsels met risico op ziekterecidief, belette de lage positieve waarde de vroegtijdige 
identificatie van patiënten die baat zouden kunnen hebben bij therapieaanpassing. De 
belangrijkste toegevoegde waarde van DWI was terug te brengen op het vroegtijdig 
herkennen van therapierespons in letsels die geen volumeafname vertoonden en dus het 
verbeteren van de positief predictieve waarde. Bovendien verbeterde DWI de identificatie van 
letsels die een onvolledige therapierespons hadden en tegelijkertijd toch een belangrijke doch 
onvolledige volumeafname vertoonden. DCE-MRI leverde geen toegevoegde informatie  voor 
vroegtijdige evaluatie van therapierespons. Mogelijks is dit gedeeltelijk wijten aan de 
radiotherapie-geïnduceerde inflammatie. 
Multivariaat analyse toonde dat DWI 2 en 4 weken gedurende chemoradiotherapie een 
onafhankelijke predictor was voor de 2-jaars locoregionale controle, terwijl dit niet het geval 
was voor volumetrie en DCE-MRI. Indien therapiestrategieën zoals dosisescalatie, 
weefselspecifieke systemische antitumorale geneesmiddelen of radio-sensibele medicatie 
beschikbaar komen, dan zou DWI kunnen helpen om patiënten uit te selecteren voor 
dergelijke bio-adaptieve therapieën. Verder onderzoek in een grotere patiëntengroep is bezig 
om de gevonden resultaten te bevestigen. 
In een studie met 29 patiënten werd een DWI en DCE-MRI uitgevoerd vóór en 3 weken na 
het beëindigen van de chemoradiotherapie. De accuraatheid van beide functionele technieken 
werd vergeleken met conventionele MRI op 3 weken na het beëindigen van chemo-
radiotherapie en met de routinematig uitgevoerde CT gemiddeld 3 maand na het beëindigen 
van de therapie. DCE-MRI kon geen significant verschil aantonen tussen letsels die een later 
tumorrecidief vertoonden en letsels met volledige remissie 2 jaar na het beëindigen van de 
chemoradiotherapie. DWI was accurater dan conventionele MRI en CT voor therapie-
evaluatie van de primaire tumorlokalisatie (DWI=97% vs. TSE-MRI=80% vs. CT= 87%) en 
lymfekliermetastasen (per nekzijde: DWI=89% vs. TSE-MRI=67% vs. CT=75%). Voor de 
primaire tumorlokalisatie verbeterde DWI vooral de positieve predictieve waarde in 
vergelijking met conventionele MRI en CT. Als dusdanig kan DWI nuttig zijn voor de 
vroegtijdige selectie van patiënten met verhoogd risico op later tumorrecidief en die dus nood 
hebben aan bijkomende chirurgie. Tijdige selectie van patiënten voor vroegtijdige chirurgie 
kan leiden tot een verbeterde lokale controle en patiëntoverleving voor T3-T4 niet-laryngeale 
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tumoren. Voor de evaluatie van lymfekliermetastasen verbeterde DWI zowel de positieve als 
de negatief predictieve waarde in vergelijking met conventionele MRI en CT. DWI toonde 
een zeer hoge negatieve predictieve waarde dewelke op een betrouwbare wijze de uitsluiting 
van persisterende tumor toeliet, ook in patiënten met persisterende vergrote adenopathieën. 
Daardoor zou DWI nuttig kunnen zijn voor de selectie tussen patiënten die baat kunnen 
hebben van een bijkomende chirurgische nekdissectie of patiënten bij wie een afwachtende 
houding gewettigd is. Hoewel de positieve predictieve waarde van conventionele MRI en CT 
sterk werd verbeterd door DWI, is verdere oppuntstelling van de techniek nodig teneinde het 
aantal vals positieven in subcentimetrische lymfeklieren verder te beperken. 
In een laatste studie werd de inter- en intraobserver variabiliteit van de manuele aflijningen 
voor ADC-berekening in lymfeklieren vergeleken tussen 2 observatoren met ervaring in 
hoofd-hals DWI. Statistische analyse toonde een hoge correlatie voor zowel de inter- als de 
intraobserver variabiliteit (inter-observer: R
2 
= 0.79, slope=0.84; intraobserver: R
2 
= 0.88, 
slope=0.97). 
Ook werd de directe berekening van de ADC van de uitgemiddelde aflijningen op de natieve 
diffusiegewogen beelden (NATIVE groep) vergeleken met de waarden bekomen uit de 
gecoregistreerde pixelgebaseerde ADC-map (ADCMAP groep), voor variabiliteit tussen de 
aflijningen in 1 observator. Preliminaire resultaten duiden aan dat de standaarddeviatie van 
het verschil tussen de herhaalde metingen 5.9 x 10
-5
 was voor de NATIVE groep, terwijl de 
standaarddeviatie van het verschil tussen de herhaalde metingen in de  ADCMAP groep 
ongeveer 40% hoger was (8.3 x 10
-5
). Dit suggereert dat ADC-berekening van aflijningen op 
de natieve diffusiegewogen beelden meer reproduceerbaar en betrouwbaar zijn dan deze 
bekomen van de pixelgebaseerde ADC-map. Hieruit kan worden geconcludeerd dat, hoewel 
een hoge overeenkomst in observaties kan worden bekomen, strikte standaardisatie van de 
beeldinterpretatie nodig is om de toepassing van DWI verder uit te breiden in de hoofd-hals 
oncologie. Momenteel is voor hoofd-hals DWI training en een minimale expertise 
noodzakelijk; daardoor blijft het gebruik beperkt tot centra met een hoge doorstroming van 
hoofd-hals oncologische pathologie. Aangezien het vrij eenvoudig is de techniek te integreren 
in het standaard beeldvormingsprotocol zonder belasting van de patiënt, zou er een 
makkelijke toegang voor verder onderzoek moeten zijn. Verdere standaardisatie zou in de 
toekomst moeten leiden tot een makkelijker beeldinterpretatie en meer verspreid gebruik van 
deze niet-invasieve techniek. 
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